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Ventilation enables the exchange of oxygen and carbon dioxide in the lungs. Since adequate 
ventilation is crucial to the survival of humans and all other mammalian species, a complex 
control system involving both feedback and feed forward reflexes is present in all mammals 
that ensures adequate ventilation and consequently stable intracellular levels of pCO2 (pH) and 
pO2. The control system makes use of specific chemoreceptors. Changes in arterial pCO2 are 
sensed by central chemoreceptors in the medulla, while changes in arterial pO2 are sensed by 
peripheral chemoreceptors that reside in the carotid bodies (at the bifurcation of the common 
carotid artery; Fig. 1). Stimuli such as hypoxia, hypercapnia and acidosis will increase minute 
ventilation, while hypocapnia and alkalosis will decrease minute ventilation. Respiratory 
centres in the brainstem integrate these stimuli and provide the neural drive to respiratory 
muscles (i.e. the diaphragm, intercostal muscles and muscles providing airway patency).1 These 
respiratory centres can easily be affected by centrally acting drugs, such as opioids. Exogenous 
opioids activate the endogenous opioid receptor system causing the slowing and at high dose 
diminishing of rhythmic breathing activity.1 Opioid-induced respiratory depression (OIRD) 
is possible since opioid receptors, especially mu-opioid receptors (MOR), are expressed on 
respiratory neurons in the brainstem2; the endogenous opioid system plays an important role 
in the fragile process of respiratory homeostasis.3 
THE OPIOID EPIDEMIC
OIRD may affect not only patients treated with potent opioids in the hospital setting, but it 
may affect all patients receiving opioid therapy, such as for the treatment of chronic low back 
pain in the outpatient clinic or prescribed by their general practitioner. The prevalence of 
OIRD is commonly underreported.3 Recent publications in the lay press suggest the presence 
of an opioid epidemic from prescription opioids. Since 1999 the number of patients in the 
United States (US) that gave died from prescription opioid abuse or misuse quadrupled.4 It is 
estimated that more than 250,000 individuals have died since the year 2000 due to opioids. The 
combination of OIRD and a high abuse potential make opioid especially dangerous, currently 
causing more deaths than illegal opioids or car accidents in the US. Interestingly, while an 
opioid epidemic is present in the US, other countries seem to be less affected despite high 
levels of opioid use. For example, in the Netherlands about 1 million patients use a prescription 
opioid for chronic pain. Still, the number of admissions because of problems due to addiction 
or otherwise is stable at 700 for many years now.5 
A BENEFIT-HARM COMPOSITE OF DRUG EFFECT
The intention to treat patients with moderate to severe acute and chronic pain is to reduce 
their symptoms and improve their quality of life. Still, opioids come with side effects of which 
OIRD is potentially life threatening. It is therefore useful to quantify the efficacy of an opioid (i.e. 
its benefits) combined with its side effect profile (i.e. the harm it induces). We want to treat the 
patient with a potent analgesic but simultaneously do not want to expose that same patient 
to serious adverse events. One way of understanding the complex behaviour of drugs that 
produce wanted effects and unwanted side effects is by integrating benefit and harm into a risk-
benefit composite. The utility or safety function is an example of such a composite measure.6 
In the case of opioid analgesia and OIRD, the utility function (UF) converts two rather distinct 




within specific patient populations. The UF is defined as the probability of benefit minus the 
probability of an adverse event. For opioids, positive values indicate that the probability of 
analgesia exceeds the probability of an adverse event such as OIRD (and vice versa). Dahan et 
al. showed earlier that the UF of the potent opioid analgesic fentanyl differs between opioid 
responders and non-responders, suggestive that opioid analgesic efficacy is uncoupled from 
OIRD.7 
TREATMENT OF OIRD WITH NON-OPIOID DRUGS 
One way of treating significant OIRD is the administration of the non-selective opioid receptor 
antagonist naloxone. It inhibits all pharmacological effects of opioids, OIRD as well as analgesia. 
It is therefore clinically relevant to develop respiratory stimulants that are without effect on the 
opioid system and reverse OIRD without affecting analgesia.3  Known respiratory stimulants 
that do not interact with the opioid system include CO2, caffeine, aminophylline, atropine, 
doxapram, almitrine, the experimental drug GAL021 and AMPAkines.8,9 These respiratory 
stimulants stimulate ventilation through non-opioidergic receptor systems. For example, 
ampakines stimulate AMPA receptors in the brainstem respiratory centers10-12; almitrine, 
Figure 1. Schematic representation of the ventilatory control system. It demonstrates ventilation is regulated by 
peripheral and central chemoreceptors, lungs and higher brain area centers that project into respiratory centres 
in the brain stem, which regulate the diaphragm and other respiratory muscles. 
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doxapram and GAL021 inhibit background potassium channels expressed on type 1 cells of the 
carotid bodies (these agents mimic the effect of hypoxia).3,13-15 The effect of all of these agents is 
highly dependent on dose and underlying conditions. For example, as discussed in this thesis, 
the effect of doxapram and GAL021 depend on the level of OIRD that requires reversal (Chapter 
2 and 4). The greater the level of OIRD, the less the efficacy of reversal. 
THESIS OUTLINE
The main aim of this thesis is to study the ability to reverse OIRD with respiratory stimulants that 
interact with the carotid bodies. Additionally, the effect of an experimental opioid analgesic on 
OIRD and the ability of naloxone to reverse its respiratory effects was studied. 
In Chapter 2 the effect of the analeptic doxapram on opioid pharmacokinetics (PK) and 
pharmacodynamics (PD) is investigated. This PK-PD/PK-PD study incorporates the effect of 
doxapram on cardiac output in the opioid’s PK-PD model.  
Chapter 3 evaluates the effect of the novel background potassium channel blocker, GAL021, on 
OIRD. Both poikilocapnic and isohypercapnic respiratory studies are performed. Additionally, 
GAL021’s effect on hemodynamic parameters and antinociception is reported. 
In Chapter 4 the results obtained in Chapter 3 are re-analysed using a population PK-PD design.
In Chapter 5 the utility function (UF) for the opioid alfentanil is constructed. 
Chapter 6 evaluates the respiratory effect of an experimental opioid (RM101) and the possible 
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Doxapram is an analeptic drug that induces ventilatory stimulation and increases wakefulness, 
blood pressure and cardiac output (CO).1,2 Early animal studies showed dose-dependent 
respiratory stimulation with increases in minute ventilation and phrenic nerve activity 
that disappeared after bilateral sectioning of the carotid sinus nerves.3,4 Consequently, the 
respiratory effect of doxapram is thought to arise at the carotid bodies (CBs), although a (small) 
central effect at the brainstem cannot be excluded.1,3 Recent work elucidated the molecular 
mechanism of action of doxapram at the CBs. Cotten et al. showed that doxapram inhibits the 
channel function of cloned TWIK-related acid-sensitive potassium channels (TASK1, TASK3 and 
the heterodimer TASK1/TASK3).5 These “background” potassium channels are expressed on type 
1 CB cells,5-7 and are inhibited by low arterial oxygen concentrations, resulting in stimulation of 
breathing.7 Given the similarity in mechanism of action, doxapram is considered a drug that 
mimics the effects of hypoxia at the CB.1 In clinical practice doxapram is used as respiratory 
stimulant in patients with respiratory failure (especially in neonates) and in the perioperative 
setting.1
Several experimental and clinical studies show amelioration of opioid- and anesthesia-induced 
respiratory depression by doxapram.8-11 None of these studies measured cardiac output and 
investigated a possible role for doxapram-induced changes in CO on pharmacokinetics (PK) 
and pharmacodynamics (PD) of the respiratory depressant drugs that require reversal. We 
hypothesize that since doxapram increases CO it may well affect PK (and consequently PD) 
through changes in distribution and elimination clearances of these drugs.12-14 It is further 
important to realize that stimulation of respiration at the level of the carotid bodies has a ceiling 
effect on the relief of respiratory depression, when the respiratory depression is due to an effect 
at the level of the brainstem.15,16 We recently showed this for GAL021, a potassium channel 
blocker that stimulates breathing via the CB but does not increase CO.15,17 While at moderate 
levels of opioid-induced respiratory depression (OIRD; alfentanil plasma concentration 40-80 
ng/mL) GAL021 produced pronounced respiratory stimulation, our model analysis predicted 
that at deeper levels of OIRD (alfentanil concentration > 100 ng/mL) the effect of GAL021 on 
respiration is small. Hence, we hypothesize that at deep levels of OIRD, doxapram will cause 
respiratory stimulation coupled to reduced analgesia, predominantly related to the decrease in 
plasma drug concentration.    
In the current study, we investigated the effect of doxapram and placebo on alfentanil-induced 
antinociception in healthy volunteers. We measured plasma concentrations of alfentanil and 
doxapram, antinociception and cardiac output. We performed a PK-PD analysis of the effect 
of doxapram on cardiac output and linked these results to a PK-PD analysis of the effect of 
alfentanil on antinociception. To get an indication of the effect of doxapram on alfentanil-
induced respiratory depression we measured end-tidal pCO2 at predefined time intervals. 
MATERIALS AND METHODS
METHODS
The study had a randomized, double blind, placebo-controlled crossover design and was 
performed between July and October 2012. The study protocol was approved by the local 
Human Ethics Committee of the Leiden University Medical Center and the Central Committee 
on Research Involving Human Subjects (CCMO, The Hague, The Netherlands). The study was 
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registered in the Dutch trial register under number NTR3500. Before participation, all subjects 
gave written informed consent. The study was performed according to the ethical principles for 
medical research involving human subjects (Declaration of Helsinki).
SUBJECTS
Healthy male volunteers, aged 18-45 years with a body mass index in between 18 and 30 kg/m2, 
participated in this study. Subjects with a history of alcohol or drugs abuse, ECG abnormalities, 
smoking, psychiatric disease or lung disease were excluded from participation. All subjects 
were asked to refrain from any food for the 8 hours prior to the administration of alfentanil.  
STUDY DESIGN
Two intravenous lines were inserted, one for administration of alfentanil (Rapifen, Janssen-Cilag, 
Tilburg, The Netherlands) and one for administration of doxapram (Dopram, Eumedica, Brussel, 
Belgium) or placebo. An arterial line was placed in the radial artery of the non-dominant arm 
to obtain samples for measurements of alfentanil and doxapram PK and to measure cardiac 
output. Throughout the experiment heart function (ECG, heart rate), blood pressure and 
oxygen saturation were measured continuously.
Experiments were performed on two occasions. On one occasion alfentanil was combined with 
doxapram, on the other with placebo. The order of occasions was randomized. Doxapram HCl 
(2 mg/mL) in 5% w/v glucose or placebo (5% w/v glucose) and alfentanil (0.5 mg/mL) were 
administered intravenously according to the following scheme: 
(1) T = 0 min: alfentanil loading dose of 8 µg.kg-1.min-1 for 2 minutes, followed by a maintenance 
dose of 0.6 µg.kg-1.min-1 for 98 minutes (ALF-low). 
(2) T = 30 min: doxapram/placebo loading dose of 40 µg.kg-1.min-1 for 9 minutes, followed by a 
maintenance infusion of 8 µg.kg-1.min-1 for 21 minutes (DOXA-low). 
(3) T = 60 min: doxapram loading dose of 55.5 µg.kg-1.min-1 for 20 minutes, followed by an 
infusion rate of 22 µg.kg-1.min-1 for 52 minutes (DOXA-high). 
(4) T = 100 min: alfentanil loading dose of 8 µg.kg-1.min-1 for 2 minutes, followed by a maintenance 
infusion of 0.9 µg.kg-1.min-1 for 30 minutes (ALF-high). 
(5) T = 132 min: all infusions stopped. 
RANDOMIZATION, ALLOCATION AND BLINDING
A randomization list was computer generated by an independent statistician who delivered 
the list to the pharmacy. The pharmacy prepared the study medication and dispensed one 
alfentanil syringe and one blinded syringe containing either doxapram or placebo on the 
morning of the experiment. Blinding was lifted after data analysis was completed. 
MEASUREMENTS
End-Tidal pCO2. Prior to any drug administration and at t = 55, 95 and 125 min, we measured 
the end-tidal pCO2 of the subjects. To that end subjects breathed through a facemask from 
which the exhaled air was sampled for 3-5 min. The average change in end-tidal pCO2 from 
baseline (ΔPETCO2) was used in the analysis. 
Cardiac output (CO). A FloTrac/Vigileo system (Edwards Lifesciences Corp., Irvine, CA, USA) was 
attached to the arterial line for the beat-to-beat measurement of CO. Minute averages of the CO 
were used in the analysis. 
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Antinociception. Transcutaneous electrical stimuli were applied to the skin overlying the 
right tibial bone at about 10 cm above the malleolus via a computer interfaced constant 
current stimulator, which was locally designed and constructed. The intensity of the noxious 
stimulation was increased from 0 mA in steps of 0.5 mA per 1 s with a pulse duration of 0.2 ms 
at 20 Hz with a cutoff of 128 mA. The subjects were instructed to press a button on a control 
box when they first experienced pain (pain threshold) and when no further increase in stimulus 
intensity was acceptable to them (pain tolerance). After a training period, baseline values were 
obtained in triplicate. The averaged baseline value was used in the data analysis. Pain responses 
were obtained at t = 28, 40, 58, 78, 97, 108, 130, 141, 156, 171, 192 and 215 minutes. 
Alfentanil concentrations in plasma. Arterial blood samples for plasma concentration of 
alfentanil were taken at T = -5 (baseline), 1, 2, 4, 5, 7, 8, 10, 19, 31, 40, 47, 59, 80, 88, 99, 101, 102, 
104, 105, 107, 110, 119, 131, 140, 155, 170 min. Separation of plasma was within 15 min of blood 
sampling after centrifugation for 10 min at 3,500 min-1. Plasma samples were immediately stored 
at -25°C until analysis. Concentrations were determined by capillary gas chromatography, as 
previously described,18,19 with the following minor modifications: internal standard was added 
to 0.5 mL plasma and a Heidolph-mixer was used to extract the organic phase before analysis 
on a HP5890 series 2 gas chromatograph with an operating temperature of the detector at 
325 °C. The residue was dissolved in 150 μL ethanol. The precision and accuracy were < 11 % in 
the quality controls and the concentration range of the standards was 11-355 ng/mL. In case 
of higher concentrations less sample was used and diluted with blank plasma. The correlation 
coefficients were > 0.997.
Doxapram concentrations in plasma. Arterial blood samples for plasma concentrations of 
doxapram were collected in K2EDTA tubes at T = -5 (baseline), 35, 40, 47, 59, 70, 80, 88, 99, 
110, 131, 140, 170 and 190 min. Plasma was analysed using a qualified liquid chromatography 
with tandem mass spectrometry method (LC-MS/MS). Calibration standards, quality controls, 
and incurred plasma samples were prepared by protein precipitation using acetonitrile. After 
centrifugation, the supernatant was used for LC-MS/MS analysis.  All samples were injected 
onto a Waters Atlantis T3 C18 column (4.6 x 50 mm, 3 µm particle), eluted using gradient elution 
with a mobile phase consisting of mobile phase A (0.1% formic acid in water, v/v) and mobile 
phase B (0.1% formic acid in acetonitrile), and detected using an AB/Sciex API-4000 QTrap 
mass spectrometer.  The ions were produced in the positive electrospray ionization mode and 
detected in multiple reaction monitoring mode using transitions at m/z 379.2 to 264.0 for 
doxapram and m/z 260.0 to 116.0 for the internal standard with retention times of 1.40 and 
1.42 min, respectively. The calibration standard concentrations ranged from 2 to 5,000 ng/mL 
with quality controls at 5, 50, and 500 ng/mL. The weighted (1/x) quadratic calibration curves 
were utilized with a lower limit of quantification of 2.0 ng/mL and correlation coefficients of 
greater than 0.999. The method precision (%CV) and accuracy (%RE) met acceptable criteria 
(within 15%) for quality control sample concentrations. 
DATA ANALYSIS
End-tidal pCO2. The change in end-tidal pCO2 relative to baseline was compared between 
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Pharmacokinetic-Pharmacodynamic (PK-PD) analysis. A PK-PD model was constructed 
in which the doxapram PK was linked to CO, which next was linked to alfentanil PK and 
subsequently to pain responses (a PK-PD/PK-PD analysis). The population analyses were 
performed in NONMEM version 7.3.0 (software for nonlinear mixed effects modeling; ICON 
Development Solutions, Hanover, MD). Model selection (e.g., number of PK compartments) was 
based on the minimum objective function value (MOFV; χ² test), standard error of estimates 
and goodness of fit plots. For both PK and PD analysis, the model parameters were assumed to 
be log-normally distributed across the population. Residual error was assumed to have both an 
additive and a relative error for concentrations and only an additive error for cardiac output and 
analgesia. All values in the PK-PD analysis are median ± SE, unless otherwise stated. p-values < 
0.01 were considered significant.
To fully understand the complex relationship between doxapram, alfentanil, CO and 
antinociception, the data were analyzed in multiple steps:
STEP 1. In Step 1 the pharmacokinetics of doxapram were characterized. Multiple compartment 
models were fitted to doxapram plasma concentration data. 
STEP 2. In Step 2 the cardiac output changes induced by doxapram were modeled as follows:
 CO(t) = COB · [1 + 0.5 · (CEDOX(t)/C50DOX)γDOX]    (1)
and CO changes induced by placebo as:
 CO(t) = COB       (2)
where CO(t) is the predicted cardiac output at time t, COB is the baseline cardiac output, CEDOX 
is the effect-site concentration of doxapram, C50DOX is the doxapram concentration causing a 
50% increase in cardiac output and γDOX a shape parameter. To eliminate a possible hysteresis 
between doxapram plasma concentration and CO, an effect compartment was postulated 
that equilibrates with the plasma compartment with a half-life t1/2ke0 (i.e., the blood-effect-site 
equilibration half-life).
STEP 3. In Step 3 the alfentanil PK data were characterized. Multiple compartment models were 
fitted to the data.
STEP 4. In Step 4A the alfentanil PK data were characterized similarly to Step 3, but now with 
separate analyses for the data obtained with versus without concomitant doxapram infusion. 
In Step 4B cardiac output, predicted by the doxapram PK-PD model (Step 2), was incorporated 
in the alfentanil PK model as a time-varying covariate, with the assumption that changes in 
CO might affect the alfentanil elimination and distribution. The covariate was incorporated as 
follows:
 CL(t) = CL0 · (1 + α1 · 0.5 · [CEDOX(t)/C50DOX])    (3)
 Q2(t) = Q20 · (1 + α2 · 0.5 · [CEDOX(t)/C50DOX])    (4)
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 Q3(t) = Q30 · (1 + α3 · 0.5 · [CEDOX(t)/C50DOX])    (5)
 
where CL0, Q20 and Q30 are the alfentanil terminal and inter-compartmental clearances prior to 
any change in cardiac output, αx the covariate coefficient and CEDOX and C50DOX as given in Step 
2. We tested whether α1 = α2 = α3 and whether αx = 0.
STEP 5. In Step 5, a population PK-PD analysis of alfentanil-induced nociception data was 
performed using the alfentanil PK empirical Bayesian estimates (EBE’s) derived from Step 4B:
 S(t) = SB · [1 + 0.5 · (CEALF(t)/C50ALF)]      (6)
where S(t) is the predicted current at time t, SB the baseline pain threshold or tolerance, CEALF 
the effect-site concentration of alfentanil and C50ALF is the alfentanil concentration causing a 
50% increase in current causing pain threshold or tolerance. To eliminate a possible hysteresis 
between alfentanil plasma concentration and pain response, an effect compartment was 
postulated that equilibrates with the plasma compartment with a half-life t1/2ke0 (i.e., the 
blood-effect-site equilibration half-life). Pain threshold and tolerance data were analyzed 
simultaneously. 
SIMULATIONS
Finally, to get an indication of the clinical implications of the effect of doxapram on alfentanil-
induced analgesia, we simulated the doxapram-analgesia relationship for doxapram 
concentrations up to 10,000 ng/mL at an arbitrary constant effect-site concentration of 
alfentanil.
Estimate ± SEE  ω2 ± SEE
Doxapram PK parameters estimates (step 1)
V1 9.0 ± 0.9 0.10 ± 0.05
V2 32.5 ± 2.1           -
CL (L/min) 0.36 ± 0.02 0.02 ± 0.03
Q (L/min) 1.0 ± 0.17 0.29 ± 0.14
PK-PD analysis: doxapram  CO (step 2)
COB 7.8 ± 0.3 0.02 ± 0.008
C50DOX (ng/mL) 5,200 ± 1,720 670 ± 610
t1/2keO (min) 3.2 ± 2.0          -
γDOX 1 (fix)          -
Table 1. Doxapram pharmacokinetic and pharmodynamic parameter estmates
PK; pharmacokinetic, PD; pharmacodynamic, V1 and V2; the volumes of  compartments 1 and 2, CL; clearance 
from compartment V1, Q; clearance from compartment V2, CO; cardiac output, COB; baseline cardiac output, 
C50DOX; doxapram effect-site concentration causing a 50% increase in cardiac output and t1/2keO; blood-effect-
site equilibration half-life and γ; shape parameters. 
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RESULTS
The data of nine subjects are included in the analyses. Two subjects decided not to participate 
after completing the first visit due to nausea and vomiting in one subject and excessive 
sedation in the other. Their data were discarded and two new subjects replaced them. The 
mean (range) age of the study population was 24.1 (20-27) years old, mean weight 85.4 (72-96) 
kg and mean BMI 25.7 (22-30) kg/m2. In Figure 1 the mean PK and PD data are given. During 
doxapram infusions, the alfentanil plasma concentrations (Cp) were lower than during placebo 
infusions (Fig. 1): 116 ± 9 ng/mL (low dose doxapram) vs. 133 ± 12 ng/mL (placebo) and 120 ± 
11 ng/mL (high dose doxapram) vs. 162 ± 16 ng/mL (placebo). Mean CO (± SD) was 7.6 ± 1.5 
L/min during placebo administration, which increased to 9.2 ± 2.1 L/min and 11.1 ± 2.1 L/min 
during low- and high-dose dose doxapram infusion, respectively (Fig. 1). In both doxapram 
and placebo experiments the CO data were noisy in some subjects. However, since the noise 
occurred randomly (Figs. 1 and 2) we do not believe that this affected our study significantly.
Baseline end-tidal pCO2 values were 38.2 ± 2.7 mmHg (mean ± SD) and 37.1 ± 3.1 mmHg on 
doxapram and placebo days, respectively. Doxapram had a respiratory stimulatory effect with 
reduced increases in end-tidal pCO2 during alfentanil infusion (linear mixed effects model p 
= 0.017). End-tidal pCO2 increases relative to baseline (ΔPETCO2) were at t = 55 min (ALF-low/
DOXA-low): 7.0 ± 4.0 (placebo) and 4.3 ± 4.2 mmHg (doxapram, p > 0.05 vs. placebo); at 95 min 
(ALF-low/DOXA-high): 7.9 ± 5.7 mmHg (placebo) and 3.9 ± 5.3 mmHg (doxapram, p = 0.02); at 
Figure 1. A. Alfentanil concentrations during placebo and doxapram treatment. B. Doxapram plasma 
concentrations. C. Cardiac output during placebo and doxapram treatment. Each symbols is a 1-min average. 
D. Pain tolerance data during placebo and doxapram treatment. All data are mean values ± 95% confidence 
interval. Doxapram treatment is depicted by the closed symbols, placebo treatment by the open symbols.
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t = 125 min (ALF-high/DOXA-high): 6.7 ± 4.8 mmHg (placebo) and 3.8 ± 4.8 mmHg (doxapram; 
p = 0.04). 
PHARMACOKINETIC-PHARMACODYNAMIC ANALYSES
Steps 1 and 2 (PK-PD modeling of the effect of doxapram on cardiac output). The doxapram 
pharmacokinetic data were best described by a two-compartmental model. Pharmacokinetic 
and pharmacodynamic parameter estimates are given in Table 1. Inspection of the data shows 
that the models adequately describe the data. PK and PD data fits are given in Figure 2 (panels 
A-F, with corresponding R2 values); goodness of fit plots in Figure 3 (A-D) showing absence 
of systematic errors for both PK and PD data. Doxapram increased CO by 50% at an effect-
Figure 2. Pharmacokinetic (PK) and pharmacodynamic (PD) data fits. The data fits are from subjects 105, 
107 and 108 and are all from alfentanil/doxapram experiments. The choice of the 3 subjects was based on the 
goodness of fit of the analgesia data fits. A-C: Doxapram PK fits; D-F: Cardiac output fits; G-I: Alfentanil PK 
fits; J-L: Best, median and worst analgesia fits (pain tolerance closed symbols, pain threshold open symbols). 
Goodness of fit was based on the coefficient of determination (R2). In each individual participant, pain tolerance 
and pain threshold were fitted simultaneously resulting in one R2 value.
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site concentration of 5,200 ± 1,720 (estimate ± SEE) ng/mL; the hysteresis between plasma 
concentration and effect (t1/2keO) was 3.2 ± 2.0 min. 
Steps 3 and 4 (alfentanil PK modeling). The alfentanil PK data were best described by a three-
compartment model (data not show; MOFV 2956.575). Since a bivariate covariate (placebo/
doxapram) significantly explained a large part of inter-occasion variability we compared 
alfentanil’s PK under placebo and doxapram conditions. During doxapram treatment the 
alfentanil clearance (CL) was 30% higher than during placebo treatment (data not shown). 
We next constructed a model incorporating CO as a time-varying covariate on the elimination 
clearance CL and intercompartmental clearances Q2 and Q3, with covariate coefficients αX 
(eqns. 3-5; Step 4B). Coefficients α were equal, i.e. α1 = α2 = α3, with a value > 0. Pharmacokinetic 
parameter estimates of Step 4B are given in Table 2. Best, median and worst data PK fits are 
given in Figure 2, panels G-I. Goodness of fit plots in Figure 3, panels E and F, showing that the 
data were well described by the model of Step 4B. The MOFV of the model was 2865.769. 
Step 5 (final PK-PD model). The final PK-PD model using the PK EBE’s of Step 4 described the 
data adequately with a MOFV of 1534.60 vs.1541.045 for a model with EBE’s from an alfentanil 
PK model without the incorporation for CO as covariate (Step 3). Best, median and worst PD 
data fits are given in Figure 2, panels J-L; goodness of fit plots are given in Figure 3, panels G and 
H. Alfentanil’s C50 was 79.1 ± 27.6 ng/mL and t1/2keO 13.3 ± 2.7 min.
Simulations. Results of the simulation is given in Figure 4, showing the non-linear decrease in 
analgesia with increasing effect-site concentrations of doxapram. At doxapram’s C50 analgesia 
was reduced by 34%.
Estimate ± SEE ω2 ± SEE v2 ± SEE
Alfentanil PK parameters estimates (Step 4B)
V1 (L) 4.9 ± 0.6 0.05 ± 0.04 0.07 ± 0.03
V2 (L) 8.7 ± 1.2           -           -
V3 (L) 16.9 ± 1.6  0.03 ± 0.02           -
CL (L/min) 0.31 ± 0.03 0.07 ± 0.03 0.02 ± 0.008
Q2 (L/min) 1.2 ± 0.09           - 0.10 ± 0.05
Q3 (l/min) 0.32 ± 0.10 0.20 ± 0.07           -
α 1.05 ± 0.21
PD analysis: alfentanil  pain tolerance (Step 5)
SB THR (mA) 8.4 ± 1.2 0.09 ± 0.04 0.04 ± 0.03
SB TOL (mA) 13.5 ± 0.9 0.02 ± 0.02 0.02 ± 0.01
C50ALF (ng/mL) 79.1 ± 27.6 1.01 ± 0.44 0.13 ± 0.20
t1/2keO (min) 13.3 ± 2.7           - 0.24 ± 0.18
Table 2. Alfentanil pharmacokinetic and pharmacodynamic parameters estimates.
PK; pharmacokinetic, PD; pharmacodynamic, V1, V2 and V3; volumes of compartments 1, 2 and 3, CL; clearance 
from compartment V1, Q2 and Q3; clearance from compartment V2 and V3, α; covariate coefficient (Eqs. 3-5), SB; 
baseline response for pain threshold (THR) and pain tolerance (TOL), C50ALF; alfentanil effect-site concentration 
causing a 50% increase in pain response and t1/2keO; blood-effect site equilibration half-life.
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Figure 3. Goodness of fit plots: doxapram pharmacokinetic (PK) analysis (A and B), cardiac output (C and 
D), alfentanil pharmacokinetics (E and F) and analgesia (G and H). A, C, E and G: measured versus individual 
predicted values. B, D, F and H: individual weighted (IWRES) residuals versus time.
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DISCUSSION
In this placebo-controlled study in healthy male volunteers, we investigated the effect of 
doxapram on alfentanil Cp, alfentanil-induced ventilatory depression and antinociception. 
Compared to placebo treatment, alfentanil Cp was reduced by 14% and 26% during low- 
and high-dose doxapram infusion, respectively. High-dose doxapram caused a reduction 
in antinociception by 25%. Our PK-PD analyses indicate that (1) the reduction in alfentanil 
concentration is well explained by the doxapram-induced increase in CO; the increased CO 
was associated with increased intercompartmental and elimination clearances, and (2) the 
reduction in alfentanil Cp explained the reduction in antinociception (see Fig. 5 for the full PK-
PD/PK-PD model). Finally, a modest reduction of respiratory depression was observed during 
high-dose doxapram infusion with reduced increase in end-tidal pCO2 by 3-4 mmHg compared 
to placebo. 
DOXAPRAM'S EFFECT ON CARDIAC OUTPUT
During alfentanil administration, doxapram increased CO by 21% and 46% during low- and 
high-dose doxapram infusion, respectively. Since no systematic changes in CO were observed 
during the combination of placebo and alfentanil infusion (Fig. 1), an effect of alfentanil on CO 
seems of limited importance in our study. The mechanism through which doxapram influences 
CO remains unknown. One possibility is an effect of doxapram at its primary target site. i.e. 
the CBs. Activated peripheral chemoreceptors of the CBs drive sympathetic outflow, causing a 
systemic pressure response.20 In hypertensive patients there is proof for enhanced pressure and 
ventilatory responses to hypoxia, while peripheral chemoreflex inhibition (by hyperoxia, CB 
ablation or denervation) reduces peripheral vascular resistance (see Paton et al. and references 
cited therein). It may therefore well be that during infusion of doxapram, the enhanced afferent 
input from the CBs to the brainstem produced an increased sympathetic outflow via activation 
of brainstem pressure centers (located in the rostral ventrolateral medulla and nucleus tractus 
solitarius) and consequently increases CO.21 Further studies are needed to understand why 
activation of the CBs by doxapram results in a systemic pressure response while activation by 
GAL021 does not.17
EFFECT OF INCREASED CARDIAC OUTPUT ON ALFENTANIL PK AND ANTINOCICEPTION
A doxapram-induced difference in opioid pharmacokinetic profile (Fig. 1A) has not been 
studied before. So far, doxapram-provoked improvement of symptoms of respiratory failure 
Figure 4. Simulation of the relationship 
between doxapram effect-site 
concentration (x-axis) and alfentanil-
induced analgesia at a fixed alfentanil 
effect-site concentration (y-axis). The 




has been exclusively attributed to doxapram’s stimulatory effects at the level of the CBs. We 
showed an effect of doxapram on alfentanil Cp explaining part of doxapram’s PD. Although 
we cannot exclude a pharmacokinetic interaction (alfentanil metabolizing CYP3A4 or CYP3A5 
enzyme induction by doxapram), we explored whether the difference in CO is the main 
causative factor for the difference in alfentanil Cp between placebo and doxapram study days. 
Data from the literature indicate that alfentanil’s distribution and elimination kinetics are CO 
dependent.12,13 Henthorn et al.12 showed in seven healthy volunteers that the tissue distribution 
of alfentanil (as measured by the intercompartmental clearances) was significantly correlated 
to CO. In halothane anesthetized pigs, Kuipers et al.13 studied alfentanil PK during increases 
and decreases in CO by administration of either propranolol or dobutamine. They observed 
that changes in CO caused corresponding changes in distribution and elimination clearances. 
Both studies are in close agreement with our findings. In Step 4B of the analyses we showed 
that incorporating the effect-site doxapram concentration (Eqns. 3-5) significantly improved 
the alfentanil PK data fits. Since doxapram increased CO (Eqn.1), the increase in CO in fact 
explains the reduction in alfentanil PK and consequently the reduction in alfentanil-induced 
antinociception (Figs. 4 and 5). Most probably, the reduced alfentanil Cp is due to increased 
tissue uptake (related to the increase in Q2 and Q3) and liver elimination (CL). We need to realize 
that alfentanil is a drug with a low to moderate liver extraction (the elimination clearance of 
alfentanil is small relative to the hepatic blood flow),13 with consequently a modest effect of CO 
on PK (14-26% reduction in Cp). Drugs with a higher hepatic extraction such as propofol may 
Figure 5. The final PK-PD/PK-PD model. The top panel is the 2-compartment doxapram PK (pharmacokinetic  
model, which is linked via an effect-compartment to cardiac output. The bottom panel is the three-
compartment alfentanil PK model, which is linked via an effect-compartment to analgesia. Doxapram’s effect-
site concentration (via its effect on cardiac output) increased the alfentanil clearances (CL, Q2 and Q3), causing 
a reduced alfentanil concentration in the effect-site and consequently a reduction of analgesia. VX is the volume 
of compartment x (x = 1, 2 or 3), CL the clearance from compartment 1, Q2 and Q3 are the intercompartmental 
clearances, ke0 is the rate constant clearing drug out of the effect-site (with half-life t1/2ke0).
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show a greater effect on Cp by changes in CO.22
DOXAPRAM’S EFFECT ON RESPIRATION DURING HIGH-DOSE OPIOID INFUSION
Relative to placebo, we observed at high doxapram infusion a small but significant reduction in 
ΔPETCO2. Taking into account previous data, this small effect is fully explained by the reduction 
in alfentanil Cp.17 This suggests that in our study doxapram’s stimulatory effect on respiration 
via the CBs was negligible. Possibly at higher doxapram concentrations some stimulatory effect 
would have occurred. The current doxapram dose was 75% of the maximal recommended dose 
as specified by the manufacturer (see the summary of product characteristics). We opted not 
to give the maximum dose to minimize the occurrence of side effects. As stated earlier, the 
absence of a stimulatory effect of doxapram on ventilation may be related to a ceiling effect. In 
comparison to previous studies,15,17 we used a relatively higher alfentanil-dosing scheme with 
maximum plasma concentrations of about 200 ng/mL. Our current data suggest that the CB 
stimulation by doxapram was unable to overcome the opioid-induced inhibition of brainstem 
rhythmic breathing activity. Our previous analyses suggest that more intense CB stimulation by 
applying higher doses of doxapram would have had only limited effect.15
CONCLUSIONS
In a population of healthy male volunteers, doxapram decreased alfentanil plasma 
concentrations with concomitant reduced alfentanil analgesia and respiratory depression. 
Pharmacokinetic modeling showed that the reduced plasma concentrations were related to 
an increase in distribution and elimination clearances that could be explained by a doxapram-
induced increase in cardiac output. The reduction of respiratory depression was fully explained 
by reduced alfentanil plasma concentrations. The absence of carotid body-mediated ventilatory 
stimulation is probably related to reduced doxapram efficacy at deeper levels of respiratory 
depression. A general observation that can be made from our study is that higher opioid doses 
may be needed to obtain similar levels of analgesia when cardiac output increases, especially 
when opioids are given with moderate to high hepatic extraction.
Finally, in this experimental mechanistic study physiological influences on the PK and PD of a 
potent opioid with rapid onset/offset of effect and low clinical margin of safety were studied. 
We show that a PK-PD model for doxapram effectively drives the PK-PD model of alfentanil. 
Although in real life such combinations are probably less likely to occur, there are various drugs 
that are used more frequently in clinical practice that influence cardiac output and consequently 
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Opioids are the cornerstone of treatment of moderate to severe acute and chronic pain. 
Opioids, however, come with serious side effects, of which respiratory depression is potentially 
lethal.1 In the perioperative setting the estimated incidence of opioid-induced respiratory 
depression (OIRD) is 0.5 to 2%.1 In chronic pain patients the incidence of OIRD is unknown.2 
Recent  publications stress the fact that the number of fatalities from legally prescribed opioids 
for treatment of chronic pain are high.2,3 This is predominantly attributed to an increased 
awareness of clinicians to diagnose and treat chronic pain and the apparent ease at which 
legally prescribed opioids change hands.3 Taken the presented data, both in perioperative 
medicine and in the treatment of chronic pain the elimination of opioid-induced respiratory 
complications is important. Not only will it reduce morbidity and mortality but it will possibly 
result in improved pain treatment with less suffering from inadequate pain relief which often 
occurs due to the fear of opioid-induced respiratory depression. 
Current clinical practice is to treat OIRD with the opioid antagonist naloxone, which, however, 
reverses OIRD as well as analgesia, and comes with other sometimes deleterious side effects.1,4 
A potent respiratory stimulant that effectively counteracts OIRD without any interaction with 
the opioid receptor system is lacking.1 Various experimental drugs that enhance respiration 
are currently under investigation including serotonin-agonists, ampakines, phosphodiesterase 
inhibitors and potassium-channel blockers.1,5 In the current study we investigated the efficacy 
of a new agent, GAL021 (Fig. 1), which inhibits calcium-activated potassium channels at the 
carotid bodies (ie. large conductance Ca2+/voltage-activated K+-channels, BKCa-channels, 
formerly known as Maxi-K-channels).6 In rodents and monkeys, GAL021 dose-dependently 
increased ventilatory drive and antagonizes opioid (morphine/fentanyl)- and non-opioid 
(midazolam, isoflurane/propofol)-induced respiratory depression.7-9
We performed two studies to assess the effect of GAL021 on respiratory and non-respiratory 
end-points. The first study was a randomized-controlled trial that was designed as a first-in-class 
study to confirm the effects of GAL021 on established (opioid-induced) respiratory depression 
under isohypercapnic conditions. The main aim of the study was to assess whether the results 
confirm the mechanism of action of GAL021 in humans under conditions of a depressed 
ventilatory control system. To further explore the properties of GAL021 we performed an 
exploratory or learn study to assess the effects of GAL021 on ventilation under non-clamped 
conditions and on non-respiratory variables (hemodynamics, antinociception, sedation, 
adverse events). Our main hypothesis is that GAL021, given on top of established opioid-
induced respiratory depression, is able to stimulate breathing without major effects on non-
respiratory end-points.  
Figure 1. The chemical structure of GAL021 dihydrosulphate.
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MATERIALS AND METHODS
Both studies (the proof-of-concept study (Study 1) and learn-study (Study 2)) had a randomized, 
double blind, placebo-controlled crossover design. The protocol was performed after approval 
was obtained from the Medical Ethics Committee of the Biomedical Research Ethics Review 
Foundation (BEBO, Assen, The Netherlands) and the Central Committee on Research Involving 
Human Subjects (CCMO, The Hague, The Netherlands) and was registered at www.trialregister.
nl under number NTR3718. The studies were conducted from October 31, 2012 to February 11, 
2013. An a priori power analysis was performed for Study 1 and yielded 12 subjects to detect a 
respiratory effect of GAL021 greater than placebo (see Section Sample Size). After completion 
of Study 1, the effect of GAL021 vs. placebo was studied in Study 2 on respiratory and non-
respiratory variables, now against a background of poikilocapnia (ie. the subjects breathed 
room air). Study 2 was designed to study (i) the effect of GAL021 on alfentanil-induced 
respiratory depression under “real life” (ie. non-carbon dioxide clamp) conditions, and (ii) to get 
an impression of the effect of GAL021 on non-respiratory variables, including hemodynamics, 
pain responses and sedation. In this learn-study, the number of subjects was set at 8, considering 
the magnitude of effects observed in Study 1. The protocol allowed expansion of Study 2 to a 
maximum of 36 subjects in case further exploration was required. In Studies 1 and 2 adverse 
events were recorded.
SUBJECTS
Healthy men, aged 18-45 years and body mass index 18-30 kg/m2, were recruited through an 
advertisement on a dedicated website. All subjects gave written and oral informed consent. 
The subjects underwent a full medical screening, including medical history taking, a physical 
examination, blood chemistry and hematology and an electrocardiogram to assess eligibility. 
Participants were healthy with no history of major medical or psychiatric disease, alcohol abuse, 
daily consumption of caffeine greater than 6 servings, smoking in the last year and any other 
investigational drug administered within three months prior to inclusion. Finally, participants 
had to fast for at least 6 hours prior to the administration of study drug.
STUDY DESIGN
Upon arrival in the laboratory all subjects received two intravenous access lines, one for 
administration of alfentanil and another for administration of GAL021 (Galleon Pharmaceuticals 
Corp., Horsham, PA, USA) or placebo (NaCl 0.9%). An arterial line was placed in the radial artery 
of the non-dominant arm for alfentanil blood sampling in Studies 1 and 2 (see Appendix 1), 
and measurement of blood pressure, cardiac output and arterial pCO2 in Study 2. For safety 
monitoring, the ECG, blood pressure, heart rate and oxygen saturation were measured 
continuously.
Drugs. GAL-021 was prepared as a sterile product ready for dilution (colorless, pH 3.1).  GAL-
021 and placebo (normal saline) were diluted in Ringer lactate (final volume ≈ 250 ml) and 
administrated intravenously by infusion pump. 
Alfentanil and GAL021 infusions in Studies 1 and 2. A stepped drug infusion regimen was 
applied as depicted in Figure 2. First, alfentanil was administered intravenously: a loading 
infusion of 1.33 µg.kg-1.min-1 for 6 min, followed by a subsequent maintenance infusion of 0.3 
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µg.kg-1.min-1 given over 104 min, in order to achieve a 25-30% decrease in minute ventilation 
(ALF-low). If this level of respiratory depression was not reached during the first infusion, a 
second dose of 1.33 µg.kg-1.min-1 was administered and the maintenance infusion was 
increased to 0.6  µg.kg-1.min-1; in case of an overshoot in respiratory depression during the 
loading infusion, the maintenance infusion was halved. After 30 min of steady-state ventilation, 
a concurrent intravenous infusion of GAL021 or placebo was started (GAL-low): a loading 
infusion of 33.3 µg.kg-1.min-1 for 10 min, followed by a maintenance infusion of 6.67 µg.kg-1.min-
1 for 20 min (total infusion time of GAL-low 30 min). Next, the GAL021 infusion was increased 
(GAL-high) with a loading infusion of 33.3 µg.kg-1.min-1 for 20 min, followed by a maintenance 
infusion of 18.3 µg.kg-1.min-1 for 60 min (total infusion time of GAL-high 80 min). During the 
final thirty minutes of the GAL-high infusion, the infusion rate of alfentanil was increased (ALF-
high) with a repeat loading as given in ALF-low (in case no adjustments were made this was 
1.33 µg.kg-1.min-1 for 6 min), followed by a maintenance dose twice that of ALF-low (in case no 
adjustments were made the maintenance infusion was 0.6 µg.kg-1.min-1 given over 24 min). The 
target reduction in ventilation at ALF-high was 50-60%. Hereafter, both alfentanil and GAL021/
placebo infusions were ended.
Figure 2. Schematic representation of the design of Studies 1 and 2. The blue line is the infusion rate of alfentanil. 
In Study1, the infusion could be adapted depending on magnitude of the ventilatory (a doubling of loading 
and maintenance dose in case the target of respiratory depression (25-30%,) was not attained; a reduction of 
the maintenance dose by 50% in case of an overshoot in respiratory depression). The orange line is the infusion 
rate of GAL021 or placebo. In Study 1, respiration was measured under isohypercapnic conditions; in Study 2 
poikilocapnic ventilatory and non-ventilatory variables were obtained. B represents baseline (no drug, no added 
inspired carbon dioxide), C represents the carbon dioxide clamp prior to any drug infusion, P1 represents low-
dose alfentanil infusion prior to GAL021 or placebo infusion (ALF-low), P2 the combination of low-dose alfentanil 
and low-dose GAL021 or placebo (ALF-low + GAL021-low), P3 the combination of low-dose alfentanil with high 
dose GAL021 or placebo (ALF-low + GAL021-high) and P4 the combination of high-dose alfentanil with high 
dose GAL021 or placebo (ALF-high + GAL021-high). Alfentanil and GAL021 infusion rate  are in µg.kg-1.min-1.
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Inhaled gas concentrations and ventilation measurements. During (breath-to-
breath) ventilation measurement the subjects breathed through a facemask connected 
to a pneumotachograph system (#4813, Hans Rudolph, Shawnee, KS). The signal from the 
pneumotachograph was integrated to yield a volume signal. The inspired and expired oxygen 
and carbon dioxide partial pressures (pO2 and pCO2) were measured at the mouth with a 
capnograph (Datex Capnomac, Helsinki, Finland). 
In Study 1, ventilation was measured at the background of isohypercapnia. To that end, varying 
concentrations of inhaled oxygen, carbon dioxide and nitrogen were delivered to the subjects 
via three computer-controlled mass flow controllers (Bronkhorst, Veenendaal, The Netherlands) 
ensuring the strict control of the end-tidal pO2 and pCO2 independent of the ventilatory 
response. See Refs.10,11 for an elaborate explanation of the dynamic end-tidal forcing technique. 
The elevated end-tidal pCO2 was such that the target pre-drug clamped minute ventilation was 
between 20 ± 2 L/min. The inspired oxygen concentration was also manipulated to keep the 
end-tidal pO2 in the normoxic range (110 mmHg) throughout the study. In Study 2, the subjects 
breathed room air without any additional inspired carbon dioxide.
Study episodes. For analyses purposes 4 time points are defined in Study 1 and 4 in Study 2 
(see also Fig. 2): 
Study 1: Period C is defined as the 10-min period prior to any drug infusion but with carbon 
dioxide clamp, P1 is the 10-min period during low dose alfentanil infusion prior to any GAL021 
or placebo infusion (ALF-low), P2 is the 10-min period where low dose alfentanil is combined 
with low dose GAL021 or placebo infusion (ALF-low + GAL-low), P3 is the 10-min period where 
low-dose alfentanil is combined with a high dose GAL021 or placebo infusion (ALF-low + GAL-
high) and P4 is the 10-min period where high-dose alfentanil is combined high dose GAL021 or 
placebo (ALF-high + GAL-high).
Study 2: Period B is the 10-min period prior to any drug infusion. P1 to P4 are defined as in Study 
1. No carbon dioxide clamp was applied in Study 2. 
Design of Study 1. When ventilation had reached a steady state at the elevated end-tidal pCO2, 
alfentanil infusion was started (see Section Alfentanil and GAL021 Infusions above). For analyses 
purposes, 10-min averages of inspired minute ventilation, tidal volume, respiratory rate, end-
tidal pCO2 and oxygen saturation were obtained at periods C, P1 to P4 (Fig. 2). Each subject 
participated twice in Study 1, once receiving alfentanil and GAL021, once receiving alfentanil 
and placebo. The washout-period between sessions was at least one week. 
Design of Study 2. Eight subjects who previously participated in Study 1 were included in 
Study 2. Selection of the subjects was based on their availability and unrelated to the respiratory 
responses in Study 1. Subjects in Study 2 were tested twice, once receiving alfentanil and 
GAL021, once receiving alfentanil and placebo, with at least 1 week between sessions. In this 
study, the infusion schemes of alfentanil and GAL021/placebo were similar to that of Study 
1. The subjects breathed room air throughout the study. The following procedures were 
performed to collect data at regular intervals (at B, P1 to P4; see Fig. 2): 




(b) Hereafter a blood sample was obtained for blood gas analysis. Here we report on the arterial 
pCO2. The sample was analyzed with an I-Stat 1 system (Abbott Point of Care, Abbott Park, IL) 
using CG8+ cartridges. 
(c) Next, alfentanil-induced antinociception was measured using an electrical pain model. Two 
electrodes were placed on the skin over the shinbone of the right leg.12 An electrical stimulus 
train was generated by a computer-interfaced current stimulator (Leiden University Medical 
Center, Leiden, The Netherlands). After starting the stimulator the current increased from 0 by 
0.5 mA.s-1 and the subject indicated, by pressing a button on the control panel, when pain was 
first observed (pain detection threshold) and by pressing another button when he could not 
tolerate the pain any further (pain tolerance). This ended the stimulus train. If a muscle response 
was triggered during this procedure, the electrodes were relocated until no further response 
was observed. This procedure was practiced at the beginning of the experimental session. Four 
baseline values were obtained prior to any drug infusion. These values were averaged and 
served as pre-drug control values. Here we present the pain threshold data. 
(d) Just before respiratory measurements, the subjects were queried about the magnitude of 
sedation by means of a visual rating scale from 1 to 100 mm where 1 equals no sedation and 
100 mm equals maximum sedation.12
(e) Throughout part 2 of the study the mean arterial pressure and cardiac output were measured 
using the FloTracTM/VigileoTM system (Edwards Lifsesciences Corp., Irvine, CA, USA) connected to 
the arterial line. Minute averages were obtained from the device.
(f ) Heart rate (Datex, Cardiocap) and oxygen saturation (Masimo SET pulse oximeter, Irvine, CA, 
USA) were collected throughout the study.
RANDOMIZATION AND ALLOCATION
This was a double-blind study. Randomization was performed by a study-independent 
statistician according to a computer-generated non-restricted randomization schedule and 
shared with the local pharmacy. Subjects were allocated in a 1:1 ratio. The pharmacy prepared 
the study drugs and dispensed them into identical syringes marked solely with the subject and 
visit number. The drugs were delivered to the research team on the morning of the experiment. 
The pharmacy further delivered alfentanil syringes in a solution of 0.5 mg/mL. Unblinding of 
the study was performed after data closure. 
SAMPLE SIZE
Sample size determination was performed for minute ventilation at P3 and P4 and was based on 
data from a previous study that showed that changes in minute ventilation (over a 10-minute 
assessment period) had an intra-subject variance ranging from 6 to 9%.13 Sample sizes of 8 
and 12 yielded respectively 80% and 90% power to observe a statistically significant within-
cohort difference (α = 0.05, 1-sided). The sample size was set at 12 subjects for Study 1. In case 
of discontinuation, the subject was replaced by another and both experimental sessions were 
performed. The sample size of part 2 of the study was set arbitrarily at 8. 
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STATISTICAL ANALYSIS
The evaluable population consisted of all subjects who completed both crossover periods in 
both studies. Data are presented as mean (95% confidence interval) and point estimates of the 
difference between treatments (95% confidence interval). To get an indication of the ability of 
GAL021 to increase ventilation relative to placebo, the data of Study 1 were analyzed with a 
mixed model analysis of covariance with treatment segment, and treatment × segment as fixed 
factors and subject, subject × treatment and subject × segment as random factors and the 
value at segment P1 (ALF-low) as covariate. Analysis was performed for segments P2, P3 and P4 
separately, with p < 0.01 considered significant (SAS, SAS Institute Inc., Cary, NC).
RESULTS
Study 1. Three subjects withdrew consent after completing one single experimental session 
for reasons of discomfort. Data of these three were not included in the analysis; three new 
subjects were enrolled and completed the study. Twelve subjects completed both experimental 
sessions. Median (range) age of the subjects was 21.5 (19-31) years, median weight 72.3 (62.9-
84.3) kg and body mass index 22.3 (20.2-26.5) kg.m-2. All subjects completed the study without 
major side effects (see paragraph Adverse Events). 
On average, carbon dioxide was clamped at 48.8 (SD 0.2) mmHg and 49.2 (SD 0.04) mmHg 
in placebo and GAL021 experiments, respectively. Ventilation levels reached at Period C were 
20.8 (19.4-22.3) L/min (placebo) and 19.8 (19.3-20.4) L/min (GAL021; Table 1). Three subjects 
required an additional loading infusion of alfentanil because of a limited effect of the initial 
loading infusion on ventilation as specified in the protocol. Six subjects received a reduced 
maintenance infusion because of an initial overshoot in ventilatory depression. The effects 
of alfentanil, GAL021 and placebo on ventilation, tidal volume, respiratory rate and oxygen 
saturation are given in Table 1. Most importantly, a separation between GAL021 and placebo on 
minute ventilation was observed at P3 (ALF-low + GAL-high) and P4 (ALF-high + GAL-high) by 
6.1 (3.6-8.6) L/min and 3.6 (1.5-5.7) L/min, respectively (both p < 0.01 vs. placebo, Fig. 3A). The 
Figure 3. Results of Study 1: Effect of GAL021 vs. placebo on minute ventilation (A), tidal volume (B) and 
respiratory rate (C). B represents baseline (no drug, no added inspired carbon dioxide), C represents the carbon 
dioxide clamp prior to any drug infusion, P1 represents low-dose alfentanil infusion prior to any GAL021 or 
placebo infusion (carbon dioxide-clamp + ALF-low), P2 the combination of low-dose alfentanil and low-dose 
GAL021 or placebo (carbon dioxide-clamp + ALF-low + GAL021-low), P3 the combination of low-dose alfentanil 
with high dose GAL021 or placebo (carbon dioxide-clamp + ALF-low + GAL021-high) and P4 the combination 
of high-dose alfentanil with high dose GAL021 or placebo (carbon dioxide-clamp + ALF-high + GAL021-high). 
Values are mean ± 95% confidence interval. * p < 0.01 vs. placebo.
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effects on minute ventilation were due to effects on tidal volume (at P3, Fig. 3B) and respiratory 
rate (at P3 and P4, Fig. 3C).  No effect of either alfentanil or GAL021/placebo was observed on 
oxygen saturation (Table 1). A scatter plot of the individual ventilation data is given in Figure 4.
Study 2. Eight subjects of Study 1 participated in Study 2 and completed both experimental 
sessions. All subjects completed the study without major side effects (see paragraph Adverse 
Events). Examination of (poikilocapnic) ventilation and arterial pCO2 (Table 2 and Fig. 5) shows 
separation between GAL021 and placebo at P3 and P4 with mean differences in effect estimates 
of 0.6 (0.1-1) L/min and -3.4 (-6.2- -0.6) mmHg at P1 and 1.0 (0.5-1.6) L/min and -1.5 (-3.1 to 
0.1) mmHg at P4, respectively. No treatment differences were observed for plasma alfentanil 
concentrations, blood pressure, cardiac output, pain threshold and sedation (Table 2). A scatter 
plot of the individual ventilation data is given in Figure 4.
Clamp P1 P2 P3 P4
Ventilation (L/min)
Placebo 20.82 (19.4-22.3) 12.63 (11.3-14.0) 12.05 (10.7-13.4) 10.77 (9.4-12.2) 9.32 (8.2-10.5)
GAL021 19.84 (19.3-20.4) 13.31 (12.2-14.4) 14.00 (12.1-15.9) 16.86 (14.1-19.6) 12.94 (10.8-15.1)
Mean difference -0.98 (-2.2 to 0.2) 0.68 (-0.6 to 2.0) 1.95 (0.6-3.3) 6.09 (3.6-8.6)* 3.62 (1.5-5.7)*
Tidal volume (mL)
Placebo 1196 (1116-1275) 823 (760-886) 818 (766-869) 811 (728-894) 812 (719-906)
GAL021 1174 (1095-1252) 851 (792-910) 901 (822-980) 1032 (927-1137) 905 (796-1014)
Mean difference -22 (-83 to 39) 28 (-26 to 82) 83 (21-146) 221 (124-318)* 93 (-13 to 198)
Respiratory rate (min -1)
Placebo 18.2 (16.8-19.6) 15.4 (14.0-16.8) 14.8 (13.4-16.3) 13.6 (12.6-14.5) 12.6 (11.2-13.9)
GAL021 17.7 (16.4-19.0) 16.0 (14.5-17.5) 15.8 (14.0-17.6) 16.5 (14.4-18.7) 14.9 (13.1-16.8)
Mean difference -0.5 (-1.3 to 0.2) 0.6 (-0.3 to 1.5) 1.0 (0.0-1.9) 3.0 (1.2-4.8)* 2.4 (0.7-4.0)*
End-tidal pCO2 (mmHg)
Placebo 48.8 (47.4-50.2) 48.9 (47.6-50.3) 48.9 (47.6-50.3) 49.0 (47.7-50.2) 48.6 (47.3-49.9)
GAL021 49.2 (47.9-50.3) 49.2 (48.0-50.3) 49.2 (47.9-50.4) 49.3 (48.2-50.4) 49.2 (48.0-50.4)
Mean difference 0.4 (-0.8 to 1.6) 0.2 (-1.0 to 1.4) 0.9 (-0.9 to 1.4) 0.3 (-0.8 to 1.5) 0.6 (-0.4 to 1.5)
Oxygen saturation (%)
Placebo 98.6 (97.9-99.3) 97.3 (96.6-98) 97.4 (96.6-98.1) 97.6 (96.4-98.7) 97.3 (96.3-98.3)
GAL021 98.9 (98.4-99.5) 97.5 (96.7-98.3) 97.7 (96.8-98.5) 98.1 (97.3-98.9) 97.0 (96.2-97.9)
Mean difference 0.3 (-0.1 to 0.8) 0.3 (-0.3 to 0.9) 0.3 (-0.3 to 0.9) 0.5 (-0.2 to 1.2) -0.3 (-0.9 to 0.4)
Table 1. Effect of GAL021 on respiratory variable obtained under clamped end-tidal pCO2 conditions (Part 1 of 
the study). Values are mean (95% confidence interval); Mean difference = GAL021 – Placebo. 
* p < 0.01 versus placebo,
Clamp is CO2 clamp prior to any drug infusion (only in part 1 of the study), P1 is low-dose alfentanil infusion prior 
to any GAL021 or placebo infusion (ALF-low), P2 is combination of low-dose alfentanil and low-dose GAL021 
or placebo (ALF-low + GAL021-low), P3 is the combination of low-dose alfentanil with high dose GAL021 or 
placebo (ALF-low + GAL021-high),  P4 is the combination of high-dose alfentanil with high dose GAL021 or 
placebo (ALF-high + GAL021-high).
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Adverse events. Both alfentanil and GAL021 were well tolerated by the subjects and no 
interventions were required. Adverse events occurring in Studies 1 and 2 are given in Table 3. 
Apart from evident opioid-related side effects such as pruritus and nausea, specific differences 
were observed between Studies 1 and 2 (feeling warm/sweating, nausea, headache) and 
between treatments (pain at infusion site). 
DISCUSSION
RESPIRATORY DEPRESSION
Opioid-induced respiratory depression remains an important concern taken its possible 
morbidity and potential fatal consequences. Indeed both in the acute and chronic opioid-use 
settings numerous (near)-fatalities have been reported.1-3 Current clinical practice to reverse 
OIRD is by intravenous or intramuscular injection of the opioid receptor antagonist naloxone. 
While naloxone is an effective reversal agent it comes with disadvantages including reversal of 
analgesia, sympathicoexcitation and risk of renarcotization if not continuously administered 
(due to its short half-life of 15-30 min).4 Furthermore, some opioids are difficult to reverse related 
to their high affinity for the opioid receptor (eg, buprenorphine).13 Hence, there is a need for an 
agent that selectively stimulates breathing without any effect on other physiological systems. 
Such an agent should stimulate respiration without any interaction with the opioid receptor 
system. Various agents have been evaluated to that end, including modulators of potassium 
channels, serotonin receptor agonists, agents that enhance glutamatergic transmission and 
phosphodiesterase inhibitors.1,5 Here we present data on a novel agent, GAL021. Earlier animal 
data demonstrated that GAL021 induces potent ventilatory stimulation during OIRD without 
affecting analgesia. In conscious rats and non-human primates (Cynomolgus monkeys) an 
infusion of GAL021 reversed morphine-induced respiratory depression producing a rapid 
and dose-dependent diminution of the evoked respiratory depression for the duration of the 
infusion.7-9 Termination of GAL021 infusion led to the return of OIRD. Importantly, GAL021 did 
not diminish morphine-induced analgesia in rats as tested by the tail-flick assay.7
Figure 4. A. Scatter plot of the effect of treatment 
on ventilation of Study 1 at baseline (B), clamped 
ventilation (C) and time points P1 (carbon dioxide-
clamp + ALF-low), P2 (carbon dioxide-clamp + ALF-
low + GAL021-low), P3 (carbon dioxide-clamp + ALF-
low + GAL021-high) and P4 (carbon dioxide-clamp + 
ALF-high + GAL021-high). In orange the subjects that 
participated in Studies 1 and 2. B. Scatter plot of the 
effect of treatment on ventilation of Study 2 at baseline 
(B) and time points P1 (carbon dioxide-clamp + ALF-
low), P2 (carbon dioxide-clamp + ALF-low + GAL021-
low), P3 (carbon dioxide-clamp + ALF-low + GAL021-
high) and P4 (carbon dioxide-clamp + ALF-high + 
GAL021-high). In orange the subjects that participated 
in Studies 1 and 2.
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Baseline P1 P2 P3 P4
Ventilaton (L/min)
Placebo 8.15 (7.7 - 8.6) 7.28 (6.6 - 8.0) 7.32 (6.8 - 7.8) 7.28 (6.7 - 7.8) 6.95 (6.3 - 7.6)
GAL021 8.58 (8.1 - 9.1) 7.23 (6.5 - 7.9) 7.74 (7.0 - 8.5) 7.84 (7.4 - 8.3) 7.98 (7.4 - 8.6)
Mean differ-
ence
0.28 (0.1 - 0.8) -0.04 (-0.6 to 0.5) 0.42 (-0.1 to 0.9) 0.56 (0.1 - 1.0) 1.03 (0.5 - 1.6)
Arterial pCO2 (mmHg)
Placebo 43.4 (42.0 - 44.8) 47.4 (44.9 - 49.9) 47.7 (46.2 - 49.3) 48.6 (46.1 - 51.0) 51.7 (48.1 - 55.3)
GAL021 42.6 (40.6 - 44.5) 46.4 (42.3 - 50.5) 46.7 (43.3 - 50.0) 45.3 (41.7 - 48.9) 48.0 (43.1 - 52.9)
Mean differ-
ence
-0.4 (-2.2 to 1.4) -0.9 (-4.3 to 2.5) -1.2 (-3.1 to 0.7) -3.4 (-6.2 to  -0.6) -1.5 (-3.1 to 0.1)
Arterial pO2 (mmHg)
Placebo 95.1 (92.1 - 98.1) 95.8 (91.7 - 99.8) 93.1 (90.3 - 96.0) 88.1 (82.3 - 93.9) 94.0 (87.1 - 100.9)
GAL021 94.7 (90.8 - 98.5) 93.8 (86.6 - 101.0) 94.6 (83.0 - 106.2) 96.0 (88.2 - 103.8) 94.2 (84.3 - 104.1)
Mean differ-
ence
0.0 (-5.3 to 5.3) -1.0 (-7.1 to 5.1) 2.6 (-2.6 to 7.8) 9.2 (0.9 - 17.5) 8.2 (4.1 - 12.3)
Cardiac output (L/min)
Placebo 7.7 (6.5 - 9.0) 6.1 (5.2 - 7.0) 6.0 (4.9 - 7.0) 6.3 (4.5 - 8.0) 6.3 (4.7 - 7.8)
GAL021 7.2 (5.6 - 8.8) 6.0 (4.6 - 7.4) 6.2 (4.4 - 8.1) 6.6 (5.2 - 8.1) 6.8 (5.3 - 8.4)
Mean differ-
ence
1.0 (-1.6 to 3.5) 0.8 (-1.2 to 2.8) 1.2 (-0.7 to 3.1) 1.5 (-0.8 to 3.8) 1.1 (-1.1 to 3.4)
Mean arterial pressure (mmHg)
Placebo 95 (89 - 101) 87 (83 - 91) 86 (83 - 90) 87 (83 - 92) 86 (82 - 90)
GAL021 95 (89 - 101) 86 (78 - 95) 87 (79 - 96) 85 (80 - 90) 83 (76 - 91)
Mean differ-
ence
13 (-16 to 42) 13 (-17 to 42) 14 (-15 to 43) 13 (-17 to 42) 10 (-19 to 39)
Heart rate (min -1)
Placebo 63 (56 - 70) 54 (50 - 58) 53 (48 - 58) 54 (49 - 59) 54 (49 - 58)
GAL021 61 (49 - 73) 53 (46 - 60) 53 (47 - 60) 57 (50 - 63) 61 (58 - 64)
Mean differ-
ence
7 (-12 to 25) 7 (-11 to 26) 8 (-10 to 26) 12 (-4 to 28) 14 (-1 to 29)
Pain threshold (% of baseline)
Placebo 100 113 (101 - 125) 118 (100 - 136) 123 (107 - 139) 140 (114 - 165)
GAL021 100 124 (98 - 150) 131 (108 - 154) 142 (108 - 175) 160 (120 - 201)
Mean differ-
ence
- 11 (-20 to 42) 13 (-14 to 40) 19 (-18 to 55) 21 (-33 to 75)
Sedation VAS (mm)
Placebo 13  (-5 - 32) 66 (46 - 86) 49 (20 - 77) 48 (24 - 71) 63 (42 - 85)
GAL021 11 (-6 - 22) 62 (44 - 80) 47 (25 - 69) 56 (32 - 80) 71 (49 - 92)
Mean differ-
ence
-2 (-5 to 0) -4 (-13 to 6) -2 (-21 to 18) 8 (-2 to 18) 7 (-9.0 to 24)
39
Effect of GAL021 on ventilation
3
Our proof-of-concept study (Study 1) assessed the ability of GAL021 to increase ventilation 
during established alfentanil-induced respiratory depression in a group of healthy male 
volunteers. This study was performed at clamped and elevated end-tidal carbon dioxide levels. 
This was done to quantify ventilatory changes without the confounding stimulatory or inhibitory 
effects of changes in arterial pCO2. Application of this technique allows the assessment of the 
true pharmacological effect of a drug on the ventilatory control system. The observations made 
in Study 1 on carbon dioxide-clamped ventilation are in close agreement with observations 
made in Study 2 on poikilicapnic ventilation and arterial pCO2 (Figs. 5B and C, Table 2). Since 
these two variables are interconnected (an increase in arterial pCO2 stimulates breathing and 
Table 2. Effect of GAL021 on poikilocapnic ventilation, artrial pCO2 and nonrespiratory variables (study 2)
Values are mean (95% confidence interval). Mean difference is GAL021 – Placebo. 
Basline is baseline (no drug, no added inspired CO2), P1 is low-dose alfentanil infusion prior to any GAL021 or 
placebo infusion (ALF-low), P2 is combination of low-dose alfentanil and low-dose GAL021 or placebo (ALF-
low + GAL021-low), P3 is the combination of low-dose alfentanil with high dose GAL021 or placebo (ALF-low 
+ GAL021-high), P4 is the combination of high-dose alfentanil with high dose GAL021 or placebo (ALF-high + 
GAL021-high). 
VAS is visual analogue scale.
Figure 5. Results of Study 2: A. Plasma alfentanil concentrations (CP) B. Poikilocapniac ventilation C. Arterial 
pCO2,. D. Cardiac output E. Sedation F. Antinociception. 
B represents baseline (no drug), P1 represents low-dose alfentanil infusion prior to any GAL021 or placebo 
infusion (ALF-low), P2 the combination of low-dose alfentanil and low-dose GAL021 or placebo (ALF-low + 
GAL021-low), P3 the combination of low-dose alfentanil with high dose GAL021 or placebo (ALF-low + GAL021-
high) and P4 the combination of high-dose alfentanil with high dose GAL021 or placebo (ALF-high + GAL021-




hyperventilation reduces arterial pCO2) their evaluation is best done jointly. Combined these 
variables show that under “real life” conditions, a separation between GAL021 and placebo on 
ventilation, during alfentanil-induced respiratory depression, is observed. The data from Study 
1 indicate that ventilation increases due to changes in tidal volume and respiratory rate.
Rat studies suggest that GAL021 acts mainly through an effect at the carotid bodies. GAL021 
dose-dependently increases carotid sinus activity, while its effects on ventilation were 
diminished upon carotid body denervation.14 The carotid bodies, located at the bifurcation of 
the common carotid artery, contain the peripheral chemoreceptors, which are responsible for 
about 30% of the tonic ventilatory drive and respond to hypoxia with a brisk hyperventilatory 
response.15 Type 1 carotid body cells (which are sensitive to hypoxia) express various potassium 
channels (including BKCa-channels). Upon blockade, BKCa-channels release neurotransmitters 
that activate the sinus nerve and consequently increase respiratory drive.16,17 In Slo-/- mice that 
lack various subunits of the BKCa-channel, the effects of GAL021 were severely diminished (but 
not abolished).18 Jointly these data suggest that GAL021 acts through blockade of the BKCa-
channel of the type 1 carotid body cells but additional mechanisms at the carotid bodies or 
other sites are not excluded.
HEMODYNAMICS
BKCa-channels are expressed in vascular smooth muscles and may play a role in regulating 
cerebral and systemic vascular tone.19 We previously observed that doxapram produces a sharp 
increase in cardiac output before any effect on ventilation was apparent.20 Apart from its effects 
at TASK-channels, doxapram, like GAL021, interacts with the BKCa-channel,21 and this channel 
may be the site of action of the cardiostimulatory effects of doxapram.19 In the current study, 
however, GAL021 was without effects on mean arterial pressure, heart rate and cardiac output. 
This indicates a differential effect of GAL021 and doxapram on the cardiovascular system and 
suggests that the BKCa-channel is not the site of action of the cardiovascular stimulatory effects 
of doxapram. 
ANALGESIA AND SEDATION
Since GAL021 primarily acts via a non-opioid mechanism and the BKCa-channel does not 
seem to be involved in nociceptive pathways, opioid-analgesia should theoretically not be 
compromised. Indeed, both in animal studies and in the current study opioid-analgesia was 


















Incidence in study 1 - Incidence in study 2
Placebo 4 - 3 1 - 1 3 - 1 6 - 1 7 - 1 0 - 0 1 - 0 0 - 0 22 - 7
GAL021 3 - 4 6 - 3 0 - 0 3 - 2 4 - 0  6 - 2 2 - 0 1 - 0 25 - 11
Table 3. Adverse events observed in studies 1 and 2
The first number represents the number of subjects that experience the adverse event in study 1, the second in 
study 2. 
41
Effect of GAL021 on ventilation
3
GAL021 on analgesia. Although the average effect of analgesia during GAL021 infusion was 
higher than during placebo infusion (difference +10-20%, Fig. 4F) further studies using multiple 
pain models are required to assess the true effect of GAL021 on opioid-analgesia. Similarly, 
we found no effect of GAL021 on opioid-induced sedation. This is important as some other 
respiratory stimulants do increase sedation.22 Like analgesia, the absence of effects of GAL021 
on sedation needs additional investigation. 
SAFETY
An important part of our studies was the assessment of the safety of GAL021. In a previous 
study, the safety of GAL021 has been addressed in 30 healthy volunteers without the presence 
of another drug.23 Apart from the observation of a burning sensation at the GAL021 infusion 
site, adverse events were similar between GAL021 and placebo treated subjects. This is in 
agreement with our observation. The observation of injection site pain could be attributed 
to the low pH of the GAL021 infusate (pH ≈ 3.5). We additionally observed perspiration and 
hot flushes in 6 (of 12) subjects receiving GAL021, especially during hypercapnia (Table 3). This 
suggests a sympathetic effect of GAL021 under hypercapnic conditions. Interestingly, some 
adverse events occurred in Study 1 but not Study 2, such as nausea and headache. We attribute 
this to the hypercapnic conditions of Study 1.
DOXAPRAM AND AMPAKINES
Apart from GAL021, various non-opioid respiratory stimulants are clinically available or under 
investigation (reviewed in references 1 and 5). One of the first agents that was developed 
to induced respiratory stimulation is doxapram, available since 1962.24 Doxapram inhibits 
background potassium channels (TASK1, TASK 3, TASK1/TASK3 heterodimer) as well as BKCa-
channels expressed on type 1 carotid body cells.21,25 A recent study in perioperative patients 
showed that a 1 mg/kg bolus dose of doxapram produces modest respiratory stimulation 
following total intravenous anesthesia.26 We recently tested the effect of a continuous infusion 
of doxapram (total dose 2.7 mg/kg given over 94 min) on alfentanil-induced respiratory 
depression (plasma concentration 60-100 ng/mL), using a study design similar to the current 
study.20 We observed no effect on ventilation under both isohypercapnic (i.e. at a clamped 
and elevated end-tidal pCO2) or poikilocapnic conditions at two-thirds of the maximum 
recommended dose. Possibly higher doxapram dosages are required to induce reversal but its 
side effects profile (which includes panic attacks, sympathicoexcitation (causing hypertension 
secondary to elevations of cardiac output), sweating, nausea, convulsions) precluded higher 
infusion rates than used by us. Newly developed TASK-3 antagonists showed an improved 
efficacy profile compared to doxapram in the rat.25 The effect in humans has not been tested 
as yet. 
Alternative respiratory stimulants which include 5HT and dopamine receptor ligands, while 
effective in animals, are without significant effect in humans.1,5  An exception is the ampakine 
CX717.22 A recent study showed that oral CX717 increased the slope of the non-steady-state 
ventilatory response to hypercapnia during alfentanil-induced respiratory depression without 
affecting analgesia in healthy male volunteers (albeit at the expense of enhanced sedation). A 
caveat of that study is the use a non-steady-state approach (rather than a steady-state approach 
as used in this study) in measuring the ventilatory response to hypercapnia prohibiting the 
exact quantification of opioid-induced respiratory depression (see Refs.27,28 for a discussion 
on this topic). Ampakines act through activation of AMPA (α-amino-3-hydroxy-5-methyl-4-
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isoxazolepropionate) receptors.1,5 Glutamatergic transmission through AMPA receptors within 
the brainstem respiratory centers (most importantly the preBötzinger complex) plays a crucial 
role in respiratory rhythmogenesis; AMPA receptor activation leads to an increase in respiratory 
frequency and not the desired increase in tidal volume. 
CONCLUSIONS
Our studies demonstrated the stimulatory effects of the BKCa -channel blocker GAL021 on carbon 
dioxide-clamped ventilation during the condition of established opioid-induced respiratory 
depression. In an exploratory study, GAL021 also stimulated poikilocapnic ventilation during 
alfentanil administration, while it had no impact on sedation, antinociception, hemodynamic 
or safety parameters. While our data suggest that GAL021 is an attractive alternative to other 
respiratory stimulants taken its observed efficacy and favorable side effect profile, the current 
studies are not definitive. Our studies may be used to power future studies, which should 
address the ability of GAL021 to reverse OIRD at higher opioid concentrations and respiratory 
depression induced by other agents (eg. anesthetics and sedatives) and drug combinations 
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Recent publications point to the many deaths that occur in the US and elsewhere from potent 
prescription opioids.1-4 Death, related to cardiorespiratory arrest, is often due to an inadvertent 
overdose in a setting of opioid abuse and misuse. In the US, the number of people that died 
from prescription opioids has tripled from 1990 to 2010 to 16,000 deaths in 2010.3,4 Taken 
the large availability of opioids (opioid analgesics are the cornerstone of modern treatment 
of moderate to severe pain and are taken daily by a large number of patients worldwide), 
eradication or reduction of OIRD is important as it will reduce the number of fatalities. 
One possibility to reverse or reduce the probability of OIRD is to co-administer respiratory 
stimulants that do not compromise opioid analgesic efficacy or have other deleterious side 
effects (such as enhancement of sedation).1,5Adding the opioid receptor antagonist naloxone 
in oral formulation is in this respect not useful, as it will undergo rapid elimination (naloxone 
has a high first-pass effect) and a parenteral formulation will reduce opioid analgesic efficacy.6 
We recently showed that the experimental blocker of the calcium-activated K+-channel 
(BKCa-channel) GAL021 reverses OIRD in human volunteers without having effects on opioid 
analgesia, sedation or the cardiovascular system.7 GAL021 targets the BKCa-channel expressed 
on type 1 cells of the chemoreceptors at the carotid bodies. These and other K+-channels at the 
carotid bodies play an important role in the hyperventilatory response to hypoxia. Inhibition 
of type 1 cell K+-channels by low oxygen levels or by specific drugs (eg. inhibition of BKCa-
channels by GAL021) will cause depolarization of the type 1 carotid body cell, influx of Ca2+-
ions through activated voltage-dependent Ca2+-channels, and the release of neurotransmitters 
that activate the carotid sinus nerve, a branch of the glossopharyngeal nerve.8 This cascade 
of events eventually results in a brisk hyperventilatory response and in case of GAL021, may 
alleviate underlying respiratory depression. In contrast to naloxone, GALA021 has the potential 
to alleviate OIRD without affecting analgesia, in both oral and parenteral formulations. 
In order to further understand the behavior of GAL021, we here present a population 
pharmacokinetic-pharmacodynamic (PK-PD) analysis of the effect of GAL021 on OIRD. The data 
were analyzed with three distinct PK-PD models, one assuming a multiplicative interaction 
between alfentanil and GAL021 without ceiling in the effect of GAL021 on ventilation (Model 
1), one assuming a multiplicative interaction with ceiling in the effect of GAL021 on ventilation 
(Model 2) and one assuming an additive interaction between alfentanil and GAL021 (Model 3). 
In Fig. 1 the differences between the models are explained graphically. 
This study is a prespecified subanalysis of the previously published randomized controlled 
Phase 1 trial on the influence of GAL021 on alfentanil-induced respiratory depression in male 
volunteers.7 The PK-PD analysis allows us to address a number of important issues. It will give an 
estimate of the speed of onset/offset of GAL021 in its ability to reverse OIRD. And it will provide 
insight in the possibility that GAL021’s respiratory stimulation may hit a ceiling in efficacy due 
to the fact that the brainstem respiratory circuitry remains affected by the opioid at central 
sites.9
MATERIALS AND METHODS 
ETHICS
After approval of the protocol by the Medical Ethics Committee of the Biomedical Research Ethics 
Review Foundation (BEBO, Assen, the Netherlands) and the Central Committee on Research 
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Involving Human Subjects (CCMO, the Hague, the Netherlands), this study was performed at 
Leiden University Medical Center (Leiden, the Netherlands). The study was registered in the 
Dutch trial register (www.trialregister.nl) under number NTR3718. Prior to participation all 
subjects gave written informed consent. The study was performed according to the ethical 
principles for medical research involving human subjects (Declaration of Helsinki, amended in 
2013). The current study describes the PK-PD analysis of GAL021 reversal of alfentanil-induced 
respiratory depression; a descriptive analysis of the data was published previously.7 
SUBJECTS
Twelve healthy male volunteers (aged 18-45 years, BMI 18-30 kg/m2) were recruited to participate 
in the study. Exclusion criteria were a history of major medical or psychiatric diseases, a history 
of alcohol or drug abuse, smoking in the last year, daily consumption of caffeine greater than 
6 servings and any other investigational drug administration within three months prior to 
inclusion. Subjects had to fast at least 6 h prior to administration of the study drugs.
STUDY DESIGN
This phase 1 study had a randomized, placebo-controlled, double blind, crossover design. In 
the study breath-to-breath ventilation was measured under isohypercapnic conditions and 
during breathing experiments blood samples were obtained for determination of alfentanil 
and GAL021 concentrations. All subjects were tested twice, once during administration of 
alfentanil and GAL021 and once during administration of alfentanil and placebo. The washout 
period between sessions was at least 1 week. GAL021 and placebo were randomized using a 
computer generated randomization schedule provided by the sponsor and were allocated in 
a 1:1 ratio.
Ventilation measurements. During the experiments, subjects breathed through a facemask 
connected to a pneumotachograph (#4813, Hans Rudolph, Kansas City, MO), which allowed 
accurate measurement of breath-to-breath ventilation. The pneumotachograph was 
connected to a computer-controlled gas mixing system from which preset inspired gas 
mixtures were delivered. Using the dynamic end-tidal forcing technique,7 the inspired O2 and 
CO2 concentrations were varied, enabling the end-tidal clamping of these two gasses. The value 
of the end-tidal pCO2 concentration during the clamp was such that pre-drug administration 
ventilation levels were 20 L/min (SD 2 L/min); the end-tidal pO2 concentration was kept constant 
at a normoxic value of 110 mmHg. The inspired and expired O2 and CO2 concentrations were 
measured at the mouth with a capnograph (Datex Capnomac, Helsinki, Finland). All measured 
variables were visualized on a computer screen in real time during the experiments and saved 
on disc for further analysis.
Study drug administration. The hospital pharmacy prepared all study drugs. GAL021 (Galleon 
Pharmaceuticals Corp., Horsham, PA, USA), a colorless product with a pH of 3.1, and placebo 
(normal saline) were diluted in Ringer lactate. Study medication and alfentanil 0.5 mg/mL 
(RapifenTM, Janssen-Cilag BV, Tilburg, The Netherlands) were prepared on the day of the study, 
identified by randomization and visit numbers in an infusion bag (study medication) or syringe 
(alfentanil). The sequence and infusion rates of the administration of the drugs are given in Fig. 
2A and Table 1.
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Blood sampling and analysis. All subjects had an arterial-line in the radial artery of the 
non-dominant arm. At multiple time points arterial blood samples were taken to determine 
plasma concentrations of alfentanil and GAL021. In total, 18 alfentanil samples were taken (one 
baseline sample and 17 samples after administration of alfentanil at times t = -29, -28,  -26, -22, 
-11, 1, 17, 50, 82, 86, 90, 99, 111, 120, 140, 170, and 220 min) and 15 GAL021/placebo samples 
were taken (one baseline sample and 15 samples at t = 5, 10, 17, 29, 40, 58, 69, 90, 111, 120, 140, 
170, and 220 min). 
Blood samples, taken for pharmacokinetic analysis of alfentanil, were collected in K2EDTA 
tubes and centrifuged at 4 °C for 15 min at 2,500 revolution/min, followed by separation of 
plasma. Plasma samples were immediately stored at -20°C until analysis. Alfentanil samples 
were analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS) as reported 
previously.7  The GAL021 pharmacokinetic samples were collected in K2EDTA tubes and 
centrifuged for 10 min at 3,200 revolution/min, followed by separation of plasma. The samples 
were placed on wet ice and frozen at -80°C within one hour. GAL021 samples were analysed 
by LC-MS/MS. Calibration standards, quality controls, and incurred plasma samples were 
prepared by protein precipitation using acetonitrile. After centrifugation, the supernatant was 
evaporated and then reconstituted in injection solvent for LC-MS/MS analysis.  All samples were 
injected onto a Luna C18(2) column (2.0 x 50 mm, 3 µm particle) (Phenomenex, Torrance, CA), 
eluted using gradient elution with a mobile phase consisting of mobile phase A (acetonitrile/
water, 20/80, v/v) and mobile phase B (acetonitrile) containing 0.1% trifluoroacetic acid, and 
detected using an AB/Sciex API-4000 mass spectrometer (ABI Sciex Qtrap, Toronto, Canada). 
The ions were produced in the positive electrospray ionization mode and detected in multiple 
reaction monitoring mode using transitions at 255.2           182.1 for GAL-021 and 269.3          190.2 
for internal standard (GAL021-d14), with retention times of 1.51 and 1.46 minutes, respectively. 
The calibration standard concentrations ranged from 0.25 to 400 ng/mL with quality controls at 
0.75, 50, and 300 ng/mL. The calibration curves were linear with a lower limit of quantification 
of 0.250 ng/mL and correlation coefficients > 0.995. The method precision (%CV) and accuracy 
t = - 40 min Elevation of end tidal pCO2; drug infusion starts upon reaching steady/state ventila-
tion.
Time point (see figure 2)
1. t = - 30 min A. Alfentanil loading infusion 1.33 µg.kg-1.min-1 for 6 min, followed by a continuous 
infusion of 0.3 µg.kg-1.min-11 for 74 min (aim: 25-30% decrease in ventilation). 
B. If the reduction in ventilation was < 25%, a second dose of 1.33 µg.kg-1.min-1 fol-
lowed by a continuous infusion of 0.6 µg.kg-1.min-1. 
C. In  case ventilation decreased by > 30%, the maintenance infusion was halved to 
0.15 µg.kg-1.min-1.
2. t = 0 mina An intravenous GAL021/placebo loading dose of 33.3 µg.kg-1.min-1 for 10 min, followed 
by a continuous infusion of 6.67 µg.kg-1.min-1 for 20 min. 
3. t = 30 mina A GAL021/placebo loading dose of 33.3 µg.kg-1.min-1 for 20 min, followed by 18.3 
µg.kg-1.min-1 for 60 min. 
4. t = 80 mina The alfentanil infusion was increased by repeating the loading dose as given in step 
1 A-C, followed by a continuous infusion with twice the infusion rate as given in steps 
1A-C (aim: 50-60% decrease in ventilation)
5. t = 110 mina Alfentanil and GAL021/placebo infusions are stopped.
Table 1. Alfentanil and GAL021 infusion protocols (see also Figure 2a). 
a Times are approximation and depend on the duration of step 1.
51
Reversal of OIRD by GAL021: a PKPD modeling study
4
(%RE) were less than 10% for all of quality control sample concentrations. 
 
PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) ANALYSIS 
The population pharmacokinetics and pharmacodynamics of alfentanil and GAL021 were 
determined in two stages using NONMEM version 7.3.0 (software for nonlinear mixed effects 
modeling; ICON Development Solutions, Hanover, MD, United States).10
Figure 1. A. Schematic representation of the pharmacokinetic (PK) nad pharmacodynamic (PD) models used 
to analyse the effects of alfentanil (A) and GAL021 (G) on ventilation. Vx is the volume of PK compartment x, CLx 
clearance from PK compartment X, keOA the rate constant of equilibration of the effect compartment with the 
plasma compartment for alfentanil, keOG the rate constant of equilibration of the effect compartment with the 
plasma compartment for GAL021, VB baseline ventilation and VE minute ventilation. Depression of ventilation 
by alfentanil is described by a sigmoid EMAX model. Stimulation of breathing by GAL021 is either modeled by a 
power model (Model 1) or a sigmoid EMAX model (Models 2 and 3). Alfentanil and GAL021 interact on ventilation 
in either a multiplicative fashion (Models 1 and 2 ) or in an additive manner (Models 3) as depicted by i. B-D. 
Simulations to exemplify the behavior of the three models. A mild 10% depression of ventilation is simulated. At t 
= 60 minutes, three constant GAL021 infusions are started (without an initial bolus infusion): 0.035, 0.07 and 0.14 
mg.kg-1.min-1 (blue, orange and green lines).  Model 1 behaves with a dose-dependent increase in effect, whereas 
the effect of Models 2 and 3 hits a ceiling thereby restricting the ventilatory stimulation. The difference between 
Models 2 and 3 is that in Model 2 (as well as Model 1) the ventilatory effect is dependent on baseline ventilation, 
whereas for Model 3 there is a fixed increase in ventilation independent of baseline. 
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Figure 2. A. Protocol of alfentanil and GAL021 infusions. B. Measured ventilation during infusion of alfentranil 
and GAL021 (blue) or placebo (orange). C. Mean plasma alfentanil concentrations (data of both GAL021 and 
placebo arems are included). D. Plasma GAL021 concentrations. E. Plasma alfentanil concentration in the 
GAL021 arm (blue symbols) and placebo arm (green symbols) of the study., The data are mean ± 95% confidence 
interval. 
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Pharmacokinetic analysis. In the first stage, the PK data of the GAL021 and alfentanil were 
characterized separately. Multiple compartment models were fitted to the GAL021 and alfentanil 
plasma concentration data, with and without covariate weight. The number of compartments 
in the pharmacokinetic analysis was determined by the magnitude of the Minimum Objective 
Function Value (MOFV; χ2-test). 
Pharmacodynamic analysis. To eliminate possible hysteresis between the alfentanil and 
GAL021 plasma concentrations and putative effect-sites, two separate effect compartments 
for alfentanil and GAL021 were postulated with blood-effect-site equilibration half-lives 
t1/2keOA and t1/2keOG, respectively. In the second stage, population pharmacodynamic model 
parameters were determined with fixed individual pharmacokinetic model parameters. Three 
distinct pharmacodynamic models were tested:
Model 1 assumes that alfentanil and GAL021 interact in a multiplicative fashion on ventilation 
(Fig. 1):11 
 VE(t) = VB ∙ EFA(t) ∙ EFG(t)      (1)
where VE is minute ventilation at time t, VB pre-drug baseline ventilation, EFA the effect of 
alfentanil on ventilation and EFG the effect of GAL021 on ventilation. For the effect of alfentanil 
on ventilation a sigmoid EMAX model was applied:11,12
 EFA(t) = 1 – [CEA(t)γA/(CEA(t)γA + C50AγA)]    (2)      
where CEA is the alfentanil effect-site concentration, C50A the alfentanil effect-site (or steady-
state) concentration causing a 50% depression of ventilation and γA the shape or Hill parameter 
for alfentanil. For the effect of GAL021 on ventilation a power model was applied:11,13                              
 EFG(t) = 1 +  0.25 ∙ (CEG(t)/C25G)γG      (3) 
where CEG is the GAL021 effect-site concentration, C25G the GAL021 effect-site (or steady-
state) concentration causing 25% increase in ventilation and γG the shape or Hill parameter for 
GAL021.
Model 2 assumes that alfentanil and GAL021 interact in a multiplicative fashion on ventilation 
as described in equations 1 and 2, but the effect of GAL021 on ventilation an EMAX model was 
applied:11,13
 EFG(t) = 1 + EMAXG ∙ [(CEG(t)/C25G)γG]/[4 ∙ EMAXG – 1 + (CEG(t)/C25G)γG] (4)
where EMAXG is the maximum possible effect of GAL021 on ventilation. 
Model 3 assumes that alfentanil and GAL021 interact in an additive fashion on ventilation:11
 VE(t) = VB ∙ EFA(t) + EMAXG ∙ [(CEG(t)/C25G)γG]/[3 + (CEG(t)/C25G)γG] (5)
and for the effect of alfentanil on ventilation a sigmoid EMAX model was applied according 
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Figure 3. Effect of GAL021 on ventilation. Best (A), median (B) and worst (C) data fits. The orange dots are 
measured ventilation data points, the blue lines are individual predicted ventilation, the black thin lines are 
the alfentanil contribution to the predicted ventilation (EFA) and the gray lines are the GAL021 contribution to 
the predicted ventilation (EFG). Alfentanil/placebo ventilation data fits are not shown. (D), (E) and (F) are best, 
median and worst alfentanil pharmacokinetic (PK) data fits, respectively. (G), (H) and (I) are the best, median 
and worst GAL021 PK data fits respectively. Goodness of fit was based on the coefficient of determination. 
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to equation 2 and for the effect of GAL021 on ventilation a model with ceiling was applied 
according to equation 4. 
Statistical analysis. For both PK and PD analyses, the model parameters were assumed to be 
log-normally distributed across the population. Residual error was assumed to have both an 
additive and a relative error for concentrations and only an additive error term for ventilation. 
Model discrimination was based on the magnitude of the Minimum Objective Function Value 
Drug Parameter Estimate ± SEE ω2 ± SEE
PK model parameters
Alfentanil V1 (L) 8.49 ± 0.35 0.02 ± 0.007
V2 (L) 11.2 ± 0.55 a
CL1 (L/min) 0.30 ± 0.01
CL2 (L/min) 0.59 ± 0.05 a
σ1 0.09 ± 0.02
σ2 5.96 ± 0.07
GAL021 V1 (L) 6.72 ± 1.92
V2 (L) 43.4 ± 1.55 a
CL1 (L/min) 1.02 ± 0.04
CL2 (L/min) 2.20 ± 0.12 a
σ1 0.09 ± 0.01
σ2 44.3 ± 6.02
PD model parameters
VB (L/min) 21.5 ± 0.65 0.002 ± 0.010
σ 1.97 ± 0.12
Alfentanil t1/2keOA (min) 2.72 ± 0.71 a
C50A (ng/mL) 54.4 ± 6.8 0.31 ± 0.15
YA 1.0b 0.33 ± 0.10
GAL021 t1/2KeOG (min) 0 a
C25G (ng/mL) 600 ± 8 a
EMAXG 1.16 ± 0.19 a
YG 1.0b 0.32 ± 0.12
Table 2. Pharmacokinetic and Model 2 pharmacodynamic parameter estimates
Subscript A denotes alfentanil, subscript G GAL021. V; volume, CL; clearance, ω2; variance of the model 
parameters across the population (in the log domain), σ1; standard deviation of the proportional error (PK 
data), σ2; standard deviation of the additive error (PK data), VB; baseline ventilation, σ; the standard deviation 
of the additive error (PD data), t1/2keO; the blood effect-site-equilibration half-life, C50A; the effect-site alfentanil 
concentration causing 50% respiratory depression, C25G; the effect-site GAL021 concentration causing 25% 
increase in ventilation. EMAXG; the maximum possible effect of GAL021 on ventilation. Y; a shape parameter. 
PK; pharmacokinetic, PD; pharmacodynamic, SEE; standard error of estimate.
a  Not estimable, b not significantly different from 1. 
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(MOFV; χ2-test). p-values < 0.01 were considered significant. All values are median ± SE unless 
otherwise stated. 
Standardized visual predictive check (SVPC). Standardized visual predictive checks were 
performed to evaluate the adequacy of the description of both fixed and random effects by 
simulating data using the model. The SVPC displays the fraction of the observations of each 
subject in the marginal distribution of the corresponding data simulations (concentration or 
ventilation) as a function of time, based on that subject’s own drug administration schedule.13
Figure 4. Goodness-of-fits plots. A and B alfentanil pharmacokinetic (PK) analysis; C and D GAL021 PK analysis; 
E and F ventilation. MEAS is measured data, IPRED is the individual predicted values and IWRES is the individual 
weighted residuals. Through the IWRES vs time data a smoothin curve was fitted (gray lines). 
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RESULTS
A complete data set was obtained in twelve subjects. There were no unexpected side effects. 
The median age (range) of the subjects was 22.0 (19-34) years, the median weight 74.3 (60.7-
84.3) kg and body mass index 22.1 (19.0-26.5) kg/m2. The alfentanil and GAL021/placebo 
infusion protocol and mean ventilatory responses following alfentanil and GAL021/placebo 
administrations are shown in Figs. 2A and B. The difference in GAL021 vs. placebo responses 
indicates an appreciable reversal effect of GAL021 on alfentanil-induced respiratory depression.
PHARMACOKINETIC ANALYSIS
Mean alfentanil and GAL021 plasma concentrations are shown in Figs. 2C-E. Peak alfentanil 
concentrations reached during low- and high-dose infusion were 51.9 ± 1.8 (mean ± SD) and 
99.2 ± 6.4 ng/ml, respectively. Peak GAL021 concentrations were 859 ± 40 and 365 ± 11 ng/mL 
during low-dose bolus and maintenance, and 1110 ± 46 and 1201 ± 54 ng/mL during high-
dose bolus and maintenance, respectively. GAL021 had no significant effect on the alfentanil 
plasma concentrations (t-test: p > 0.05), but a small reduction in the plasma concentrations 
during GAL021 infusion cannot be excluded. The final PK models for both GAL021 and alfentanil 
consisted of a two-compartment model with one central (V1) and one peripheral compartment 
(V2). Covariate weight did not improve the GAL021 and alfentanil PK fits. The pharmacokinetic 
parameter estimates are displayed in Table 2. Best, median and worst alfentanil and PK data 
Figure 5. Standardized visual predictive checks for alfentanil 
pharmacokinetic (PK) data (A), the GAL021 PK data (B) and 
ventilation (C). The broken lines represent the 2.5 and the 97.5% 
confidence limits. For all three measures, the 95% of the data lies 
within the 95% confidence intervals. P is probability. 
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fits are given in Fig. 3. Goodness of fit plots are shown in Fig. 4. Inspection of the individual 
data fits and the goodness of fit plots indicate that the pharmacokinetic data are adequately 
described by the GAL021 and alfentanil PK models. A small misfit is, however, visible at the lower 
concentration ranges (occurring immediate after the start of infusion or following changes in 
infusion rate), where the predicted alfentanil concentrations are overestimated, predominantly 
just after the first administration, while GAL021 predicted concentrations are underestimated 
at the last sample times. 
PHARMACODYNAMIC ANALYSIS
Alfentanil-induced respiratory depression ranged from 33% (low-dose) to 55% (high-
dose) during administration of placebo; GAL021 effectively reversed these effects (Fig. 2B). 
Pharmacodynamic model selection was based on the Minimum Objective Function (MOF) 
value. MOF values favored the model in which GAL021 shows ceiling in its efficacy to reverse 
respiratory depression (Model 2) above the model that shows no ceiling (Model 1) with MOF 
values for Model 2 of 10364 versus Model 1 of 10379 (p < 0.01). The multiplicative model (Model 
2) was superior in terms of MOF values to the additive Model 3 (MOF value 10405). The results 
of the analysis with Model 2 will be presented here.   
Best, median and worst ventilation data fits (based on the coefficient of determination) are 
shown in Fig. 3 for the data derived from the GAL021 arm of the study (the placebo fits are 
not shown). In panels #A-C, the measured (closed symbols) and predicted VE (blue lines) are 
given together with the two contributions to predicted effect, EFA  (alfentanil contribution, 
black lines) and EFG (GAL021 contribution, grey lines). Inspection of the individual fits and the 
goodness of fit plots (Figs. 3 and 4) indicate that the model adequately describes the data. 
Estimated model parameter values (estimate ± SE) are given in Table 2. The effect of alfentanil 
on ventilation was rapid with a value for t1/2keOA of 2.7 ± 0.7 min and C50 of 54.4 ± 6.8 ng/mL. 
GAL021 produced a median increase in ventilation of 25%, which occurred at an effect-site or 
steady-state concentration of 600 ± 8 ng/mL. The value of GAL021’s t1/2keOG was not significantly 
different from zero. 
STANDARDIZED VISUAL PREDICTIVE CHECK (SVPC)
SVPCs are shown in Figure 5. With alfentanil and GAL021 inputs similar to those used in the 
current study, the accuracy of the PKPD model was acceptable with 95% of the data points 
within the 2.5 to 97.5 percentiles.
DISCUSSION
GAL021, a blocker of the BKCa-channel at the carotid bodies, effectively reverses OIRD induced 
by the potent μ-opioid alfentanil. Here we show that the interaction between GAL021 and 
alfentanil is best described by a pharmacodynamic model consisting of two parts that interact 
in a multiplicative fashion: a sigmoid EMAX function that describes the inhibitory effects of the 
opioid on breathing and a function that describes the stimulatory effects of the K+-channel 
blocker. The model predicts that GAL021 displays ceiling in its efficacy to reverse OIRD. 
We further observed that the GAL021 onset/offset times are rapid with a blood-effect site 
equilibration half-life not different from zero. 
In current clinical practice, reversal of OIRD is by administration of naloxone. Naloxone is a 
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non-selective competitive antagonist at the μ-opioid receptor with fast receptor association 
and dissociation kinetics. Following intravenous administration, naloxone rapidly enters the 
brain compartment and causes a brisk reversal of opioid activity at the respiratory centers 
in the brainstem.14 Albeit effective, naloxone has various disadvantages including reversal of 
analgesia, activation of the sympathetic system and risk of renarcotization.1 Multiple respiratory 
stimulants have been developed that may serve as attractive alternatives to naloxone as they 
are devoid of effect at the opioid receptors.5 This is advantageous for two reasons. Apart from 
not interfering with analgesia, such agents are not dependent on opioid-receptor kinetics in 
their ability to reverse OIRD. Some opioids (eg. buprenorphine and to a lesser extent morphine) 
have slow receptor kinetics, which reduces the probability and speed of their reversal in case of 
a serious OIRD and therefore require relatively high naloxone doses or a continuous naloxone 
infusion.1,14
Figure 6. Simulation of the effect of bolus and combined bolus and continuous GAL021 infusions on alfentanil-
induced repsiratory depression. In these simulations, the effects of GAL021 on moderate (50%, A and B) and 
severe (90%, C and D) respiratory depression are simulated. At t = 0, the effect of a GAL021 bolus of 1.3 mg/kg 
(A and C) or a bolus of 1.3 mg/kg followed by a continuous infusion of 0.14µg.kg-1.min-1 (B and D) are simulated. 
GAL021's bolus effects are rapid and require a continuous infusion of a persistent effect. The multiplicative 
nature of the interaction between alfentanil and GAL021 causes the difference in GAL021 ventilatory effect when 
reversing severe or moderate opioid-induced respiratory derepssion (OIRD). 
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Most effective non-opioid agents developed to prevent or treat OIRD in humans include drugs 
that increase glutamatergic neurotransmission at brainstem respiratory centers (ampakines 
including CX717) and potassium channel blockers acting at the peripheral chemoreceptors 
of the carotid bodies (GAL021, doxapram, almitrine).1,5,9,15 Drugs acting at the peripheral 
chemoreceptors through blockade of K+-channels mimic the effect of hypoxia, which 
exclusively acts at the carotid bodies. The afferent information from the carotid bodies is 
translated into an increased ventilatory drive in brainstem respiratory centers. Since opioids 
depress the hypoxic drive at these same respiratory centers,2,16 the efficacy of drugs acting via 
carotid body stimulation may be limited in effect and could possibly results in a ceiling in ability 
to reverse OIRD.9 Indeed, the results from our modeling study suggest ceiling in reversal of OIRD 
by GAL021. Based on the MOF values, the multiplicative model with ceiling in GAL021 effect 
(Model 2) was deemed best and hence was assumed the most probable model to describe 
GAL021 reversal of OIRD. Further studies at higher GAL021 doses are needed to confirm the 
model-based prediction of ceiling.
Since GAL021 interacts in a multiplicative manner with alfentanil (i.e. that the amount of 
reversal is dependent on the magnitude of alfentanil-induced respiratory depression) the 
model predicts that at extreme levels of OIRD (for example opioid-induced apnea), the effect 
of GAL021 is limited (i.e. multiplication factor < 1). See also Fig. 6. If true, reversal must then be 
induced by other means or the patient should be ventilated. Model 1 was attempted initially as 
in a previous study of GAL021 in volunteers there were suggestions of a linear doses response 
relationship from 600 ng/mL on.17 However, in that study no opioids were administered. This 
implies that the ventilatory sensitivity of GAL021 is altered in narcotized compared to non-
narcotized subjects. This may be related to the central depressant effects of opioids that remain 
unaffected by GAL021 or due to the presence of a CO2-clamp in the current study. Our analysis 
gives a clear indication of the site of action of GAL021. The blood-effect site equilibration 
half-life was not different from zero, which indicates that GAL021 acts at a site close to the 
arterial vascular bed (i.e. the sample site). The carotid bodies are located at the bifurcation of 
the common carotid arteries and are highly perfused with arterial blood through branches of 
the external carotid artery.18 The concentration of GAL021 at the carotid body receptor site will 
therefore be close to that of arterial blood. These findings are in agreement with animal studies 
showing that in carotid body denervated rats and in BK-channel knockout mice the effect of 
GAL021 is greatly reduced.19,20
To better understand the properties of GAL021 as described by Model 2 we performed 
simulations on the effect of GAL021 infusion on alfentanil-induced moderate (50%, Figs 6A and 
B) and severe (90%, Figs. 6C and D) respiratory depression. In these simulations the alfentanil 
infusion is continued when GAL021 is infused, to mimic the effect of long-acting opioids such 
as fentanyl, buprenorphine and morphine. The onset of effect of a GAL021 bolus is rapid but 
respiratory stimulation dissipates within 5-10 min. To ensure a continuous effect, a bolus 
combined with an infusion is required. Given the multiplicative nature of the alfentanil GAL021 
interaction, GAL021 has less effect at severe OIRD (compare panels A and C, B and D); higher 
infusion rates have then limited effect.
The rapid onset of action of GAL021 makes it an attractive alternative to naloxone in the 
treatment of OIRD. Further studies, however, are needed to assess whether GAL021 is able 
to reverse severe levels of OIRD such as apnea. Also naloxone is not always able to reverse 
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OIRD and in cases of severe OIRD artificial ventilation to overcome the period of OIRD is often 
the best option.6,21 GAL021 has the potential to be used as long-term respiratory support 
following an opioid respiratory event, in the treatment of less severe respiratory depression, 
and as concomitant administration in a combination therapy, aimed to reduce the probability 
of OIRD without affecting analgesia. However, it is then important to know whether tolerance 
would develop to multiple doses of GAL021. Animal data show that there is no diminution in 
effect during long-term infusion (Galleon Pharmaceuticals Corp., data on file). GAL021 has 15-
35% bioavailability (animal data on file); an oral compound, GAL160, is currently in preclinical 
development for the hospital and post discharge setting (up to 14-28 days). Naloxone remains 
useful as diagnostic as well as a therapeutic agent in severe OIRD. 
Our PK analysis had some strong and weak points. A strong point is the use of arterial blood 
samples. Using arterial rather than venous samples has the advantage of obtaining more 
reliable PK and PD data fits.22 A weakness of the study is the characterization of the disposition 
of alfentanil and GAL021 with two- rather than with three-compartment models.23 This 
resulted in PK misfits: the goodness-of-fit plots show that at low concentrations the PK models 
overestimate the alfentanil concentrations and underestimate the GAL021 concentrations 
(Figs. 4A and C). For alfentanil, this occurred after the start of infusion and upon changes in 
infusion regimen, for GAL021 only at the last sample times. We relate the failure to characterize 
three-compartment PK models to the paucity in the PK data when concentrations are changing 
rapidly,23 i.e. after administration of a loading dose (for alfentanil) and after discontinuation of 
an infusion (for GAL021). The parameter standard errors estimated with a three-compartment 
model were unacceptable (>100% coefficient of variation) for both drugs. We consider the 
small misfits in a minority of data not of major significance. 
We evaluated the performance of the PK-PD model (Model 2) using a standardized visual 
predictive check (SVPC; Fig. 5). Visual predictive checks address the adequacy of fixed and 
random effects. Due to the variation in dosing among subjects in our study, the conventional 
VPC is not useful. We therefore applied the SVPC, which provides similar information as a VPC, 
but displays observations and predictions on a standardized scale.24 As observed in Fig. 6, the 
SVPCs of the PK and PD data show that the simulated data are evenly distributed across the 
percentile of observations over time (P in Fig. 6, ranging from 0 to 1). This indicates that the 
model is an adequate descriptor of the data. 
In conclusion, we performed a population PK-PD analysis of the reversal of alfentanil-induced 
depression of breathing by the potassium-channel blocker GAL021. GAL021 interacted in 
a multiplicative fashion with the opioid. Specific model predictions such as the presence of 
ceiling in GAL021’s efficacy to reverse respiratory depression and the inability of GAL021 to 
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Benefit versus toxicity of opioid 
analgesia: novel utility functions of 
analgesia and respiratory depression
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Opioid analgesics, especially those opioids that are full agonists at the μ-opioid-receptor, have 
a high likeability, rendering them high-risk drugs of abuse, misuse and eventually addiction.1,2 
Equally important, μ-opioid receptors are abundantly expressed on brainstem respiratory 
neurons and activation of these receptors is associated with bradypnea, hypoventilation and 
apnea.3 This is especially true when the opioid is overdosed or used in combination with other 
centrally acting depressant drugs such as alcohol, benzodiazepines or other illicit substances.4 It 
is currently well understood that the combination of misuse/abuse and respiratory depression 
is a serious threat especially to a society in which opioid prescriptions for non-cancer-related 
pain reached epidemic proportions.5,6 For example, in 2013 in the Netherlands, 1 million 
individuals (on a population of 17 million) received a prescription for opioid treatment, a 
doubling since 2004.7 There are no numbers of opioid deaths in the Netherlands but in the 
US prescription opioids have been implicated in 165,000 deaths since 1999.6 Also in the acute 
setting such as postoperative care, opioid analgesics are associated with cardiorespiratory 
arrest and mortality.3,8-10
Despite these alarming numbers, opioid analgesics remain the cornerstone of modern 
medicine in the treatment of moderate to severe acute and chronic pain. The main reason is 
their high efficacy and current lack of adequate alternatives. Presently, novel opioid drugs are 
being developed with specific modes of action (e.g., acting at multiple receptor systems that 
offset respiratory depression or so called “biased ligands” that circumvent the opioid respiratory 
pathway) that possibly have advantages over full μ-opioid-receptor agonists with less risk of 
respiratory depression.11,12 There are various methods that allow assessment of opioid safety. 
For example, data obtained from post-marketing studies give some indication of safety in 
large patient populations. However, such studies are available only after development and 
registration. We propose the development and use of utility or safety functions to determine 
opioid toxicity (e.g., respiratory depression but it may be any negative outcome such as 
sedation, dizziness, etc.) in light of opioid benefit (analgesia).13,14 These utility functions may be 
created and reviewed early on in development (in phase 1 or 2 trials) and allow an objective 
and reliable characterization of the opioid benefit and risk to determine an optimal dosing 
regimen.14 Additionally, utility functions may be used to compare drugs and establish which 
drug has a better benefit-risk behavior over the other in specific patient populations.15
In this study, we further developed the concept of the utility function by calculating probabilities 
of benefit and risk and calculate the probabilities of four distinct conditions: the probability 
of presence of benefit (adequate analgesia) with or without toxicity (respiratory depression, 
respectively) and the probability of inadequacy of benefit (inadequate analgesia) with or 
without toxicity (respiratory depression). We calculated these probabilities for the μ-opioid 
receptor agonist alfentanil by analysis of data derived from three different previously published 
data sets. Probabilities were calculated as function of concentration and as function of time 
following a bolus infusion.
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The construction of the alfentanil utility function is based on three different study protocols 
where the effects of alfentanil on ventilation and/or analgesia were analyzed. Part of the results 
of these three studies have been published previously.16-18 In two studies (studies 1 and 2) both 
alfentanil-induced respiratory depression and antinociception were measured in the same 
subjects,17,18  in one study (study 3) just alfentanil-induced antinociception was measured.16 
In studies 1 and 2 breath-to-breath ventilation data were collected at isohypercapnia using 
the “end-tidal forcing” technique.17,18 The end-tidal pCO2 was increased producing a ventilation 
level of 20 ± 2 L/min after which alfentanil was infused; during infusion the end-tidal pCO2 was 
maintained at baseline level. The technique is described elsewhere in detail.19 In brief, subjects 
breathed through a facemask attached to a pneumotachograph and pressure transducer system 
(Hans Rudolph Inc., Kansas City, MO, USA) and to three mass flow controllers (Bronkhorst High 
Tech, Veenendaal, The Netherlands) for the delivery of oxygen, carbon dioxide and nitrogen. 
All three controllers received input using custom made RESREG/ACQ software. Inhaled and 
exhaled oxygen and carbon dioxide partial pressures were measured at the mouth using a 
capnograph (Datex Capnomac, Helsinki, Finland). In studies 1-3, antinociception (or analgesia) 
was measured using an electrical pain model.16-18 Two electrodes were placed on the skin over 
the shinbone of the right leg, 2 cm apart and 10 cm above the lateral malleolus. A custom 
made computer-interfaced current stimulator (Leiden University Medical Center, Leiden, the 
Netherlands) generated a current, which increased with 0.5 mA/s and started at 0 mA. The 
subject had to indicate on a control box when pain threshold (first pain was observed) and pain 
tolerance (pain could not be tolerated any further) were reached. Pressing the button for pain 
tolerance ended the stimulus train.
Design of study 1 (a  study on the influence of respiratory stimulant GAL021 on alfentanil-
induced respiratory depression and antinociception).17 Subjects were dosed twice on separate 
visits, once with GAL021 and once with placebo; only the placebo data are included in the 
current analysis. Alfentanil was administered using a stepped drug infusion design. After 
reaching isohypercapnic steady-state ventilation, an initial intravenous infusion of 1.33 µg.kg-1.
min-1 for 6 min was given (loading dose), followed by a continuous infusion of 0.3 µg.kg-1.min-1 
for 104 minutes. This was done to achieve a 25-30% decrease in ventilation. If the reduction in 
ventilation was less than 25%, a second dose of 1.33 µg.kg-1.min-1 was given and the subsequent 
continuous infusion was increased to 0.6  µg.kg-1.min-1. If the loading dose caused ventilation 
to decrease by more than 30%, the continuous infusion was reduced to 0.15 µg.kg-1.min-1. 
Next (110 min after the start of infusion), another loading dose of 1.33 µg.kg-1.min-1 alfentanil 
was given for 6 min followed by a continuous infusion, which was twice the earlier infusion 
dose. After another 30 min, the alfentanil infusion ended. Total infusion time was 140-146 min. 
Arterial blood samples were taken a t = 0 (baseline), 1, 2, 4, 8, 19, 31, 47, 80, 112, 116, 120, 129, 
141, 170, 200 and 250 min; t = 0 is start of alfentanil infusion. 
Design of study 2 (a study on the influence of respiratory stimulant doxapram on alfentanil-
induced respiratory depression and antinociception).18 All subjects were dosed twice on 
separate visits, once with doxapram and once with placebo; only the placebo data are included 
in the current analysis. The study protocol was in accordance with study 1, except for differences 
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in infusion regimen and sample times. In this protocol, the loading dose was 8 µg.kg-1.min-1 for 
2 min, followed by a maintenance infusion of 0.6 µg.kg-1.min-1 for 98 min. Hereafter, the loading 
dose was repeated and maintenance infusion was increased to 0.9 µg.kg-1.min-1 for 30 min. Total 
infusion time was 132 min. Arterial blood samples were taken at t = 0 (baseline), 1, 2, 4, 5, 7, 8, 
10, 19, 31, 40, 47, 59, 80, 88, 99, 101, 102, 104, 105, 107, 110, 119, 131, 140, 155 and 170 min. 
Design of study 3 (a pharmacokinetic-pharmacodynamic modeling study on alfentanil-
induced antinociception).16 All subjects were dosed twice on separate visits, once with 
alfentanil and once with placebo; only the alfentanil data are included in the current analysis. 
Subjects received a target-controlled-infusion of alfentanil with plasma concentration targets 
of 50 ng/mL for 10 min, followed by 100 ng/mL for another 10 min and 150 ng/mL for a final 10 
min. Antinociception was measured during and for 270 min following infusion. Arterial blood 
samples were obtained at t = 0 (baseline), 3, 5, 9, 13, 15, 19, 23, 25, 29, 31, 33, 35, 38, 43, 53, 60, 
75, 90, 120, 150, 180, 240 and 300 min. 
PHARMACOKINETIC-PHARMACODYNAMIC ANALYSIS
The population pharmacokinetics (PK) and pharmacodynamics (PD) of alfentanil were 
determined in two stages using NONMEM version 7.3.0 (software for non-linear mixed effects 
modeling; ICON plc, Gaithersburg, MD).20 In the first stage, the PK data were analyzed with a 
three-compartment model based on previous analyses.16-18 To eliminate a possible hysteresis 
between alfentanil plasma concentration and effect site, an effect compartment was postulated 
with blood-effect site equilibration half-life t1/2keO. In the second stage, population PD model 
parameters were determined with fixed individual PK model parameters as determined in the 
first stage. 
Ventilation data were modeled by:13,17
 V(t) = VB · [1 + (CE(t)/C50V)YV]-1      (1)
where the V(t) is the ventilation at time t, VB baseline ventilation, CE(t) is the effect-site 
concentration at time t, C50V the effect-site concentration producing a 50% decrease in 
ventilation and yv the shape or Hill parameter for ventilation.
Transcutaneous electrical pain responses were modeled by:13,16
 P(t) = PB · [1 + 0.5 · (CE(t)/C50A)YA]     (2)
Where the P(t) is the pain stimulus intensity at which a pain tolerance response occurs at time t, 
PB is the pre-drug or baseline stimulus intensity at which pain tolerance response occurs, CE(t) 
is the effect-site concentration at time t, C50A the effect-site concentration producing a 50% 
increase in stimulus intensity and yA the shape or Hill parameter for analgesia. 
Model parameters were assumed to be log-normally distributed. Residual error was assumed 
to contain an additive and a relative error for concentration and an additive error for effect 
parameters. 
Utility Functions. The utility functions (U) were calculated as previously described.13 In brief, 
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Figure 1. Goodness of fit plots of the pharmacokinetic and pharmacodynamic analysis. A. Alfentanil 
concentration: measured versus individual predicted values. B. Alfentanil concentration: individual weighted 
residuals (IWRES) versus time. C. Ventilation: measured versus individual predicted values. D. Ventilation: 
individual weighted residuals (IWRES) versus time. E. Analgesia: measured versus individual predicted values. F. 
Analgesia: individual weighted residuals (IWRES) versus time.
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one thousand pharmacodynamic profiles as functions of concentration, U(CE), and time, U(t), 
were simulated according to the medians and inter-individual variabilities (ω2) as listed in Table 
1. The number of times severe respiratory depression and adequate analgesia occurred were 
divided by N, to obtain estimates of the probabilities of their occurrence. A 50% reduction in 
minute ventilation was taken as a threshold for severe respiratory depression, i.e. P(R > 0.5), 
and both a 25% and a 50% increase in tolerated electrical current were taken as threshold for 
analgesia, i.e. P(A > 0.25) and P(A > 0.5), respectively. The utilities U1 were defined as: 
 U1(A > 0.25) = P(A > 0.25) – P(R > 0.5)      (3)
and 
 U1(A > 0.5) = P(A > 0.5) – P(R > 0.5)     (4)
A disadvantage of this definition is that the U1 cannot be interpreted as a probability, because 
its values range between -1 and 1. The utility may be positive although the probability of 
adequate analgesia is small. We therefore calculated utility U2 giving the probability of adequate 
analgesia without severe respiratory depression (a desirable condition), with the probability of 
adequate analgesia defined as P(A > 0.25) or P(A > 0.5): 
Figure 2. Probability of analgesia and respiratory depression. A. Probability of analgesia versus effect-site 
concentration for P(A(CE) > 0.25) (orange lines) and P(A(CE) > 0.5) (blue lines). B. Probability of respiratory 
depression versus effect-site concentration for P(R(CE)  > 0.5). C. Probability of analgesia versus time following 
a bolus infusion of 50 μg alfentanil for P(A(t) > 0.25) (orange lines) and P(A(t) > 0.5) (blue lines). D. Probability of 
respiratory depression versus time following a bolus infusion of 50 μg alfentanil for P(R(t) > 0.5). The broken lines 
are the 95% confidence intervals.
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 U2(A > 0.25) = P(A > 0.25 AND R ≤ 0.5)     (5)
and
 U2(A > 0.5) = P(A > 0.5 AND R ≤ 0.5)     (6)
Finally we defined the utility U3 that gives the probability of severe respiratory depression and 
inadequate analgesia (the least desirable condition) for P(A ≤ 0.25) and P(A ≤ 0.5): 
 U3(A ≤ 0.25) = P(R > 0.5 AND A ≤ 0.25)     (7)
and 
 U3(A ≤ 0.5) = P(R > 0.5 AND A ≤ 0.5)     (8)
To assess the uncertainty in these measures, the above procedure was repeated for 1,000 
bootstrap-derived replicated estimates of the model parameters (medians and expected 
value η covariances). Because the full bootstrap is not feasible with respect to computer time, 
we used the simplified nonparametric bootstrap method as implemented in NONMEM.21 
In short, rather than sampling from individual data to create bootstrap data sets and fitting 
each data set, the simplified bootstrap samples from the empirical Bayesian estimates of the 
interindividual variability terms (η) from the fit of the original data. This yields estimates of the 
interindividual variabiltity in the model parameters for each simplified bootstrap iteration, so 
that the uncertainty in the interindividual variability estimates - and hence the uncertainty in the 
utility functions - can be assessed. PK-PD profiles were calculated in the software environment 
R rather than in NONMEM to gain speed (with analytical expressions for concentrations after a 
bolus dose).
RESULTS
In the analysis we included PK data sets from 48 subjects, ventilation PD data from 19 subjects 
and analgesia data from 32 subjects. All subjects were Caucasian with a mean age (range) of 
23.7 (19-31) years, mean weight of 78.8 (70.5-99.8) kg and mean body mass index 24.0 (20.2-
29.5) kg/m2. 
PHARMACOKINETIC ANALYSIS
The PK model consisted of three compartments; one central compartment (V1) and two 
peripheral compartments (V2 and V3). The PK parameters estimates are shown in Table 1. Two 
error terms were incorporated in the model, an additive (σ1) and a relative (σ2). Goodness of 
fits plots are shown in Figure 1, panels A and B. Inspection of the data demonstrates that the 
model adequately describes the data. There is a small misfit in the alfentanil PK data in the 
lower concentration ranges as described previously (data from study 1).17 
PHARMACODYNAMIC ANALYSIS
The goodness of fits plots, shown in Figure 1 panels C to F, show that the PD models adequately 
describes the ventilation and analgesia data. PD parameter estimates are given in Table 1. 
The blood-effect-site equilibration half-life of alfentanil-induced ventilatory depression was 
relatively small (estimate = 3.99 ± 1.6 min); the C50V or potency parameter estimate = 81.6 ± 20.5 
ng/mL. Compared to ventilation, the blood-effect-site equilibration half-life for analgesic effect 
was greater by a factor of 3 (t1/2keO for analgesia = 11.7 ± 5.2 min), while potency parameter C50A 
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was of the same order of magnitude (C50 for analgesia  = 97.9 ± 19.4 ng/mL). 
UTILITY FUNCTIONS
The sigmoidal relationships between effect probability and effect-site concentrations are given 
in Fig. 2A for P(A(CE) > 0.25) and P(A(CE) > 0.5) and for P(R(CE) > 0.5) in Fig. 2B. The relationships are 
given ± the 95% confidence intervals (CI). The probability of effect in the time domain following 
a bolus administration of 50 μg/kg alfentanil is given in Fig. 2C for P(A(t) > 0.25) and P(A(t) > 0.5) 
and in Fig. 2D for P(R(t) > 0.5). As expected the probabilities of at least 25% analgesia exceed 
that of at least 50% analgesia in both concentration and time domains. Directly following the 
bolus infusion (Figs. 2C and D) the probability of analgesia > 25% and respiratory depression 
> 50% both approach 1. Due the rapidly decreasing effect-site concentration the probabilities 
drop towards zero, albeit at a greater speed for respiratory depression than for analgesia (P(A(t) 
> 0.25): not different from zero at t > 200 min; P(R > 0.5): not different from zero at t > 130 min).
 
U1. The calculated utility functions ± 95% confidence intervals as function of effect-site 
Figure 3.  Utility functions. A. Probability of at least 25% analgesia minus the probability of at least 50% 
respiratory depression versus effect-site concentration. B. Probability of at least 50% analgesia minus the 
probability of at least 50% respiratory depression versus effect-site concentration.  C. Probability of at least 25% 
analgesia minus the probability of at least 50% respiratory depression versus time following a bolus infusion 
of 50 μg alfentanil. D. Probability of at least 50% analgesia minus the probability of at least 50% respiratory 
depression versus time following a bolus infusion of 50 μg alfentanil. The continuous lines represent the utility 
function, the broken lines the 95% confidence intervals.
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concentration are shown in Figs. 3A and B for P(A(CE) > 0.25) – P(R(CE) > 0.5)  and P(A(CE) > 0.5) 
– P(R(CE) > 0.5). The utility function P(A(CE) > 0.25) – P(R(CE) > 0.5) is positive over the effect-site 
concentration range of 0-300 ng/mL but only significantly different from zero from 26-158 ng/
mL (Fig. 3A). This indicates that over the effect-site concentration range of 26 to 168 ng/mL 
P(A > 0.25) > P(R > 0.5). The maximum effect (U1(CE) = 0.31, 95% CI 0.08-0.52) occurred at an 
effect-site concentration of 52 ng/mL. The utility function P(A(CE) > 0.5) – P(R(CE) > 0.5) was not 
different from zero over the effect-site concentration range of 0-300 ng/mL (Fig. 3B), indicative 
of a balance between the probability for analgesia and respiratory depression, i.e. P(A(CE) > 0.5) 
= P(R(CE) > 0.5). 
The utility in the time domain, given for a bolus dose of 50 µg/kg (Figs. 3C and D), is biphasic 
for both P(A(t) > 0.25) and P(A(t) > 0.5). For P(A(t) > 0.25) – P(R(t) > 0.5) the function is negative 
from t = 2 to 6 min (peak effect -0.25, 95% CI -0.043 to -0.08, at t = 2 min) followed by values 
significantly greater than zero from t = 22-124 min (Fig. 3C). Thereafter the function is not 
different from zero, indicative of similar probabilities for analgesia and respiratory depression. 
For P(A(t) > 0.5) – P(R(t) > 0.5) the function is negative from t = 1 to 21 min (peak effect -0.54, 
95% CI -0.74 to -0.36, at t = 2 min), after which the function is not different from zero (Fig. 3D). 
Figure 4. A. Probability of at least 25% analgesia AND no more than 50% respiratory depression versus effect-
site concentration. B. Probability of at least 50% analgesia AND no more than 50% respiratory depression versus 
effect-site concentration. C. Probability of at least 25% analgesia AND no more than 50% respiratory depression 
versus time following a bolus infusion of 50 μg alfentanil. D. Probability of at least 50% analgesia AND no more 
than 50% respiratory depression versus time following a bolus infusion of 50 μg alfentanil. The continuous lines 
are the probabilities, the broken lines the 95% confidence intervals.
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U2. The desirable outcome of opioid treatment of pain is analgesia with limited respiratory 
depression. We give the utility functions P(A(CE) > 0.25 AND R(CE) ≤ 0.5) and P(A(CE) > 0.5 AND 
R(CE) ≤ 0.5) in Fig. 4. In the concentration domain the probability of at least 25% analgesia 
but less than 50% respiratory depression reaches a maximum of 0.41 (95% CI 0.29-0.55) at an 
effect-site concentration of 68 ng/mL (Fig. 4A), while for at least 50% analgesia and less than 
50% respiratory depression the maximum of 0.21 (95% CI 0.12-0.31) is reached at an effect-site 
Parameter Estimate ± SEE ω2 ± SEE ν2 ± SEE
Pharmacokinetic parameter estimates
V1 (L) 5.73 ± 0.82 0.08 ± 0.03 0.04 ± 0.02
V2 (L) 3.02 ± 1.41 0.58 ± 0.42 0.03 ± 0.02
V3 (L) 12.1 ± 0.56 0.05 ± 0.02 *
CL (L/min) 0.29 ± 0.01 0.11 ± 0.04 0.01 ± 0.004
Q2 (L/min) 1.55 ± 0.18 * 0.08 ± 0.03
Q3 (L/min) 0.43 ± 0.05 0.04 ± 0.02 *
σ1 2.85 ± 0.85
σ2 0.14 ± 0.01
Pharmacodynamic parameter estimates
Ventilation
VB 19.5 ± 1.18 0.0719 ±0.0237
C50V (ng/mL) 81.6 ± 20.5 0.896 ± 0.305
YV 1 (FIX) 0.746 ± 0.616
t1/2keOV (min) 3.99 ± 1.63 *
σV 2.26 ± 0.189
Analgesia
PB 16.0 ± 1.12 0.176 ±0.0589
C50P (ng/mL) 97.9 ± 19.4 1.08 ± 0.428
YP 1 (FIX) 0.193 ± 0.079
t1/2keOP (min) 11.7 ± 5.22 0.219 ± 0.155
σP 3.60 ± 0.655
Table 1. Pharmacokinetic and pharmacodynamic parameter estimates
SEE; standard error of the estimate, ω2; variance of the model parameter across the population, ν2; variance of 
between-occasion variability, V1, V2, V3; volume of compartments 1, 2, and 3, CL; clearance of compartment V1; 
Q2 and Q3; inter-compartmental clearances between compartments V2 - V1 and V3 - V1, σ1; standard deviation 
of absolute residual variability, σ2; standard deviation of relative variability, VB; baseline ventilation, C50V; effect-
site concentration causing 50% reduction of ventilation, YV; a shape parameter for ventilation, t1/2keOV; the 
blood-effect-site equilibration half-life for ventilation, σV; standard deviation of the absolute residual variability 
for ventilation, PB; baseline pain toleranc, C50P; the effect-site concentration causing a 50% increase in stimulus 
intensity, YA; a shape parameter for analgesia, σP; standard deviation of the absolute residual variability for 
analgesia; * not estimable.
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concentration of 93 ng/mL (Fig. 4B). The utilities in the time domain (after a bolus of 50 µg/kg 
alfentanil) are given in Fig. 4C and D. 
U3. The least desirable outcome of opioid therapy is a severe respiratory depression, P(R > 0.5) 
with inadequate analgesia, P(A(CE) ≤ 0.25) or P(A(CE) < 0.5). We give the utility functions P(R(CE) 
> 0.5 AND A(CE) ≤ 0.25) and P(R(CE) > 0.5 AND A(CE) ≤ 0.5) in Fig. 5. In the concentration domain 
the probability of at least 50% respiratory depression with no more than 25% analgesia (Fig. 5A) 
is small with a peak at an effect-site concentration of 69 ng/mL (probability 0.13, 95% CI 0.7-
0.21). The probability of at least 50% respiratory depression with no more than 50% analgesia 
(Fig. 5B) is greater, the greatest probability (0.29, 95% CI 0.20-0.41) was observed at an effect-
site concentration of 98 ng/mL. The utilities in the time domain (after a bolus of 50 µg/kg 
alfentanil) are given in Fig. 5C and D. 
Utility surface. In Figures 6A-6D, we plotted the continuum of probabilities of presence or 
absence of alfentanil analgesia in combination with presence or absence of serious respiratory 
depression, i.e. the utility surface. In panel A and B of Figure 6, we plotted the probabilities 
Figure 5. A. Probability of at least 50% respiratory depression AND no more than 25% analgesia versus effect-
site concentration. B. Probability of at least 50% respiratory depression AND no more than 50% analgesia versus 
effect-site concentration. C. Probability of at least 50% respiratory depression AND no more than 25% analgesia 
versus time following a bolus infusion of 50 μg alfentanil. D. Probability of at least 50% respiratory depression 
AND no more than 50% analgesia versus time following a bolus infusion of 50 μg alfentanil. The continuous lines 
are the probabilities, the broken lines the 95% confidence intervals.
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Figure 6. Alfentanil response surface: continuum of probabilities of alfentanil-induced analgesia and respiratory 
depression. A and B Probability vs. alfentanil effect-site concentration. C and D Probability vs. time following 
a 50 μg/kg alfentanil bolus at time t = 0. The colour shading from green to yellow and red to orange represents 
the context dependency of the utility functions on the postulated threshold for analgesia. The lines in panels B 
and D are the curves of utility functions U2 and U3 (compare with Figs. 4 and 5). The surfaces are defined by A 
and R with A++ at least 50% analgesia, A+ at least 25% analgesia, A- less than 25% analgesia, R+ at least 50% 
respiratory depression and R- less than 50% respiratory depression.
against effect-site concentration, in panel C and D the probabilities against time following a 50 
µg/kg alfentanil bolus infusion (or 3.5 mg for a 70 kg patient) at time t = 0. 
The utility surface analysis results in multiple conditions presented by colored surfaces and iso-
utility lines (panels B and D); the iso-utility lines are the curves of the utility functions defined 
by U2 and U3 (compare with curves in Figs. 4 and 5), while the surfaces are defined by A and 
R with A++ at least 50% analgesia, A+ at least 25% analgesia, A- less than 25% analgesia, R+ at 
least 50% respiratory depression and R- less than 50% respiratory depression. This results in the 
following six conditions:
- Green surface: analgesia without respiratory depression (A++R- and A+R-);
- Red surface: no analgesia with respiratory depression (A-R+ and A+R+);
- Yellow surface: no analgesia and no respiratory depression (A-R-);
- Orange surface: analgesia with respiratory depression (A++R+). 
The smooth transitions between colors are transients in between the given states. 
It is clear from Figures 4 and 6 (panels A and B) that the optimum analgesia probability without 
serious respiratory depression (green surface in Fig. 6) is reached at an effect-site concentration 
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Figure 7. Fentanyl response surface: continuum of probabilities of fentanil-induced analgesia and respiratory 
depression. A and B Probability vs. alfentanil effect-site concentration. C and D Probability vs. time following a 
50 μg/kg alfentanil bolus at time t = 0. The colour shading from green to yellow and red to orange represents the 
context dependency of the utility functions on the postulated threshold for analgesia. The lines in panels B and D 
are the curves of utility functions U2 and U3. The surfaces are defined by A and R with A++ at least 50% analgesia, 
A+ at least 25% analgesia, A- less than 25% analgesia, R+ at least 50% respiratory depression and R- less than 
50% respiratory depression.
of 60 ng/mL, thereafter the probability of analgesia is reduced and eventually exceeded by 
the probability of serious respiratory depression (orange surface). Figures 6C and D shows that 
following a single injection (50 µg/kg) maximum analgesia with serious respiratory depression 
(orange surface) peaks at 10 min, an optimum in analgesia probability without serious 
respiratory peak at 60 min after which both analgesia and respiratory depression dissipate. 
DISCUSSION
In the treatment of pain and nociceptive responses we aim to provide optimal analgesic effect 
with preferably no (or very little) side effects. Still, the most common group of drugs used in pain 
medicine and anesthesia to relief moderate to severe pain and blunt nociceptive responses, i.e. 
the opioid analgesics, produces a myriad of side effects. Since “benefit” (analgesia) and “harm” 
(side effects) coincide but often with dose or concentration-effect relationships that are distinct, 
i.e. not parallel, it is often difficult to reliably combine multiple end-points into one number or 
function.14 Sheiner and Melmon introduced a concept derived from economic decision theory 
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that allows combining of different end-points into one number, the utility, which they defined 
as the benefit of a drug minus the harm it produces.22 They applied their concept to describe 
the benefit and harm of antihypertensive therapy. The concept was later used by Cullberg to 
define the outcome of anti-thrombin therapy.23 In earlier studies, we applied the concept of the 
utility function to characterize a serious and potentially lethal opioid-side effect, respiratory 
depression, relative to the obtained analgesic efficacy. We tested various opioids including 
fentanyl, oxycodone and the relatively new opioids tapentadol and cebranopadol.11,13,15,24 
Our main aim was to create a set of utility functions that allows comparisons among drugs. 
We argued that a drug with positive utilities over the clinical concentration range (i.e., with 
a higher probability for analgesia than respiratory depression) is preferable over a drug with 
a negative utility (i.e., with a higher probability for respiratory depression than analgesia). 
In their editorial, Kharasch and Rosow argued that while the benefit-risk measure that we 
developed (i.e. the utility function) “appears to be precise and reproducible [and] also seems to 
be an excellent method for combining high-quality estimates of population pharmacokinetic-
pharmacodynamic modeling”, it requires refinement and validation that it predicts relevant 
clinical outcomes.14 In the current study we further developed the utility function. We estimate 
95% confidence limits around the function based on bootstrap sampling of the nonparametric 
distribution of the model parameters. Furthermore, we calculate the probabilities of a series of 
distinct conditions: the probability of adequate analgesia with or without severe respiratory 
depression (A++R-, A+R-, A++R+ and A+R+; Figs. 6 and 7) and the probability of inadequate 
analgesia with or without severe respiratory depression (A-R+, A-R-, Figs. 6 and 7). We argue 
that the use of these adapted utility functions is preferable above a utility function that is the 
result of the subtraction of one probability from the other, that is constrained in magnitude 
between values -1 to +1 and that gives no indication of the probability of distinct outcomes, 
such as desired (A++R-) and undesired outcomes (A-R+) and all possibilities in between.  
In the current study we applied the adapted utility functions to the μ-opioid analgesic 
alfentanil. We combined the results of three previous pharmacokinetic-pharmacodynamic into 
one analysis. The analyses were performed in multiple steps. A population PK analysis led to 
individual PK parameters estimates that were inputted into the PD models of analgesia and 
respiratory depression. We subsequently calculated the probabilities of P(A > 0.25), P(A > 0.5) 
and P(R > 0.5) in both concentration and time domains (Fig. 2) by performing 1000 simulations 
for both end-points. Subsequently, the original (U1) and adapted utility functions (U2 and U3) 
were determined (Figs. 3-5). As stated previously, the utility function is context sensitive, in 
which the context is the numerical response threshold.13 For example, for P(A) we applied two 
thresholds: A > 0.25 and A > 0.5; the difference in thresholds reflects the difference in analgesic 
effect, i.e. a 25% and 50% increase in tolerated electrical current. We regard the 25% threshold 
as the clinically more realistic end-point for chronic pain therapy (the effect-site concentration 
producing a 25% increase in stimulus intensity is in the range of concentrations observed in 
postoperative pain therapy),25 while the 50% threshold may be more relevant in anesthesia 
practice.26 Further studies will need to confirm whether our extrapolation of experimental data 
to clinical data is valid.
The results of our analyses are summarized in the utility surface of Fig. 6, which combines 
multiple conditions into one graph: analgesia without respiratory depression (green surface), 
respiratory depression without analgesia (red surface), neither respiratory depression nor 
analgesia (yellow surface) and analgesia combined with respiratory depression (orange surface). 
If we compare the two extremes (red vs. green surfaces), it is obvious that the probability of 
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the desired effect (green surface) exceeds the probability of the most unwanted effect (red 
surface). At an effect-site concentration of 68 ng/mL the probabilities differ significantly  (odds 
ratio = 4.0; Fig. 6A and B); similarly, 1 hour after a bolus dose of 50 μg/kg, the probabilities differ 
(odds ratio 4.0; Fig. 6C and D). 
It is important to realize that while the probabilities of the most desired condition (adequate 
analgesia without respiratory depression) and the least desired condition (inadequate analgesia 
with respiratory depression) are both maximal at about the same effect-site concentration, their 
probabilities are different. The probability of the most desired condition is much higher than 
the probability of the least desired condition, which would be expected of a clinically useful 
drug. Even if the probabilities were about the same, or reversed, the utility function would 
retain its utility as classifying it as a drug with lower clinical utility. The concentrations where 
the probabilities of the conditions are maximal depend on the thresholds chosen, as can be 
seen in Figure 6, and the potencies for the desired and side effects. The point is that the clinical 
utility of drugs may be compared, under the condition that the chosen thresholds are the same.
As we stated above, we consider the utility function suitable for a comparisons among drugs. As 
an example we compared the utility surfaces of alfentanil and fentanyl. Both are fenylpiperidines 
mu-opioid analgesics, are used as intravenous anesthetics. In Fig. 7, we plotted the fentanyl 
utility surface based on our previous population pharmacokinetic pharmacodynamic analysis.13 
Figs. 7A and B (utility vs. fentanyl CE) may be compared to Figs. 6A and B (utility vs. alfentanil 
CE). These response surfaces of the two opioids are similar and implies that fentanyl is more 
potent by a factor of 70 to 80 (in terms of effect-site concentration). This potency difference 
derived from the utility surface is similar to the potency ratio of 75 observed for the effect-
site concentration that causing one-half of the EEG-slowing (6.9 ng/mL for fentanyl and 520 
ng/mL for alfentanil).26 These similarities  give further validity to our approach. The surface 
similarity indicates that for the same probability of analgesia, a similar probability of respiratory 
depression is observed for these two opioids. While we believe that the comparison between 
these two opioids is valid (both drugs were tested in a similar population of healthy volunteers 
using identical experimental set-ups), we, however, need to realize that our data are derived 
from young volunteers without pain or co-morbidities, and further studies should address the 
utility of opioid treatment in patients. For example, our approach is suitable to compare the 
utility of analgesic medication between patient sub-populations, such as patients with and 
without sleep apnea syndrome, patients with and without chronic pain, opioid-naïve patients 
and chronic opioid users. Additionally, our approach enables construction of utility functions 
of drug efficacy versus slowly emerging complications of long-term drug therapy, such as 
development of tolerance, hyperalgesia, cognitive dysfunction or the late occurrence of tissue 
damage.
In conclusion, we further refined the utility function as (surrogate) measure of opioid benefit vs. 
harm. We defined four distinct states of analgesia and respiratory depression that reflect four 
clinical conditions that are either desirable (analgesia without respiratory depression) or highly 
undesirable (respiratory depression without analgesia) and two intermediate (undesirable) 
states (neither analgesia nor respiratory depression and analgesia combined with respiratory 
depression). Our utility function may be used to compare the respiratory effects of analgesics 
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Chapter 6
Respiratory effects and naloxone 
reversal of the novel opioid analgesic 
RM101





According to the WHO pain ladder, weak opioids can be used for treatment of moderate pain 
while potent opioids are useful in the treatment of moderate to severe pain.1-3 Common adverse 
events of opioids include dizziness, nausea/vomiting, constipation and respiratory depression 
(respiratory depression occurs due to activation of the µ-opioid receptor (MOR) in the 
respiratory centers of the brainstem).  Additionally, opioids are drugs of abuse and especially the 
combination of abuse/misuse and respiratory depression is potentially life-threatening. Indeed, 
since 1999 the number of overdose deaths due to prescription opioids quadrupled in the US 
alone, with more than 250,000 deaths since 2004. Among the 47,055 drug overdose deaths that 
occurred in the United States in 2014, 28,647 (60.9%) involved an opioid.3,4 Consequently, there 
is the need for an immediate solution to this devastating problem. One solution would be the 
development of an opioid without respiratory depression but with retained effective analgesia. 
For example, opioids that interact with multiple opioid receptors (MOR, κ-opioid receptor (KOR), 
δ-opioid receptor (DOR) or the nociceptin/orphanin FQ (NOP) receptor) might produce less 
respiratory depression due to less reliance on the MOR for effective analgesia and a respiratory 
stimulatory effect from activation of the DOR or NOP receptor.5 Examples of such opioids are 
buprenorphine (MOR/KOR activation) and cebranopodol (MOR/NOP receptor activation). Both 
opioids show ceiling (i.e. plateau phase in maximal effect) in respiratory depression.6-8 
In the current study, we performed a population pharmacokinetic-pharmacodynamic (PK-PD) 
modelling study in healthy volunteers to determine the respiratory effects of yet another novel 
opioid analgesic, acting at the three classical opioid receptors, RM101. Varying doses of this 
opioid were administered to objectify its depressant effects on isohypercapnic ventilation. 
Additionally, the ability of naloxone to reverse the respiratory effects of RM101 was studied. 
MATERIALS AND METHODS 
SUBJECTS
Healthy male subjects, aged 18-45 years with a body weight of 60 to 100 kg and a body mass 
index (BMI) of 18 to 30 kg/m2, were allowed to participate in the study. Prior to enrolment, the 
local Human Ethics Committee of the Leiden University Medical Centre approved the protocols 
and written informed consent was obtained from the participants. They all underwent a 
medical screening (medical history, physical examination, 12-leads ECG, blood chemistry, 
hematology and virology) before randomization. Exclusion criteria were presence or history 
of a major medical condition, history of alcohol abuse or illicit drug use, use of medication 
(vitamins, herbal and mineral supplements included), smoking of more than 20 cigarettes 
per day, positive urine drug screen or alcohol breath test on the morning of the experiment, 
abnormalities in the blood chemistry/hematology/virology, QTc interval > 450 msec and known 
drug allergies. All participants had to refrain from food and drinks for at least 6 hours prior to 
dosing until 8 hours post-dosing.
STUDY DESIGN
We performed a randomised, placebo-controlled, double blind, dose-escalating respiratory 
study in 28 subjects, followed by a single-dose randomised study to determine the ability of 
naloxone to reverse the effect of RM101 in 8 subjects.
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Respiratory study. Subjects were divided in dose-escalating cohorts: 0.2 µg/kg (cohort 1), 
0.25 µg/kg (cohort 2), 0.3 µg/kg (cohort 3) and 0.4 µg/kg (cohort 4). Each cohort consisted 
of 6 subjects receiving RM101 and one subject who received a placebo infusion. Study drug 
administration occurred in 10 min. If two subjects within one cohort hit one or more stopping 
rules the cohort was discontinued. Stopping rules were: apnea > 90 sec, end-tidal pCO2 > 67.5 
mmHg, increase in QTc time > 60 msec above baseline values or QTc time > 500 msec. 
Reversal study. Subjects were dosed with 0.25 µg/kg RM101 in 10 minutes. Five minutes after 
RM101 infusion, naloxone 0.4 mg intravenous was administered in 90 seconds. Depending 
on the effect, naloxone was repeated at 4 minute intervals, as necessary up to a maximum of 
4 doses (1.6 mg in 12 minutes). Reversal was deemed effective when ventilation returned to 
baseline ventilation ± 20%. 
Drugs and randomization. All drugs (RM101, naloxone, placebo) were prepared by the 
local pharmacy on the day of the study and delivered in identical syringes that contained a 
clear unidentifiable liquid. The syringe was coded with subject and visit numbers. RM101 
was dissolved in citrate buffer (pH 5); placebo contained the buffer solution. Randomization 
was performed by the study sponsor using a validated system that automates the random 
assignment of treatment groups to randomization numbers. 
Respiratory measurements. Subjects breathed through a facemask (fitted over nose and mouth). 
The airway gas flow was measured by a pneumotachograph (#4813; Hans Rudolph, Kansas City, 
MO) connected to a pressure transducer, which yields a volume signal. The pneumotachograph 
was heated (37°C) throughout the study period. This signal was calibrated with a 1-l calibration 
syringe (Hans Rudolph). The pneumotachograph was connected to a T-piece; one arm of the 
T-piece received a gas mixture at a flow rate of 45 l/min from a gas mixing system, consisting 
of three mass-flow controllers (Bronkhorst High-Tec, Veenendaal, The Netherlands) via which 
the flow of oxygen (O2), nitrogen (N2) and carbon dioxide (CO2) could be set individually at 
any desired level. A computer provided control signals to the mass-flow controllers allowing 
adjustment of the inspired gas mixture to force the end-tidal gas concentrations of oxygen and 
carbon dioxide to follow a specific pattern in time. Gas concentrations were measured with 
a gas analyzer (Datex Multicap, Helsinki, Finland); arterial hemoglobin oxygen saturation was 
measured via a finger probe with a Masimo pulse oximeter (Irvine, CA).
Respiration was measured at a clamped increased end-tidal carbon dioxide tension (pCO2) 
using the  “Dynamic End-Tidal Forcing” technique.  In each subject, the end-tidal pCO2 was 
increased in steps of 2–3 mmHg until isohypercapnic ventilation reached a value 20–24 L/
min. The end-tidal pCO2 was kept constant at this level throughout the study (baseline end-
tidal pCO2 level). The end-tidal oxygen concentration (pO2) was kept constant at 110 mmHg 
throughout the study. After a steady state in isohypercapnic ventilation was obtained, the 
medication was infused in 10 minutes, and breath-to-breath ventilatory measurements were 
continued during infusion and obtained for the next 60 min. Thereafter, isohypercapnic 5-min 
measurements were obtained at 30-min intervals until t = 8 h after the administration, or until 
return within 10% of isohypercapnic baseline ventilation for two consecutive measurements for 
the respiratory study and 20% in the reversal study. The following variables were collected on 
a breath-to-breath basis on a computer disc for further analysis: inspiratory minute ventilation, 
end-tidal pCO2, end-tidal pO2, and oxygen saturation. 
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Blood sampling. All subjects received an arterial line in the radial artery of the non-dominant 
arm for blood sampling. In total 19 arterial samples were taken at t = 0, 2, 5, 8, 10, 12, 15, 18, 20, 
25, 30, 40, 60, 90, 120, 180, 240, 300 and 480 min after the start of infusion of RM101/placebo at 
t = 0. In the reversal study, the arterial samples were used to determine plasma concentrations 
of naloxone at t = 0, 18, 20, 25, 30, 40, 60, 90, 120, 180, 240, 300 and 480 min. Plasma was 
separated within 30 minutes after collection and stored at -20 °C until analysis. Plasma samples 
were analysed using validated LC-MS/MS methods, with lower limits of quantification of 5 and 
5 pg/ml respectively. 
PHARMACOKINETIC-PHARMACODYNAMIC ANALYSES
The pharmacokinetic (PK)-pharmacodynamic (PD) data were analysed with the mixed-effects 
modelling software package NONMEM VII (ICON Development Solutions, North Wales, MD) 
using a population approach. We performed a two-stage approach. From the first stage (PK 
analysis), for each individual, empirical Bayesian estimates of the PK parameters were obtained 
and were applied in the second stage (PD analysis). 
Pharmacokinetic analysis. To obtain the best pharmacokinetic model, two and three 
compartment models were fitted to the pharmacokinetic data. The number of compartments 
in the model was determined by the magnitude of decrease in the minimum objective function 
value (MOFV; χ2-test; P < 0.01 was considered significant). Weight and dose were considered as 
covariates. The best model will be reported.  
Figure 1. A. Mean plasma RM101 concentrations. B. Mean plasma naloxone concentrations. C. Measured 
ventilation during infusion of RM101 in different dosages. D. Measured ventilation during infusion of RM101 
with naloxone (orange) or placebo (blue). In A and C RM101 0.2 µg/kg; blue symbols, RM101 0.25 µg/kg; green 
symbols, RM101 0.3 µg/kg; orange symbols. 
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Pharmacodynamic analysis. Ventilation data of each subject was averaged over 1-min 
periods. We assume that:
  Ventilation(t) = VN(t) + G(t) · (P(t) – PB)     (1)
Here, VN is normocapnic baseline ventilation, G is CO2 sensitivity, PB is baseline end-tidal pCO2, 
and P (t) is the measured end-tidal pCO2 at (t), delayed with half-life t1/2keOP. It is assumed that 
RM101 affects both VN and G, using a sigmoid EMAX models:
 VN (t) = VN / (1 + CE (t) / C50γVN)     (2)
 G (t) = G / (1 + CE (t) / C50γG)       (3)
Where CE is the effect-site concentration at (t), C50VN the RM101 effect-site concentration 
causing a 50% depression of ventilation, C50G the RM101 effect-site concentration causing a 
50% decrease in CO2 sensitivity and γ the shape or Hill parameter for respectively baseline 
ventilation (γVN) or CO2 sensitivity (γG). To eliminate a hysteresis between the estimated drug 
concentrations and effect, an effect compartment was postulated. This effect compartment 
equilibrates with the plasma compartment with half-life t1/2keOVN for VN and t1/2keOG for G, 
respectively. 
The effect of naloxone was assumed to be on parameter C50VN and C50G, assuming a linear 
relationship between dose and effect:
 C50’= C50VN · (1 + CNLX / C100NLX)     (4)
 C50’= C50G · (1 + CNLX / C100NLX)     (5)
Where C50’ is the C50VN, respectively C50G after administration of naloxone, CNLX is the effect-site 
concentration naloxone and CNLX is the naloxone concentration in which the C50 of RM101 
doubles.  
Model parameters were assumed to be log-normally distributed. Residual error was assumed 
to have both an additive and a relative error for concentrations and only an additive error for 
all effect parameters. Model discrimination was based on the magnitude of the MOF value (χ2-
test). P-values < 0.01 were considered significant. 
RESULTS
The data of 19 subjects are included in the respiratory analysis. Twenty-five subjects gave 
informed consent; three subjects were excluded due to either previous drug abuse or medical 
history. Of the 22 subjects, 3 subjects were randomized to placebo infusion and not included 
in the respiratory analysis. In cohort 3, one subject reached a stopping rule; he desaturated 
due to apnea (SpO2 < 85%). In cohort 4, only one subject was dosed due to the fact that this 
one subject reached two stopping rules; apnea > 90 sec and his QTc time increased > 60 
msec. Hereafter, this respiratory study was terminated.  In the reversal study, 14 subjects were 
randomized. After 5 experiments (3 naloxone, 2 placebo), the RM101 dose was decreased to 0.2 
µg/kg due to excessive vomiting after administration of naloxone. Eleven subjects (3 subjects 
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with 0.25 µg/kg, 8 subjects with 0.2 µg/kg) were included in the analysis. The average age of the 
subjects was 23.8 ± 0.4 years (mean ±  SEM) and weight 78.5 ± 1.8 kg. In the reversal study, the 
average age was 23.5 ± 0.9 years and weight 81.3 ± 2.3 kg. 
PHARMACOKINETIC ANALYSIS
In Fig. 1 the mean RM101 and naloxone plasma concentrations are shown. Peak arterial plasma 
RM101 concentration was reached after 10 min: 550 ± 52 ng/mL, 704 ± 16 ng/mL and 729 
± 46 ng/mL (mean ± SEM) for respectively 0.2 µg/kg, 0.25 µg/kg and 0.3 µg/kg RM101. The 
Figure 2. RM101 pharmacokinetic (PK) data fits. Best (A), median (B) and worst (C) pharmacokinetic data fits. 
(D), (E) and (F) are the best, median and worst ventilation data fits. (G), (H) and (I) are the best, median and 
worst naloxone PK data fits. (J), (K) and (L) are the best, median and worst ventlation with naloxone data fits.  
Goodness-of-fit was based on the coefficient of determination. 
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Table 1. Pharmacokinetic and pharmacodynamic parameter estimates of RM101 and naloxone. 
SE; standard error of the estimate, ω2 ; variance of the model parameter across the population, V1, V2, V3; volume 
of compartments 1, 2, and 3, CL; clearance of compartment V1, CL2 and CL3; inter-compartmental clearances 
between compartments V2 - V1 and V3 - V1, σ1; standard deviation of absolute residual variability, σ2; standard 
deviation of relative variability, VN; normocapnic baseline ventilation, G; CO2 sensitivity, PB; baseline end-tidal 
CO2, t1/2keOVN; the blood-effect-site equilibration half-life for normocapnic ventilation, t1/2keOVG; the blood-
effect-site equilibration half-life for CO2 sensitivity, C50VN; RM101 effect-site concentration causing 50% reduction 
of ventilation, C50G; effect-site concentration causing 50% reduction in CO2 sensitivity, YVN ; a shape parameter 
for baseline ventilation, YG; a shape parameter for CO2 sensitivity, t1/2keOVNLX; the blood-effect-site equilibration 
half –life for naloxone, C100N ; the naloxone concentration in which the C50 of RM101 doubles, t1/2keOP; the blood-
effect-site equilibration half-life for normocapnic ventilation, σ; standard deviation of the absolute residual.
* Not estimable.
Estimate ± SEE ω2 ± SEE Estimate ± SEE ω2 ± SEE
                                        RM101 PK parameter estimates Naloxone PK parameter estimates
V1 (L) 5.59 ± 0.54 0.06 ± 0.04 25.3 ± 3.92 *
V2 (L) 25.2 ± 2.95 0.05 ± 0.02 160 ± 11.1 *
V3 (L) 56.1 ± 6.97 0.08 ± 0.05
CL1 (L/min) 1.12 ± 0.05 0.03 ± 0.02 3.66 ± 0.15 0.01 ± 0.01
CL2 (L/min) 2.33 ± 0.20 0.09 ± 0.03 3.86 ± 0.73 0.13 ± 0.06
CL3 (L/min) 0.50 ± 0.07 0.16 ± 0.08
σ1 0.14 ± 0.02 0.35 ± 0.02
σ2 8.2 ± 3.24
                                         PKPD analysis: RM101          Ventilation PKPD analysis: RM101 + naloxone 
Ventilation
VN (L) 8.52 ± 0.43 0.04 ± 0.01 9.04 ± 0.43 0.05 ± 0.02
G (kPa) 5.12 ± 0.08 * 5.29 ± 0.11 0.01 ± 0.003
PB (kPa) 11.6 ± 1.47 0.12 ± 0.05 13.3 ± 1.08 0.11 ± 0.04
t1/2keOVN (min) 4.48 ± 1.11 0.40 ± 0.30 1.97 ± 0.22 *
t1/2keOG (min) 31.3 ± 3.95 0.17 ± 0.07 33.6 ± 12.2 1.52 ± 0.06
C50VN (ng/mL) 400 ± 74.1 0.19 ± 0.07 353 ± 105 *
C50G (ng/mL) 51.5 ± 6.51 * 33.3 ± 12.0 1.26 ± 0.48
γVN 0.82 ± 0.19 0.71 ± 0.23 1.11 ± 0.16 *
γG 2.46 ± 0.22 0.11 ± 0.04 1.73 ± 0.20 0.08 ± 0.03
t1/2keONLX (min) 22.8 ± 4.89 0.56 ± 0.40
C100NLXVN (ng/mL) 0.12 ± 0.04 *
C100NLXG (ng/mL) 1.24 ± 0.33 *
t1/2keOP (min) 10.4 ± 2.73 0.37 ± 0.13 7.28 ± 1.57 0.33 ± 0.13
σ 1.42 ± 0.08 1.69 ± 0.01
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Figure 3. Goodness of fit plots of the pharmacokinetic and pharmacodynamic analysis. A. RM101 concentration: 
measured versus individual predicted values. B. RM101 concentration: individual weighted residuals (IWRES) 
versus time. C. Ventilation: measured versus individual predicted values. D. Ventilation: individual weighted 
residuals (IWRES) versus time. E. Naloxone concentration: measured versus individual predicted values. F. 
Naloxone concentration: individual weighted residuals (IWRES) versus time. G. Ventilation with naloxone: 
measured versus individual predicted values. H. Ventilation with naloxone: individual weighted residuals 
(IWRES) versus time.
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pharmacokinetic model of RM101 consisted of a three-compartment model with one central (V1) 
and two peripheral compartments (V2 / V3). The pharmacokinetic model for naloxone consisted 
of a two-compartmental model with one central (V1) and one peripheral compartment (V2). 
Covariate weight or dose did not improve the fits. The PK parameter estimates are shown in 
Table 1. Best, median and worst fits (based on the coefficient of determination) are shown in 
Fig. 2 (RM101 Figs. 2A-C, naloxone Figs. 2G-I). Goodness of fit plots are shown in Fig. 3 (RM101 
Figs. 3A-B, naloxone Figs. 3E-F). Inspection of the individual data and the goodness of fit plots 
indicate that the PK data are adequately described by the pharmacokinetic models of RM101 
and naloxone. 
PHARMACODYNAMIC ANALYSIS
RM101 induced a rapid respiratory depressant effect within 15 min, which ranged from 54% 
(0.2 µg/kg) to 68% (0.3 µg/kg). Eight subjects demonstrated effective reversal of the opioid-
induced respiratory depression (naloxone dose 0.4-1.6 mg); in 3 subjects naloxone was unable 
to reverse respiratory depression. 
Inspection of the individual fits and the goodness of fit plots indicate that the model adequately 
described the data (Figs. 2 and 3). In Figure 2 best, median and worst fits are shown (data of 
both studies are included). RM101 had an effect on VN and G (CO2 sensitivity). The effect on 
ventilation occurred rapidly with a t1/2keOVN of 4.5 ± 1.1 min and a C50VN of 400 ± 74 ng/ml. The 
effect on CO2 sensitivity was slower (t1/2keOG 31.3 ± 4 min), but took place at substantially lower 
plasma concentrations than the effect on ventilation (C50G 51.5 ± 6.5 ng/ml).  
At a steady-state arterial naloxone plasma concentration of 0.12 ± 0.04 ng/mL (C100NLXVN), 
the arterial plasma concentration of RM101 causing a 50% depression of ventilation (C50VN) 
doubled from 353 to 707 ng/mL. At an arterial plasma naloxone concentration of 1.24 ± 0.33 
ng/ml (C100NLXG), the arterial RM101 plasma concentration that induces a 50% decrease in CO2 
sensitivity (C50G) doubled from 33 to 66 ng/mL. The equilibration half-life of naloxone’s reversal 
on ventilation and CO2 was 22.8 ± 4.9 min. 
DISCUSSION
In this placebo-controlled, dose-escalating, double blind and randomized study, the effect of 
the novel MOR, KOR and DOR opioid agonist RM101 on ventilation was studied. The PK-PD 
analysis demonstrated that RM101 had two distinct actions: at low plasma concentrations a 
slow effect on CO2 sensitivity, at higher plasma concentrations a more rapid effect on ventilation. 
We further observed that naloxone antagonized RM101-induced respiratory depression by 
doubling plasma RM101 concentrations needed to decrease ventilation with 50%.
Developments in the prevention of opioid-induced respiratory depression (OIRD) focus either 
on the reversal or prevention of OIRD through the co-administration of respiratory stimulants 
or on the development of an opioid without/with reduced effect on ventilation. Recently 
tested non-opioid respiratory stimulants are for example ampakines, 5HT receptor agonists, 
phosphodiesterase inhibitors and potassium channel blockers.5,9-11 Opioids with reduced 
respiratory effects often act at multiple opioid or receptor systems or at opioid and non-opioid 
receptor systems.5 Examples of the former are cebranopadol, a MOR and NOP receptor agonist 
that displays ceiling in respiratory depression due to a respiratory stimulatory effect due to NOP 
activation.8 Another example of the latter is tapentadol, a MOR agonist that also inhibits cellular 
noradrenaline reuptake. Noradrenaline acts at alpha2-adrenergic receptors within the spinal 
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dorsal horn. The activation of MOR and adrenergic pathways produces synergistic analgesic 
effects with a reduced side effect profile.12 RM101 produced respiratory depression. Although 
Fig. 1D suggests ceiling in respiratory effect, our PK-PD analysis could not confirm this. Hence 
our results show that RM101 behaves differently from either buprenorphine or cebranopadol, 
although the respiratory effects are best viewed in light of RM101’s analgesic effects. To that 
end analgesic studies (preferably performed in the same subject population but certainly in 
the same laboratory) need to be added allowing the construction of so-called safety or utility 
functions that estimate the probability of analgesia minus the probability of respiratory 
depression and consequently allow comparison among opioids.13-15 
The study naloxone reversal of OIRD is highly relevant. Some opioids with a high affinity for the 
MOR are resistant to naloxone reversal (such as buprenorphine).16,17 Moreover, since naloxone 
has a short half-life (15-20 min), renarcotization is possible following naloxone administration, 
especially when dealing with opioids with a slow onset and offset (such as morphine and 
buprenorphine).5 Naloxone is a non-selective competitive antagonist at the μ-opioid receptor 
(MOR) with fast receptor association and dissociation kinetics.18 In this study, naloxone was 
administered in four doses of 0.4 mg, with 4 minutes between each administration. The 
naloxone dose to reverse RM101-induced respiratory depression ranged from 0.4 to 1.6 mg. 
Importantly, in two subjects the respiratory depression was not reversed by naloxone. This 
could be a dosing effect with higher naloxone doses (> 1.6 mg) needed to cause reversal in 
these two subjects. This then suggests a relative high affinity of RM101 for the MOR (at least in 
these two receptors), similar to our earlier observation with buprenorphine, but more research 
is needed to fully understand this issue.
We estimated a value for t1/2keOP (time constant of the dynamic ventilatory response to CO2) of 
10.4 ± 2.7 min. This is relatively long compared to previous observations of a half-life of about 
2-3 min. We have no explanation for this discrepancy. The ventilatory CO2 half-life is determined 
by (1) cardiac output, (2) brain blood flow and wash-in of CO2 into the brain compartment and 
(3) neuronal dynamics. Any of these factors may have been affected in our studies, possibly 
related to an interaction with the tested opioid. 
We performed the study at a clamped end-tidal pCO2 but due to the sometimes brisk respiratory 
effects, end-tidal control was suboptimal and end-tidal pCO2 occasionally inclined above the 
clamped target value. The fluctuations may have underestimated the effect of RM101 but since 
they were rather small we argue that the effects were minimal. 
In conclusion, the novel opioid analgesic RM101 produced respiratory depressant effects due 
to a rapid effect on ventilation and a slower effect on CO2 sensitivity, without ceiling. Naloxone 
reversal was observed in most but not all subjects, which is best explained by a dosing effect 
and possibly a high affinity of the drug for the MOR. More research is needed to determine the 
utility or safety function of RM101 and to determine the naloxone dose that reverses RM101’s 
respiratory effect in all subjects.  
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Chronic pain is quite prevalent in the Western world with an incidence of about 18% in the 
Netherlands, similar to estimates from other European countries and the United States of 
America (USA).1 This indicates that on a population of 17,1 million, there are about 3 million 
pain patients in the Netherlands. Treatment of chronic pain generally consists of non-
pharmacological interventions, for example physical or behavioural therapy, often combined 
with medication such as non-steroidal anti-inflammatory drugs or opioids. The intention of 
pain treatment in patients with moderate to severe acute and chronic pain is to reduce their 
symptoms and improve their quality of life. Opioids alleviate pain, however they can cause side 
effects which may be life threatening. Both in the US and the Netherlands there is a sharp rise 
in the prescription of opioids.2-5 In the Netherlands, from 2004 to 2013, the number of opioid 
users doubled to 1 million individuals.2 The majority of patients (80%) received an opioid for 
treatment of non-cancer pain, predominantly musculoskeletal pain such as lower back pain. 
Recent data show a further increase in opioid consumption in the Netherlands to 1,2 million 
users or 7% of the population in 2016. In the US the epidemic has led to a  rise in drug deaths 
with 16,000 to 20,000 prescription opioid deaths per year.3,5 Recent preliminary data suggest 
that in 2016 59,000-65,000 people died from drug overdoses in the US, of which more than 
20,000 people died from fentanyl overdose.6 Numbers of drug deaths in the Netherlands due 
to opioids are not known. 
Deaths due to opioids are related to diversion, abuse, addiction and combining opioid use 
with other centrally acting drugs such as alcohol and benzodiazepines. The cause of death is 
almost always cardiorespiratory collapse secondary to opioid-induced respiratory depression 
and cardiac arrest. Due to the rise in opioid-related mortality, the development of a treatment 
for opioid-induced respiratory depression (OIRD) is necessary. Nearly half of all opioid overdose 
deaths involve a prescription opioid, all other overdose deaths occur due to the illicit use of illegal 
opioids and heroin.7 Currently, in the United States (US) a campaign is launched (Turn The Tide 
Rx), which includes a pledge to educate clinicians to treat pain safely and effectively, screening 
patients for opioid use disorder and provide them with evidence-based treatment.8 Although 
prevention is the first step to reduce mortality caused by OIRD, the only available treatment 
of OIRD is administration of naloxone. Naloxone is a non-selective opioid receptor antagonist 
which inhibits all pharmacological effects of opioids, benefit (analgesia) and harm (side effects 
such as OIRD). The extent and the duration of naloxone reversal of OIRD is highly variable and 
related to many factors as the specific opioid used, dose administered, administration mode, 
concurrent medication, underlying disease and the exogenous stimulatory factors.9 With all 
opioids that have a longer plasma half-life than naloxone, there is a chance of recurrence of 
the OIRD, i.e. renarcotization. However this can be prevented by continuous administration 
of naloxone.10 In the US firefighters, paramedics, police officers and relatives of opioid addicts 
carry naloxone in their cars in a FDA-approved nasal spray. The FDA approved naloxone nasal 
spray in 2015. Intranasal administration of naloxone demonstrated to be as effective or exceed 
intramuscular administration of naloxone.11 
Due to the disadvantage of complete reversal of opioids activity by naloxone (OIRD as well as 
analgesia), there  is  a  need for treatment of OIRD by non-opioid drugs as potassium channel 
blockers, AMPAkines and 5-HT receptor agonists. These drugs may restore breathing to an 
acceptable level, or even prevent OIRD, without affecting analgesia. The goal of this thesis 




might prevent OIRD. In this final chapter, I will give a summary of the observations made during 
my thesis project. Here after, I will discuss the benefit-harm composite of drugs, followed by 
a recapitulation of the possible treatments of OIRD. Finally, the conclusions of this thesis are 
presented. 
SUMMARY 
In chapter 2 the effect of the TASK1/TASK3 channel blocker doxapram was investigated on 
ventilation, analgesia and cardiac output. Eight healthy volunteers were included and a 
stepped-infusion of doxapram or placebo infusion was combined with alfentanil infusion on 
two separate occasions in random order. During administration poikilocapnic (ambient air) 
ventilation, cardiac output and analgesia were measured. Ventilation was measured breath-to-
breath, cardiac output with a FloTrac/Vigileo connected to an arterial line in the radial artery and 
analgesia with a transcutaneous electrical stimulation (TES) on the lower leg. Arterial plasma 
samples of alfentanil and doxapram were taken. A PK-PD model was constructed in which the 
doxapram plasma concentrations (PK) were related to cardiac output (CO), whereafter the CO 
was related to alfentanil plasma concentrations (PK) and subsequently to pain responses (a 
PK-PD/PK-PD analysis). Compared to placebo treatment, alfentanil plasma concentration was 
reduced by 14% during low and 26% during high dose infusion of doxapram. This induced 
a reduction in antinociception of 25%. Our PK-PD model demonstrated that the reduction 
in alfentanil concentration is well explained by the doxapram-induced increase in CO due to 
increased intercompartmental and elimination clearances. Due to the reduction in alfentanil 
plasma concentration, there was a reduction in the level of antinociception. 
In Chapter 3 and Chapter 4 the efficacy to reverse alfentanil-induced respiratory depression of 
novel agent GAL021 is determined. GAL021 inhibits calcium-activated potassium channels at 
the carotid bodies. In Chapter 3 we describe the effect of GAL021 on ventilation, hemodynamic 
parameters and antinociception. Chapter 3 describes two studies: the first study determined 
the effect of GAL021 on alfentanil-induced respiratory depression under isohypercapnic 
conditions, in the second study the effect of GAL021 on poikilocapnic (ambient air) ventilation 
and other variables as hemodynamic effects, antinociception, sedation and adverse events 
were determined. In total, twelve healthy volunteers were included and received a stepped-
drug infusion of GAL021/placebo and alfentanil. As in chapter 2, ventilation was measured on 
a breath-to-breath basis, analgesia with TES on the lower leg and cardiac output monitoring 
with a FloTrac/Vigileo on an arterial line in the radial artery. Sedation was measured with a NRS 
(numerous rating scale). In study 1, GAL021 showed to increase ventilation with 6.1 (3.6-8.6) L/
min and 3.6 (1.5-5.7) L/min during high GAL021 infusion, combined with low alfentanil infusion, 
respectively high alfentanil infusion. This effect was due to an increase in respiratory rate and 
tidal volume. Poikilocapnic ventilation and arterial pCO2 showed a significant difference with 
GAL021 vs. placebo treatment in the second study. No major side effects occurred during the 
study. No treatment differences were observed for plasma alfentanil concentrations, blood 
pressure, cardiac output, pain threshold and sedation. These data demonstrates stimulatory 
effect of GAL021 on ventilation and pCO2 without serious adverse effects and might be used as 
a respiratory stimulant in the future. 
To further understand the novel molecule GAL021, chapter 4 describes a pharmacokinetic-
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pharmacodynamic (PD-PD) analysis of the effect of GAL021 on alfentanil-induced respiratory 
depression in twelve healthy volunteers. It is a sub-analysis of the study described in Chapter 3. 
The data were analyzed with three different PK-PD models. Model 1 assuming a multiplicative 
interaction between alfentanil and GAL021 without ceiling in the effect of GAL021 on 
ventilation, Model 2 assuming a multiplicative interaction with ceiling in the effect of GAL021 
on ventilation and Model 3 assuming an additive interaction between alfentanil and GAL021. 
Model selection was based on the minimum objective function (MOF) value, which favored 
the model in which GAL021 shows ceiling in its efficacy to reverse respiratory depression. This 
suggests that GAL021 efficacy is reduced at low ventilation levels. GAL021 onset/offset times 
are rapid with a blood-effect site equilibration half-life not different from zero. 
In chapter 5 a utility function of alfentanil is described. The utility function is developed to 
determine the opioid’s toxicity (harm as respiratory depression, sedation, dizziness) in light 
of its benefit (analgesia) and to define an optimal dosing regimen. In this study the concept 
of utility function was further developed with the determination of the probabilities of four 
distinct conditions: probability of presence of benefit (analgesia) with or without severe toxicity 
(respiratory depression) and the probability of the inadequacy of benefit (inadequate analgesia) 
with or without severe toxicity, where the probability of analgesia was defined as P(A > 0.25) 
and P(A > 0.5) as a 25 and 50% increase in tolerated electrical current and P(R > 0.5) as a 50% 
reduction in minute ventilation. In this analysis, the data of three previous PK-PD analysis were 
combined and forty-eight subjects were included in the analysis. The analysis demonstrated 
that the optimum analgesia probability without serious respiratory depression is reached at an 
effect-site concentration of 60 ng/mL. With increasing the effect-site concentration of alfentanil 
the probability of serious respiratory depression prevails. 
Chapter 6 describes a population PK-PD modelling study in healthy volunteers to determine 
the effect of a novel opioid analgesic, RM101, on isohypercapnic ventilation. Furthermore, we 
analyzed the possibility to reverse the respiratory effect with naloxone. As previous mentioned, 
ventilation was measured on a breath-to-breath analysis in an isohypercapnic condition where 
after RM101 was administered in a dose-escalating manner. RM101 demonstrated to have a 
dual effect on ventilation, first a rapid effect on the minute volume, followed by a slower effect 
on CO2 sensitivity, which did not to have a ceiling effect. Naloxone reversal was observed in 
most but not in all subjects, which is best explained by a dosing effect and possibly a high 
affinity of RM101 on MOR. 
TREATMENT OF OIRD WITH NON-OPIOID DRUGS 
Opioid-induced analgesia and respiratory depression arise from stimulation of µ-opioid 
receptors (MORs). Due to stimulation of MORs there is an increase in pCO2 and a reduction 
in tidal and minute volume.12 Partial pressure carbon dioxide (pCO2) was the first respiratory 
stimulant discovered by Haldane. He concluded that the respiratory center adjusts to changes in 
arterial pCO2, which was transferred to the respiratory center through arterial blood.
13 However, 
an increase in pCO2 could cause depression of the central nervous system and administration 
of CO2 for the treatment of respiratory depression did not become common practice. Since 
1960s multiple drugs have been designed to alleviate OIRD with varying results, as caffeine, 




serotonin) receptor agonists, ampkakines and potassiumchannel blockers as doxapram and 
GAL021. These respiratory stimulant drugs manipulate neuronal transmission to stimulate 
respiratory drive. 
Serotonin receptor ligands are involved in multiple neuromodulatory processes in the 
nervous system. 5-HT is a respiratory stimulatory neurotransmitter. Different 5-HT receptor 
agonist demonstrated to alleviate OIRD in animals without an effect on antinociception.16-19 
Manzke et al. demonstrated that one half of all 5-HT4A receptors in the pre-Botzinger complex 
co-expressed MORs and stimulation of the 5-HT4A receptors alleviated fentanyl-induced 
respiratory depression in rats and maintained a stable respiratory rhythm without loss of 
fentanyl’s analgesic effect.16 Multiple 5-HT ligands have been tested, but the availability for 
human administration is limited. Two studies were performed, one with mosapride, a 5-HT4 
receptor agonist and one with buspirone, a 5-HT1A receptor agonist. Mosapride failed to 
prevent morphine-induced respiratory depression in a double-blind cross over study in 
human volunteers, while combining morphine with naloxone demonstrated a reversibility in 
morphine-induced respiratory depression. The authors of the study explain the negative result 
by decreased plasma concentrations in the brain versus abdominal plasma concentrations 
after oral administration.20 Buspirone (60 mg) co-administration with morphine did not prevent 
respiratory depression but led to a significant increase in intensity of nausea. Higher buspirone 
dosing was not possible due to the nausea. However, when comparing data to animal data 
(intravenous administration), a PKPD analysis demonstrated the negative result might be due 
to low effect site concentrations after oral ingestion.21
Ampakines are a group of compounds which modulate the AMPA (α-amino-3-hydroxy-5-
methyl-4-isoxazole-proprionis acid) receptor by increasing the duration of inward currents 
of glutamate.22 It is hypothesized that ampakines modulate the central respiratory drive by 
glutamate-mediated transmission in the pre-Botzinger complex to generate respiratory rhythm 
through an increase in glutamate-mediated excitatory inspiratory drive.23-25 AMPA receptor 
modulators do not interact with the receptor as an agonist, but binds to an allosteric site 
within the glutamate receptor complex. Different classes of AMPA receptor modulators have 
been described, but the most promising group are the benzamides (also known as ampakines; 
CX516, CX546, CX614, CX717).10 CX717 is the most studied ampakine. It demonstrated to 
alleviate fentanyl-induced respiratory depression (60 µg/kg) without significantly altering 
analgesia in rats and when administered prior to fentanyl, it prevented the fentanyl-induced 
respiratory depression.26  In vivo administration of CX717 with propofol provided protection 
against respiratory depression, but CX717 was not effective in rescuing propofol-induced 
respiratory effects.27 In humans, CX717 was studied in a double-blind, placebo-controlled, 
crossover study to access the effect of pre-treatment with CX717 combined with alfentanil in 
a target concentration of 100 ng/mL. Oertel et al. demonstrated CX717 to prevent respiratory 
depression without effecting analgesia. Ventilatory response to hypercapnic challenge (VE55) 
was alleviated by CX717 (41% vs 54%) without effecting antinociception. However, CX717 led 
to a significantly more pronounced increase in sedation. Due to the oral formulation CX717 
cannot be used in the peri-operative setting with a peak plasma concentration after 2 hours.28 
Potassium channel blocker doxapram is one of the oldest respiratory stimulant known. 
Doxapram inhibits background K+ channels (TASK1, TASK 3, TASK 1/3) on type 1 carotid body 
cells. In response to hypoxia the carotid body glomus cells (type 1) are involved in a signaling 
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protein cascade with closure of the oxygen-sensitive K+ channels, followed by depolarization of 
the membrane of the carotid body type 1 cells and Ca2+-dependent neurotransmitter release.29 
Other channels possibly involved in the hypoxia-sensitive K+ current in glomus cells are the Kv 
and BK channels, but the signaling pathways of the inhibition of hypoxia are not well defined 
(Kim, AMP on TASK 1-3 and Ca concentration ,2014). Antagonism of the hypoxia-sensitive K+ 
current stimulates respiration. The effect of doxapram on ventilation is described in multiple 
species and it thought to increase ventilation predominantly due to an increase in tidal volume 
with little effect on respiratory rate.14 After total intravenous anesthesia, doxapram showed to 
fasten arousal, return to spontaneous breathing, extubation with increased tidal volumes and 
respiratory rate in 90 patients for laparoscopic surgery.30 In patients with obstructive sleep apnea 
doxapram 100 mg was administered intravenously before extubation after bariatric surgery 
with total intravenous anesthesia. Patients with doxapram had lower sedation scores, shorter 
mean recovery room stay and no patients developed post-operative respiratory complications 
(atelectasis, bronchospasm, hypopnea) versus 29% in the placebo group.31 Doxapram was 
originally used as an analeptic with sympaticoexcitation, sweating, convulsions, anxiety, panic 
attacks, hypertension and increased cardiac output. In our study (Chapter 2), no respiratory 
effects of doxapram on alfentanil-induced respiratory depression were observed. Recently, two 
other TASK channel antagonist were discovered (PK-THPP and A1899). The magnitude of effect 
of PK-THPP and A1899 showed to exceed that of doxapram without any effect on mean arterial 
blood pressor.32 These drugs have not yet been studied on human volunteers. 
GAL021 is a novel potassium channel blocker. It blocks the BKCa channel. GAL021 stimulates 
ventilation and attenuates opioid-induced respiratory depression without effecting analgesia 
(Chapter 4 and 33,34). GAL021 reverses drug-induced respiratory depression by isoflurane, 
propofol and midazolam. Ventilatory stimulation is accompanied by enhanced carotid sinus 
nerve activity, although carotid nerve transection does not completely abolish the respiratory 
effect of GAL021.35 More studies need to be performed with GAL021 to determine the clinical 
applicability. 
A novel development in the possible prevention of OIRD is the treatment of analgesia with 
biased ligands.36  Biased ligands are ligands that selectively promotes pharmacological 
responses that differ from traditional agonist and circumvent the opioid respiratory pathway.37 
The biased ligands are envisioned to change the classic two-state model of receptor function 
(agonist, antagonist, later partial agonist and inverse agonist) to a more specific pharmacologic 
profile. For MOR a biased ligand is currently studied: TRV130. It is a biased ligand of the MOR that 
activates G protein signaling with little β-arrestin recruitment. In rodents TRV demonstrated 
potent analgesia with less gastro-intestinal dysfunction and respiratory depression in 
equianalgesic doses compared to morphine.38 In healthy volunteers the effect of ligand-biased 
TRV130 has been analyzed for analgesic properties, respiratory depression has been analyzed 
with surrogated markers as oxygen saturation and capnometry. This study, not powered to 
determine the respiratory effects, demonstrated smaller reductions in hypercapnia-induced 
ventilatory thrive than morphine.39 Yet the respiratory effects need to be studied in the future. 
 
A BENEFIT-HARM COMPOSITE OF DRUG EFFECT




unwanted side effects is by integrating benefit and harm into a risk-benefit composite as a utility 
of safety function. Previously the drug toxicity was expressed  as the therapeutic index, which 
equals the ratio of TD50 (dose causing toxicity in 50% of the population) and ED50 (dose causing 
benefit in 50% of the population). Sheiner and Melmon introduced a concept derived from 
economic decision theory that allows combining of different end-points into one number, the 
utility, which they defined as the benefit of a drug minus the harm it produces.40 They applied 
their concept to describe the benefit and harm of antihypertensive therapy. The concept was 
later used by Cullberg to define the outcome of anti-thrombin therapy.41 The utility function 
(UF) of opioids is defined as the probability of opioid analgesia minus the probability of OIRD, 
where the probability of analgesia (P(A)) is defined as an increase in pain tolerance of ≥ 50 % 
after electrical or thermal stimulus and the probability of OIRD (P(R)) as a reduction in minute 
ventilation of ≥ 50%.
UF = P (A ≥ 50%) – P (R ≥ 50%)
Thusfar some opioids have been described by a UF.42-45 The UF is context-sensitive, meaning that 
the function will differ depending on the definition of analgesia and respiratory depression. 
Previous UFs have chosen to describe analgesia with a P(A>50%), which is an increase in pain 
tolerance of 50% of more. In chapter 5 we described a UF where we have described analgesia 
with P(A>50%) and P(A>25%). The UF might allow comparison among drugs to determine the 
best opioid prescription for each patient.
After a bolus of 0.13 mg/kg morphine, the UF comparing the probability of analgesia versus 
the probability of respiratory depression was positive, which indicates that the probability 
of developing analgesia exceeds the probability of developing respiratory depression.44 
For fentanyl (i.v. bolus of 3.5 µg/kg) the UF was negative in the first 90 minutes after fentanyl 
administration (probability for respiratory depression was higher than for analgesia). After 90 
minutes the probability of both end-points was in the same order of magnitude.43 Alfentanil 
had a biphasic UF after an intravenous bolus of 50 µg/kg. In the first 6 minutes after alfentanil 
administration the UF was negative compared to a positive UF at 22 minutes after the 
administration. When the UF was used to compare the probability of analgesia and respiratory 
depression between oxycodone immediate release 20 mg and tapentadol 100 mg it was clearly 
demonstrated that the UF of tapentadol was beneficial over the UF of oxycodone. The UF of 
oxycodone was negative in the first 3 hours after administration (higher probability of respiratory 
depression than of analgesia), after which the probability returned to zero (equal probability 
of respiratory depression and analgesia). The UF of Tapentadol was zero over the whole study 
period independent of time of administration.46 Besides comparing different opioids with the 
UF after a bolus administration, the UF can describe the probability as a function of plasma 
concentrations of the desired opioid. To determine this UF, pharmacokinetic parameters 
are necessary to define the effect-site concentration of the opioid. For example, we showed 
that when the plasma concentration of morphine is higher than 5 ng/mL the probability for 
analgesia exceeds that of respiratory depression, which continues to be positive up to a plasma 
concentration of 30 ng/mL. On the other hand, the UF of fentanyl is only positive up to a plasma 
concentration of 0.6 ng/mL. At higher plasma concentrations the UF becomes negative, which 
indicates that the probability for respiratory depression exceeds the probability for analgesia. 
Alfentanil had a positive UF over the effect-site concentration range of 0 – 300 ng/mL. 
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Although equianalgesic doses of oral opioids versus intravenous opioids is difficult to compare, 
comparison based on the utility function suggests that tapentadol and morphine have a more 
favorable respiratory profile compared to the other opioids. However the desired outcome of 
opioid treatment, i.e. analgesia, can be objectified with multiple assays as an electrical current, 
pressure or thermal measurements. At this moment, only the UF of fentanyl is analyzed with 
a thermal and an electrical assay, demonstrating more negative UF with thermal assay versus 
electrical assay. For comparison between different opioids, the analgesia effect of the opioid 
should be measured with a comparable nociceptive assay. 
The disadvantage of the above mentioned formulation of the UF is that a positive UF does not 
mean that respiratory depression does not occur. Therefore, in chapter 5 we have remodeled 
the UF and added the probability of adequate analgesia without severe respiratory depression 
(U2, desirable condition) and the probability of inadequate analgesia with severe respiratory 
(U3, least desirable condition). This modification of the original UF has not been calculated for 
other opioids. 
Thus far, the UF is based on data obtained in a healthy population (i.e. volunteers without pain) 
and are not calculated in patients with opioid treatment. Further studies should address the 
utility of different opioids in chronic pain patients or patients with postoperative pain to further 
objectify the UF and support the comparison of opioid treatment in patients.
CONCLUSIONS
From the data presented in this thesis, the following can be concluded:
1) Doxapram reduces alfentanil-induced antinociception, which was related to an increase 
in alfentanil distribution and elimination. These changes might be best explained by the 
doxapram-induced increase in cardiac output. 
2) GAL021, a novel calcium-activated potassium channel blocker, produces an increase in 
tidal volume and respiratory rate  during opioid-induced respiratory depression without 
affecting the obtained opioid analgesic effect
3) GAL021 efficacy on alfentanil-induced respiratory depression reduces at low ventilation 
levels and demonstrates ceiling in its efficacy to reverse opioid-induced respiratory 
depression
4) The utility function of alfentanil is further developed to assess specific conditions in terms 
of wanted and unwanted effects (analgesia with or without respiratory depression, no 
analgesia with or without respiratory depression). This refined utility function may be used 
to compare the respiratory effects of analgesics and might allow for comparison between 
different opioid treatments.  
5) RM101 causes respiratory depression in all subjects with a rapid effect on ventilation and a 
slower effect on CO2 sensitivity. Since complete reversal of the respiratory effect of RM101 
is not observed in all subjects, RM101 might have a high affinity for the µ-opioid receptor.
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Chronische pijn komt in de Westerse wereld frequent voor met een incidentie van 18% in 
Nederland, dit is gelijk aan schattingen in andere Europese landen en de Verenigde Staten 
(VS).1 Op een bevolking van 17,1 miljoen mensen in Nederland zijn er 3 miljoen patiënten met 
pijn. De behandeling van chronische pijn is vaak door niet-farmacologische  behandeling, 
zoals cognitieve of gedragstherapie, gecombineerd met medicatie zoals niet-steroide anti-
inflammatoire geneesmiddelen of opioiden. In patienten met matige tot ernstige acute 
en chronische pijn is het doel van de behandeling om de symptomen te verlichten en de 
kwaliteit van leven te verbeteren. Opioïden zijn effectieve pijnstillers, maar gaan gepaard 
met bijwerkingen die levensbedreigend kunnen zijn. Zowel in de VS als in Nederland is er 
een forse toename in de hoeveelheid voorgeschreven opioiden.2-5 In Nederland is het aantal 
gebruikers van opioïden tussen 2004 - 2013 verdubbeld tot 1 miljoen gebruikers.2 De meeste 
patienten (80%) gebruiken opioïden voor pijn niet veroorzaakt door maligniteiten, veelal voor 
musculoskeletale pijn als lage rugpijn. Recente data toont verdere toename in het gebruik van 
opioiden in Nederland tot 1.2 miljoen gebruikers of 7% van de totale populatie in 2016. In de 
VS is er een toename in drugs/medicatie gerelateerde doden, in totaal zijn er 16.000 – 20.000 
doden op basis van voorgeschreven opioïden per jaar geregistreerd.3-5 Recente voorlopige 
resultaten suggereren dat in 2016 er 59.000 – 65.000 doden waren op basis van overdosis 
door drugs of medicatie, waarvan er meer dan 20.000 zijn overleden op basis van fentanyl 
overdosering.6 Hoeveel personen in Nederland zijn overleden door opioïden is niet bekend. 
Overlijden door opioïden is gerelateerd aan  misbruik, verslaving en het gecombineerd gebruik 
van opioïden met andere centraal werkende medicatie zoals alcohol en benzodiazepines. De 
oorzaak van het overlijden is bijna altijd door cardiorespiratoire collaps op basis van opioïd-
geïnduceerde ademdepressie (OIRD). Door de toename van opioïd gerelateerde mortaliteit is 
de ontwikkeling van een behandeling tegen OIRD nodig. Bijna de helft van alle overdoses op 
basis van opioïden zijn voorgeschreven door artsen, de overige komen door illegale opioïden 
en heroïne.7 Momenteel is er in de VS een campagne (Turn the Tide Rx) om onderwijs te geven 
over de veilige en effectieve behandeling van pijn aan artsen, leren hoe opioïd verslaafden 
te herkennen zijn en hoe zij te behandelen zijn.8 Hoewel preventie de eerste stap is in het 
verminderen van mortaliteit door OIRD,  is momenteel de enige beschikbare behandeling 
met medicatie (naloxon). Naloxon is een niet-selectieve opioïd receptor antagonist wat alle 
farmacologische activiteiten van opioiden remt; de voordelen (analgesie) en de nadelen 
(bijwerkingen zoals OIRD). De mate en de duur van het effect van naloxon op ademhaling is erg 
variabel en gerelateerd aan vele factoren als het gebruikte opioïd, gebruikte dosis, manier van 
toediening, andere medicatie, onderliggende ziekte en exogene stimulantia.9 Alle opioïden 
met een langere plasma halfwaardetijd dan naloxon, hebben een kans op het terugkeren van 
de OIRD, i.e. renarcotizeren. Dit kan voorkomen worden door een continue toediening van 
naloxon.10 In de VS hebben brandweermannen, ambulance broeders, politieagenten, familie 
en vrienden van opioïd verslaafde naloxon in hun auto in de vorm van een FDA-goedgekeurde 
neusspray. De FDA heeft de naloxon neusspray goedgekeurd in 2015. Intranasale toediening 
van naloxone is even effectief of zelfs effectiever dan intramusculaire toediening van naloxon.11 
Door het volledig antagoneren van het effect van opioïden door naloxon (zowel OIRD als 
analgesie) is er behoefte aan een behandeling van OIRD door niet-opioïde geneesmiddelen 
als kalium kanaal blokkers, AMPAkines en 5-HT receptor agonisten. Deze geneesmiddelen 




effect te hebben op analgesia. Het doel van dit proefschrift was om de mogelijkheden te 
onderzoeken om OIRD te voorkomen met geneesmiddelen die ademhaling stimuleren en om 
geneesmiddelen te onderzoeken die mogelijk OIRD kunnen voorkomen. 
In dit laatste hoofdstuk zal ik een samenvatting geven van de uitgevoerde studies tijdens 
mijn promotie onderzoek. Hierna zal ik analyse om de voor-/nadelen van verschillende 
geneesmiddelen bespreken en een samenvatting geven van de mogelijke (experimentele) 
behandelingen van OIRD. Uiteindelijk presenteer ik de conclusies van mijn proefschrift. 
SAMENVATTING
In hoofdstuk 2 is het effect van TASK1/TASK3-kanaal blokker doxapram beschreven op 
ventilatie, analgesie en hartminuutvolume. Acht gezonde vrijwilligers zijn geïncludeerd 
in de studie en hebben een gefaseerde infusie van doxapram of placebo ontvangen in 
combinatie met alfentanil op twee verschillende onderzoeksdagen. Tijdens het toedienen 
van de geneesmiddelen is de poikilocapnische (lucht zoals in dagelijks leven) ventilatie, 
hartminuutvolume en analgesia gemeten. De ventilatie is gemeten op breath-to-breath (i.e. 
iedere ademhalingsteug werd gemeten), hartminuutvolume door een FloTrac/Vigileo met een 
arterielijn in de arteria radialis en analgesia met een transcutane electrische stimulatie (TES) op 
het onderbeen. Arteriele plasma monsters van alfentanil en doxapram zijn afgenomen. In het PK-
PD model is de plasma concentratie (PK) van doxapram van invloed op het hartminuutvolume 
(HMV), waarna het HMV van invloed is op de alfentanil plasma concentratie (PK) en dit 
uiteindelijk de analgesie beïnvloedt (een PK-PD/PK-PD model). Tijdens doxapram infusie in 
vergelijking met een placebo infusie was de alfentanil plasma concentratie verminderd met 
14% tijdens lage dosering doxapram en 26% tijdens hoge dosering doxapram. Dit leidden 
tot een vermindering in analgesie van 25%. Het PK-PD model toont dat de vermindering in 
alfentanil concentratie verklaard kan worden door de doxapram-geïnduceerde toename in 
hartminuutvolume door een toename in intercompartmentale en eliminatie klaring. Door een 
vermindering in alfentanil plasma concentratie was er een vermindering in analgesie. 
In hoofdstuk 3 en hoofdstuk 4 is de mogelijkheid onderzocht om de door alfentanil-geïnduceerde 
ademdepressie ongedaan te maken door toediening van GAL021. GAL021 remt de calcium-
geactiveerde kalium kanalen in de receptoren in de carotiden. In hoofdstuk 3 beschrijven we 
het effect van GAL021 op ventilatie, hemodynamische parameters en analgesie. Hoofdstuk 
3 beschrijft twee studies: de eerste studie beschrijft het effect van GAL021 op alfentanil-
geïnduceerde ademdepressie tijdens isohypercapnische (een op een vast niveau gefixeerde 
verhoogde pCO2) condities en de tweede studie het effect van GAL021 op poikilocapnische 
ventilatie en andere variabele als hemodynamische parameters, analgesia, sedatie en 
bijwerkingen. In totaal zijn er twaalf proefpersonen geïncludeerd in de studie en hebben zij 
een stapsgewijze infusie gekregen van GAL021/placebo en alfentanil. Net als in hoofdstuk 2 is 
ventilatie gemeten op basis van iedere ademhaling, analgesie met TES en hartminuutvolume 
met een FloTrac/Vigileo monitor en een arterielijn in de arteria radialis. Sedatie is gemeten met 
een NRS (numerous rating scale, numerieke schaalverdeling). In studie 1 zorgde GAL021 voor 
een toename in ventilatie van 6.1 (3.6-8.6) L/min en 3.6 (1.5-5.7 L/min) tijdens hoge dosering 
GAL021 gecombineerd met lage alfentanil toediening danwel hoge alfentanil toediening. 
Dit effect werd veroorzaakt door een toename van ademhalingsfrequentie en teugvolumes. 
Poikilocapnische ventilatie en arteriele pCO2 toonde een significant verschil tijdens GAL021 
behandeling vs. placebo behandeling in de tweede studie. Er traden geen benoemenswaardige 
110
Chapter 8
bijwerkingen op tijdens de studie. Er werd geen verschil geobjectiveerd in alfentanil plasma 
concentraties, bloeddruk, hartminuutvolume, analgesie of sedatie. Deze data tonen een 
stimulerend effect van GAL021 op ventilatie en pCO2 zonder serieuze bijwerkingen en GAL021 
kan mogelijk in de toekomst worden gebruikt als een geneesmiddel om ademhaling te 
stimuleren.  
Om meer over het experimentele medicijn GAL021 te weten te komen beschrijft hoofdstuk 
4 de farmacokinetische-farmacodynamische (PK-PD) analyse van het effect van GAL021 op 
alfentanil-geïnduceerde ademdepressie in twaalf gezonde vrijwilligers. Het is een subanalyse 
van de studie beschreven in hoofdstuk 3. De data zijn geanalyseerd door middel van drie 
verschillende PK-PD modellen. Model 1 gaat uit van een multiplicatieve interactie tussen 
alfentanil en GAL021 zonder ‘ceiling’ (plafond effect) in het effect van GAL021 op ventilatie, 
model 2 gaat uit van een multiplicatieve interactie met ceiling in het effect van GAL021 op 
ventilatie en model 3 gaat uit van een additief effect tussen alfentanil en GAL021. De selectie 
van het model (Model 2) is gebaseerd op de minimum objective function (MOF) waarde,  
waarbij GAL021 ceiling toont in het antagonere van de ademdepressie. Dit suggereert dat de 
effectiviteit van GAL021 is verminderd bij lage ademminnutvolumes. De effecten van GAL021 
treden snel op, de bloed-effect equilibratie tijden zijn gelijk aan met nul. 
Hoofdstuk 5 beschrijft een utility functie van alfentanil . De utility functie is bedacht om 
de toxiciteit van een opioïd (bijwerkingen als ademdepressie, sedatie, duizeligheid) vs. het 
voordeel (analgesie) te bepalen en een ideaal doseringsschema te definiëren. In deze studie 
hebben wij het concept utility functie verder ontwikkeld door de kans op vier verschillende 
mogelijkheden te formuleren: de kans op de aanwezigheid van het voordeel (analgesie) 
met of zonder ernstige toxiciteit (ademdepressie) en de kans op het niet aanwezig zijn van 
het voordeel (geen analgesie) met of zonder ernstige toxiciteit (ademdepressie), waarbij de 
kans op analgesie gedefiniëerd was als P(A > 0.25) en P(A > 0.5) zijnde 25 en 50% toename in 
toegediende elektrische pijnprikkel en P(R > 0.5) zijnde 50% afname in ademminuutvolume. 
Voor deze analyse is de data van drie eerdere PK-PD analyses gecombineerd waarbij er 
achtenveertig proefpersonen zijn geïncludeerd in de analyse. De studie toonde dat de grootste 
kans op analgesie zonder ernstige ademdepressie bereikt wordt bij een effect-site concentratie 
van 60 ng/mL. Met een oplopende alfentanil effect-site concentratie neemt de kans op ernstige 
ademdepressie toe. 
Hoofdstuk 6 beschrijft een PK-PD studie in gezonde vrijwilligers om het effect van een nieuw 
opioïd, RM101, op isohypercapnische ventilatie te bepalen. Verder analyseren we het effect 
om de ademdepressie veroorzaakt door RM101 te antagoneren met naloxon. Ventilatie 
werd gemeten op basis van iedere ademhaling in een isohypercapnische conditie waarna 
RM101 werd toegediend in een oplopende dosis. RM101 toonde op twee manieren effect 
te hebben op ventilatie; als eerste een snel effect op het ademminuutvolume, gevolgd door 
een langzaam effect op CO2 gevoeligheid, wat geen ceiling effect toonde. Door naloxon werd 
de ademdepressie geantagoneerd in veel, maar niet in alle proefpersonen. Dit kan het beste 





BEHANDELING VAN ADEMDEPRESSIE MET NIET-OPIOIDE GENEESMIDDELEN
Opioïd-geïnduceerde analgesie en ademdepressie komen door stimulatie van de µ-opioid 
receptor (MOR). Door stimulatie van de MOR is er een toename in pCO2 en een vermindering 
in teug- en ademminuutvolume.12 Het eerste geneesmiddel, uitgevonden door Haldane, wat 
ademhalings stimuleerde was pCO2. Hij concludeerde dat de respiratoire centra in de hersenen 
reageerden op veranderingen in arteriele pCO2.
13 Echter veroorzaakte een toename in pCO2 
depressie van het centrale zenuwstelsel en het gebruik van CO2 voor de behandeling van 
ademdepressie werd niet meer toegepast. Sinds 1960 zijn er meerdere geneesmiddelen met 
wisselend succes ontworpen om opioid-geinduceerde ademdepressie te verminderen, zoals 
caffeïne, aminofylline, atropine en almitrine.10,14,15 Meest belovende geneesmiddelen zijn de 
5-hydroxytryptamine (5-HT, serotonine) receptor agonist, ampakines en kaliumkanaal blokkers 
als doxapram en GAL021. Deze respiratoire stimulerende geneesmiddelen manipuleren 
neuronale transmissie om de ademprikkel te stimuleren. 
Serotonine receptor agonisten zijn betrokken bij meerdere neuromodulerende processen in 
het zenuwstelsel. 5-HT is een respiratoire stimulerende neurotransmitter. Verschillende 5-HT 
receptor agonisten hebben in dieren aangetoond om opioïd-geïnduceerde ademdepressie te 
verminderen zonder een effect te hebben op analgesie.16-19 Manzke et al. toonde aan dat de helft 
van alle 5-HT4A receptoren in de pre-Botzinger complex ook MORs hebben en door stimulatie 
van de 5-HT4A receptoren fentanyl-geïnduceerde ademdepressie verminderd werd zonder 
effect te hebben op de analgetische effecten van fentanyl in ratten.16 Meerdere 5-HT agonisten 
zijn getest, maar de beschikbaarheid voor menselijke toediening is beperkt. In totaal zijn er 
twee studies uitgevoerd, één met mosapride (5-HT4 receptor agonist) en één met buspirone (5-
HT1A receptor agonist). Mosapride had geen effect op morfine-geïnduceerde ademdepressie 
in een dubbelblinde, cross-over studie in gezonde vrijwilligers, terwijl het combineren van 
morfine met naloxon de morfine-geïnduceerde ademdepressie antagoneerde. De auteurs van 
de studie verklaarde het negatieve resultaat door een verminderde plasma concentratie in de 
hersenen versus de plasma concentratie abdominaal na orale inname.20 Buspirone (60 mg) 
toegediend in combinatie met morfine voorkwam geen ademdepressie, maar veroorzaakte 
wel een significante toename in misselijkheid. Hogere buspirone dosering was niet mogelijk 
in verband met de misselijkheid bij de proefpersonen. Bij het vergelijken van de data met 
proefdier data (intraveneuze toediening), toonde de PK-PD analyse dat het negatieve resultaat 
mogelijk veroorzaakt werd door een te lage effect-site concentratie na orale inname.21 
Ampakines zijn een groep geneesmiddelen welke effect hebben op de AMPA (α-amino-
3-hydroxy-5-methyl-4-isoxazole-proprionis acid) receptor door de duur van de inwaartse 
actiepotentiaal van glutamaat te verlengen.22 De hypothese is dat ampakines de centrale 
ademhalingsprikkel moduleren door glutamaat-gemedieerde transmissie in het pre-Botzinger 
complex om een ademhalingsritme te creëren door een toename in glutamaat-gemedieerde 
excitatoire inspiratoire stimulans.23-25 AMPA receptor modulatoren hebben geen interactie met 
de receptor als een agonist, maar hechten aan een allosterische binding in het glutamaat-
receptor complex. Verschillende klasse van AMPA receptor modulatoren zijn beschreven, de 
meest belovende groep zijn de benzamides (ook bekend als ampakines: CX516, CX546, CX614, 
CX717).10 De meeste studies zijn verricht met CX717. CX717 toonde aan fentanyl-geïnduceerde 
ademdepressie (60 μg/kg) te verminderen zonder effect te hebben op analgesie in ratten. 
Wanneer CX717 gecombineerd werd met fentanyl, voorkwam CX717 fentanyl-geïnduceerde 
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ademdepressie.26 In vivo beschermt CX717 tegen propofol-geïnduceerde ademdepressie, maar 
CX717 was niet effectief in het antagoneren van propofol-geïnduceerde ademdepressie.27 In 
mensen is CX717 in een dubbelblinde, placebo-gecontroleerde, cross-over studie onderzocht 
om het effect van CX717 in combinatie met toediening van alfentanil in een target concentratie 
van 100 ng/mL. Oertel et al. toonde aan dat CX717 ademdepressie voorkomt zonder effect 
te hebben op analgesia. De ventilatoire response op een hypercapnie (VE55) was verminderd 
door CX717 (41% vs 54%) zonder effect te hebben op analgesie. Echter leidde CX717 tot een 
significante toename in sedatie. De orale toedieningsvorm van CX717 kan niet gebruikt worden 
peri-operatief in verband met een plasma concentratie piek na 2 uur.28 
Kalium-kanaal blokker doxapram is één van de oudste ademhalingsstimulantia. Doxapram 
remt achtergrond K+ kanalen (TASK1, TASK3, TASK 1/3) op type 1 cellichamen in de carotiden. 
Als reactie op hypoxie stimuleren de type 1 cellichamen in de carotiden een eiwit cascade 
door het sluiten van de zuurstof-gevoelige K+ kanalen, waarna er een depolarisatie is van het 
membraam van de type 1 cellichamen en afgifte van Ca2+-afhankelijke neurotransmitters.29 
Andere mogelijke kanalen die mogelijk betrokken zijn bij de zuurstof afhankelijke K+ kanalen 
in de type 1 cellichamen zijn de Kv en BK kanalen, echter zijn de remmende signalen door 
hypoxie niet geheel duidelijk.30 Antagoneren van de hypoxie gevoelige K+ kanalen stimuleert 
ademhaling. Het effect van doxapram op ventilatie is beschreven in verschillende diersoorten. 
Het effect van doxapram op ademhaling is voornamelijk door een toename in teugvolume 
met minimaal effect op ademhalingsfrequentie.15 Na intraveneuze anesthesie geeft doxapram 
eerder herstel van bewustzijn, sneller herstel van spontane ademhaling, grotere teugvolumes 
en ademhalingsfrequentie bij extubatie in 90 patiënten na laparoscopische chirurgie.30 In 
patiënten met slaap-apneu syndroom is 100 mg doxapram intraveneus toegediend aan 
patiënten na bariatrische chirurgie voor extubatie. Deze patiënten hadden lagere sedatie scores, 
kortere verblijfsduur op de uitslaapkamer en geen enkele patiënt ontwikkelde postoperatieve 
respiratoire problemen (atelectase, bronchospasme, verminderde ademhaling) versus 29% van 
de patiënten in de placebo groep.31 Doxapram was oorspronkelijk gebruik als analepticum 
met sympathico-excitatie, zweten, convulsies, angst/paniek aanvallen, hypertensie en een 
toegenomen hartminuutvolume. In onze studie (hoofdstuk 2) werden er geen respiratoire 
effecten van doxapram  op alfentanil-geïnduceerde ademdepressie waargenomen. Onlangs 
zijn er twee andere TASK-kanaal antagonisten ontdekt (PK-THPP en A1899). Het effect van 
deze antagonisten overtreffen het effect van doxapram zonder de bloeddruk te beinvloeden.32 
Echter zijn deze geneesmiddelen nog niet getest op vrijwilligers.
GAL021 is een recent ontdekte K+ kanaal blokker. Het blokkeert het BKCa kanaal. GAL021 
stimuleert ventilatie en vermindert de OIRD zonder effect te hebben op analgesie (hoofdstuk 
4 en 33,34). GAL021 vermindert ademdepressie geïnduceerd door isoflurane, propofol en 
midazolam. Ademhalingsstimulatie vindt plaats door een toegenomen zenuwactiviteit in de 
carotiden, echter houdt GAL021 respiratoire effecten na het verwijderen van de carotiden en is 
het effect dus niet enkel op de carotiden.35 Meer studies met GAL021 moeten verricht worden 
voor het gebruikt kan worden in de kliniek. 
Een nieuwe ontwikkeling in het mogelijk voorkomen van OIRD is, zijn ‘biased ligands’.36 Biased 
ligands zijn moleculen die selectief het farmacologisch gewenste effect stimuleren en het 
ademhalingsdepressieve effect omzeilen.37 De biased ligands beïnvloeden het klassieke 
model betreft receptor functie (agonist vs antagonist, later toegevoegd partiele agonist en 




er momenteel een biased ligand onderzocht: TRV130. TRV130 activeert het G-eiwit met 
minimale β-arrestin betrokkenheid. TRV130 toonde in muizen dat het voldoende analgesie 
geeft met minder bijwerkingen (gastro-intestinaal en ademdepressie) dan in een equivalente 
dosering morfine.38 In gezonde vrijwilligers is het analgetische effect van TRV130 bepaald, 
echter is het effect op ademhaling geanalyseerd met afgeleide meetwaardes als zuurstof 
saturatie en capnometrie. De studie toonde minder effect op hypercapnische geïnduceerde 
ademhalingsprikkel dan morfine.39 De respiratoire effecten van TRV130 moeten in de toekomst 
beter onderzocht worden.
EEN BEREKENING VAN GENEESMIDDEL EFFECT: VOORDEEL VS. NADEEL
Een manier om inzicht te krijgen in het gedrag van geneesmiddelen met het oog op gewenste 
effecten en ongewenste effecten is het integreren van deze effecten in een berekening, als een 
utility functie. Eerder werd de toxiciteit van een geneesmiddel uitgedrukt met de therapeutische 
index, de ratio tussen de TD50 (dosis die in 50% van de populatie toxisch is) en de ED50 (dosis 
die in 50% van de populatie effectief is). Sheiner en Melmom hebben een concept, gebaseerd 
op een economische principe, geïntroduceerd om verschillend eindpunten te combineren 
in één berekening, waarbij het voordeel van het geneesmiddel minus de toxiciteit van het 
geneesmiddel gecombineerd werd. De eerste utility functions die zijn beschreven, hebben 
betrekking op antihypertensieve medicatie en anticoagulantia.40,41 De utility functie van 
opioïden is gedefinieerd als de kans op analgesia minus de kans op OIRD, waarbij de kans op 
analgesia (P(A)) gedefinieerd is als een toename in pijn tolerantie van ≥ 50% na een elektrische 
of warmte stimulus en de kans op OIRD (P(R)) als een afname in ademhalingsvolume van ≥ 50%.
UF = P (A ≥ 50%) – P (R ≥ 50%)
Momenteel zijn er enkele opioïden beschreven door middel van een utility functie (fentanyl, 
morfine, oxycodon, cebranopadol en alfentanil).42-45 De UF is context gevoelig, wat betekent 
dat de functie afhankelijk is van de definitie van analgesie en ademdepressie. Eerdere UFs 
hebben analgesia beschreven met een P (A > 50%), wat een toename in pijn tolerantie van 
50% of meer is. In hoofdstuk 5 beschrijven wij een UF waarin analgesia is geanalyseerd met een 
P (A > 50%) en een P (A > 25%). De UF geeft wellicht de mogelijkheid om geneesmiddelen te 
vergelijken en zo de beste therapie voor elke patient te bepalen. 
Na een bolus van 0.13 mg/kg morfine is de UF van morfine positief (kans op analgesie is groter 
dan de kans op ademdepressie).43 Na een bolus van 3.5 µg/kg fentanyl intraveneus is de UF 
negatief gedurende de eerste 90 minuten waarna de kans op analgesie en ademdepressie even 
groot is.42 Alfentanil heeft een bifasische UF na een bolus van 50 µg/kg. De eerste 6 minuten 
zijn negatief, waarna de UF significant toeneemt na 22 minuten (hoofstuk 5). Een vergelijking 
tussen oxycodon met directe afgifte en tapentadol 100 mg toonde een gunstigere UF voor 
tapentadol dan voor oxycodon. Oxycodon had een negatieve UF in de eerste 3 uur, waarna de 
UF herstelt naar nul. Tapentadol had continue een UF rond de nul, onafhankelijk van de tijd na 
inname.45 Naast het vergelijken van verschillende UF na een bolus toediening, kan de UF ook 
de kans berekenen op basis van de plasma concentratie van het gewenste opioïd. Om deze UF 
te berekenen zijn farmacokinetische parameters noodzakelijk om de effect-site concentratie 
van het opioïd te bepalen. Een plasma concentratie van > 5 ng/mL morfine geeft meer kans 
op analgesie dan op ademdepressie. Fentanyl toont een minimaal positieve UF tot een plasma 
concentratie van 0.6 ng/mL, bij hogere plasma concentratie is de UF negatief en de kans op 
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ademhalingsdepressie groter dan de kans op analgesie. Alfentanil toont een positieve UF over 
de effect-site concentraties van 0 – 300 ng/mL.
Hoewel equianalgetische doseringen van orale opioïden versus intraveneuze opioïden lastig 
is om te vergelijken, toont een vergelijking op basis van UF dat tapentadol en morfine een 
gunstiger profiel heeft met betrekking tot ademdepressie dan andere opioïden. Echter kan het 
gewenste effect van opioïden, i.e. analgesie, geobjectiveerd worden met verschillende testen 
zoals elektrische, druk of warmte stimuli. Op dit moment is de UF van fentanyl geanalyseerd met 
warmte en elektrische stimuli met een meer negatieve UF met warmte stimuli vs. elektrische 
stimuli. Om verschillende opioïden te vergelijken moet het analgetische effect met dezelfde 
nociceptieve stimulus onderzocht worden. Het nadeel van de UF is dat een positieve UF niet 
betekent dat er geen ademdepressie optreedt. In hoofdstuk 5 hebben wij daarom aan de 
UF twee andere berekeningen toegevoegd: de kans op adequate analgesie zonder ernstige 
ademdepressie (U2, gewenste uitkomst) en de kans op inadequate analgesie met ernstige 
ademdepressie (U3, minst gewenste uitkomst). Deze toegevoegde analyse aan de UF is niet 
eerder voor andere opioïden berekend. 
Tot op heden is de UF gebaseerd op data verkregen in een gezonde populatie (i.e. gezonde 
vrijwilligers zonder pijn) en niet gebaseerd op patiënten die behandeld worden met opioïden. 
Toekomstige studies moeten het gebruik van de UF met verschillende opioïden in chronische 
pijn patiënten of postoperatieve patiënten analyseren en de mogelijkheid geven tot het 
vergelijken van opioïd behandeling tussen patiënten. 
CONCLUSIES
Uit de data gepresenteerd in dit proefschrift kunnen de volgende conclusies worden getrokken:
1) Doxapram vermindert alfentanil-geïnduceerde antinociceptie door een toegenomen  
alfentanil distributie en eliminatie. Dit kan het beste verklaard worden door de toename in 
hartminuutvolume na doxapram administratie. 
2) GAL021, een nieuw calcium-geactiveerde kalium kanaal blokker, geeft een toename in 
teugvolume en ademhalingsfrequentie bij opioid-geïnduceerde ademhalingsdepressie 
zonder het pijnstillende effect van het opioid te beïnvloeden. 
3) GAL021's effectiviteit op alfentanil-geïnduceerde ademhalingsdepressie vermindert 
bij lage ademminuutvolumes en toont een plafond aan in zijn effectiviteit om opioid-
geïnduceerde ademhalingsdepressie te verminderen. 
4) De utility functie van alfentanil is verder ontwikkeld om specifieke effecten naar gewenste 
en ongewenste effecten (analgesie met of zonder ademhalingsdepressie, geen analgesie 
met of zonder ademhalingsdepressie) te onderzoeken. Het kan mogelijk gebruikt worden 
om de effecten op ademhaling van opioïden en tussen opioïden te vergelijken.
5) RM101veroorzaakt ademhalingsdepressie in alle proefpersonen met een snel effect op 
ventilatie en een langzamer effect op CO2 gevoeligheid. Gezien het effect op ventilatie 
met naloxon niet volledig geantagoneerd kon worden in alle proefpersonen, heeft RM101 
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AMPA α-amino- 3- hydroxyl-5-methyl-4-isoxazolepropionate
BoF Best of fit








ED50 Dose causing 50% of effect
EFA Predicted ventilation with alfentanil/placebo
EFG Predicted ventilation with alfentanil/GAL021
FDA US Food and Drug Administration
GoF Goodness of fit
IPRED Individual predicted values





MOF Minimum Objective Function
OIRD Opioid Induced Respiratory Depression
P Probability
pCO2 Carbon dioxide partial pressure
PD Pharmacodynamic
PETCO2 End-tidal partial pressure of carbon dioxide
PK Pharmacokinetic
pO2 Oxygen partial pressure
Qn Clearance of compartment n
R2 Coefficient of determination
SEE Standard error of estimate
SVPC Standardized visual predictive checks
σ Standard deviation of the error
t1/2keO Blood effect-site equilibration half-life
TES Transcutaneous electrical stimulation







Vn Volume of compartment n
ω2 Inter-subject variability
Y Shape parameter
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